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Background: Drug repurposing applies existing drugs to novel indications to identify 
potential treatments in a more rapid and cost-effective manner than traditional drug 
development. Antihypertensive drugs are priority repurposing candidates for dementia 
prevention, however current evidence for their use is inconclusive. Furthermore, little 
research has been conducted into the factors that influence prescribing of licensed 
dementia drugs, which will be an important consideration should a drug repurposing 
candidate be identified.  
 
Methods: Join point analysis was used to identify factors that have potentially influenced 
prescribing trends for the licensed dementia drugs in the Clinical Practice Research 
Datalink (CPRD). Instrumental variable analysis was then conducted in two ways to 
assess the potential for repurposing antihypertensives for dementia prevention. The first 
analysis used physicians’ prescribing preference as an instrument, also in the CPRD. 
While the second analysis used genetic variants to proxy the targets of antihypertensive 
drugs in a two-sample Mendelian Randomization framework. 
 
Results: Prescriptions of dementia drugs have increased since their launch, but the join 
point analysis suggested that different classes of drugs have been affected by different 
factors during this time. The instrumental variable analysis using physician’s prescribing 
preference suggested that small differences exist between antihypertensive drug classes in 
terms of their effect on dementia prevention, but the magnitude of the differences is 
smaller than previously reported. Finally, Mendelian randomization provided limited 
evidence that lowering systolic blood pressure, via antihypertensive drug classes, affected 
Alzheimer’s disease risk. This suggests that if specific antihypertensive drug classes affect 
the risk of Alzheimer’s disease, they may not do so via systolic blood pressure. 
 
Conclusions: This thesis has provided new evidence concerning the potential repurposing 
of antihypertensives for dementia prevention using causal inference methods. In 
addition, it has examined factors that may have affected dementia drug prescribing, 
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This chapter presents the problem that the research conducted in this thesis seeks to 
address and an outline of the main output of this thesis: new evidence concerning 
repurposing antihypertensives for dementia prevention using genetic and non-genetic 
instrumental variable analyses. This chapter then introduces three issues that arose and 
have been addressed during the conduct of this research. They are: how to calculate 
power for instrumental variable analyses in pharmacoepidemiology; how to use 
Mendelian randomization to predict drug repurposing opportunities; and what factors 
have effected prescribing of existing dementia drugs. This chapter concludes with the 
aims and objectives of this thesis, a summary of its organization and a list of the 
associated outputs. 
 
1.2. Statement of the problem 
 
There is a substantial unmet clinical need for treatments for dementia where significant 
benefits to patients, society and the public purse can be gained. Despite this, some drug 
companies have recently withdrawn from this therapy area due to failed and costly efforts 
to find new treatments. (1,2) Drug repurposing, the identification of properties in existing 
or abandoned compounds for other clinical conditions, offers significant advantages over 
traditional drug discovery approaches. This includes immediate access to human safety 
data from the original clinical development work, which can accelerate testing in clinical 
trials, saving both time and money. (3–5)  
 
Many antihypertensive medications have been proposed as drug repurposing candidates 
for the prevention of dementia. In part, because of research to better understand several 
reports of observed associations between midlife hypertension and later-life risk of 
Alzheimer’s disease and vascular dementia. (5–8) There is also increasing recognition 
that one of the earliest pathological events in the development of Alzheimer’s disease is 
vascular dysregulation. (9) As well as suggestions that some antihypertensives, 
specifically those that block angiotensin receptor and calcium channel signalling, may 




Several observational studies have investigated repurposing antihypertensives for 
dementia prevention. (12–19) However, these studies have typically used case-control 
designs with logistic regression and cohort designs with survival analysis, both of which 
are observational study designs that may be subject to unmeasured or residual 
confounding and reverse causation. Specific concerns of observational studies are 
confounding by indication, where the reasons that a patient receives a treatment relate to 
the reasons that the patient is at an increased risk of the outcome; and healthy adherer 
bias, where patients initiating or adhering to a drug for prevention of a condition are 
more likely to be healthy. There is also potential for reverse causation due to preclinical 
or early stages of the disease, which could lead to more frequent contacts with general 
practitioners (GPs) and lead to raised blood pressure being more likely to be detected. 
This, in turn, could lead to the prescription of an antihypertensive drug in advance of 
dementia being formally diagnosed. Consequently, current evidence concerning 
repurposing antihypertensives for dementia prevention is considered inconclusive. 
 
1.3. New evidence concerning repurposing antihypertensives for dementia prevention 
using instrumental variable analysis 
 
Instrumental variable analysis, which estimates the causal effect of an exposure on an 
outcome by using a third variable (the instrument), can be robust to confounding and 
reverse causation if certain assumptions are met. That is: 
IV1. The instrument must associate with the exposure  
IV2. The instrument must only affect the outcome through the exposure 
IV3. The instrument and the outcome must have no common causes  
These assumptions can be represented on a directed acyclic graph, as shown in Figure 
1.1. Instrumental variable analysis, with other sources of evidence, can be used in a 
triangulation framework to obtain a reliable answer concerning the potential repurposing 
of antihypertensives for dementia prevention. (20) This thesis presents two forms of 
instrumental variable analysis to provide new evidence concerning this hypothesis. The 
first uses physicians’ prescribing preference as a non-genetic instrument in electronic 
health record data obtained from the United Kingdom (UK) Clinical Practice Research 
Datalink (CPRD). The second uses single nucleotide polymorphisms (SNPs) i.e. 
differences in the deoxyribonucleic acid (DNA) nucleotides between individuals, which 




antihypertensive drug classes, as a genetic instrument in an approach more commonly 
known as Mendelian randomization. The results of both these instrumental variable 
analyses have been made available via the following references. (21,22) 
 
1.4. Calculating power for instrumental variable analysis in pharmacoepidemiology 
 
Instrumental variable analysis is an increasingly popular method in the field of 
pharmacoepidemiology. (23–28) However, the power calculators that were available for 
studies using instrumental variable analysis at the start of my PhD – such as Mendelian 
randomisation power calculators – did not allow for the structure of research questions 
using non-genetic instruments (for example, physicians’ prescribing preference) in this 
field. (29,30) This is because analysis using non-genetic instruments in pharmaco-
epidemiology will typically have stronger instruments and so can detect smaller causal 
effects. Consequently, there was a need for dedicated power calculators for these type of 
research questions in pharmacoepidemiology. In this thesis, I investigate how to conduct 
Figure 1.1: A directed acyclic graph illustrating the basic instrumental variable analysis model.  
 
Directed acyclic graphs are a visual representation of a model, which represent variables by ‘nodes’ 
and the relationships between them by ‘directed edges’. (68) The graphs are defined as acyclic 
because edges cannot form ‘cycles’, whereby the edges all act in the same direction. This prevents a 
variable from being both a cause and a consequence of itself. Directed acyclic graphs are a common 
tool in epidemiology and, more specifically, causal inference when edges are given a causal 
interpretation, as they allow researchers to depict their model and its assumptions using a common 




power calculations for pharmacoepidemiological studies, which use a single binary 
instrument to analyse the causal effect of a binary exposure on a continuous outcome. I 
also provide an online calculator, as well as packages in both R and Stata, for the 
implementation of the formula by others (https://github.com/venexia/PharmIV). This 
work has been published in the International Journal of Epidemiology. (31) 
 
1.5. Using Mendelian randomization to predict drug repurposing opportunities 
 
Identification of drug repurposing opportunities can maximize the benefit of a drug. 
However, as highlighted before, the more traditional observational research methods 
used to investigate these opportunities are subject to several biases. These include 
confounding by indication, reverse causality, and missing data. In this thesis, I propose 
Mendelian randomization as a novel approach that can be used for the prediction of drug 
repurposing opportunities. Mendelian randomization addresses some of the limitations 
associated with the existing methods in this field. Furthermore, it can be applied either 
pre- or post-approval of the drug and could therefore prevent the potentially harmful 
exposure of patients in clinical trials and beyond. This thesis includes discussion of 
examples from the literature that have used Mendelian randomization to predict drug 
repurposing opportunities and covers the strengths and limitations associated with using 
this method for this purpose. There was relatively little discussion focussed on using 
Mendelian randomization for drug repurposing when I commenced my PhD and I have 
since published on this topic. (32) 
 
1.6. Factors effecting existing dementia drug prescribing 
 
Drugs for dementia have been available in England from 1997. However, since their 
launch, there have been several changes to national guidelines and initiatives that may 
have influenced prescribing. These include changes in National Institute for Health and 
Care Excellence (NICE) guidance; several government dementia strategies; the addition 
of dementia to the Quality and Outcomes Framework (QOF); and the expiry of drug 
patents. Despite this, little research had been conducted prior to my PhD into the effect 
of these events on prescribing. (33,34) In this thesis, I investigate prescribing trends in 
England since the launch of these drugs up to 1st January 2016 using data from the 




identify factors that have affected prescriptions of existing treatments that may also 
influence repurposed drug candidates in the future. However, the results from this 
analysis could also be used to identify breaks in the prescription of these drugs that could 
be exploited as natural experiments for progression studies. For example, if these drugs 
were not prescribed when the NICE guidelines stopped recommending their use between 
2006 and 2011, the progression of people diagnosed during this time who did not access 
the drugs could be compared with the progression of people diagnosed before and after 
this time who did have access to the drugs. The results presented in this chapter have 
been published in Alzheimer’s Research & Therapy. (35) 
 
1.7. Aims and objectives 
 
The objective of this thesis was to use instrumental variable analysis methods, in existing 
data sources, to triangulate evidence for repurposing antihypertensive drugs for the 
prevention of dementia.  
 
The specific aims were as follows: 
 
1. Develop a power calculator for non-genetic instrumental variable analysis studies 
in the context of pharmacoepidemiology. 
2. Describe the use of genetic instrumental variable analysis, namely Mendelian 
randomization, for predicting drug repurposing opportunities. 
3. Examine the impact of regulatory guidance and patent expiry on dementia drug 
prescribing. 
4. Investigate whether antihypertensive drugs have a causal effect on incident 
dementia using instrumental variable analysis with electronic health record data. 
5. Investigate whether antihypertensive drugs have a causal effect on incident 
dementia using instrumental variable analysis with genetic data. 
 
1.8. Organization of this thesis 
 
Chapter 2 provides the background necessary for the rest of this thesis through the 
introduction of dementia, the concept of drug repurposing, and discussion of the existing 




strengths and limitations of observational pharmacoepidemiology and explains why it 
might be preferable over ‘gold standard’ randomized controlled trials for some 
hypotheses. Chapter 3 describes instrumental variable analysis, the method utilized 
throughout this thesis, and documents the development of a power calculator for this 
method in the context of pharmacoepidemiology (Aim 1). Chapter 4 introduces the idea 
of using Mendelian randomization, a form of instrumental variable analysis that uses 
genetic variants as instruments, for drug repurposing and covers the strengths and 
limitations of this approach (Aim 2). Chapter 5 describes the CPRD and my use of this 
data source. Chapter 6 covers the current treatments available for dementia and factors 
affecting their prescription in England based on data from the CPRD (Aim 3). Chapter 7 
presents an assessment of the effects of antihypertensive drugs on dementia prevention 
using instrumental variable analysis with data from the CPRD (Aim 4); while Chapter 8 
presents an assessment of the effects of antihypertensive drugs on dementia prevention 
using instrumental variable analysis with genetic data (Aim 5). The thesis concludes with 
a discussion in Chapter 9 that brings together all the elements of this thesis and discusses 
their implications. 
 
1.9. Outputs from this thesis 
 
1.9.1. Contributions to scientific literature 
 
Contributions to scientific literature arising from this thesis are detailed below and 
provided in Appendix A. 
 
The protocol for the observational work using CPRD data to investigate drug 
repurposing opportunities is published in the BMJ Open. (36) Its contents are referenced 
in several places throughout this thesis, particularly Chapter 5: 
 
Walker VM, Davies NM, Jones T, Kehoe PG, Martin RM. Can commonly prescribed 
drugs be repurposed for the prevention or treatment of Alzheimer’s and other 
neurodegenerative diseases? Protocol for an observational cohort study in the UK 





The power calculator for instrumental variable analysis in pharmacoepidemiology, 
described in Chapter 3, is published in the International Journal of Epidemiology (31): 
 
Walker VM, Davies NM, Windmeijer F, Burgess S, Martin RM. Power calculator for 
instrumental variable analysis in pharmacoepidemiology. Int J Epidemiol. 2017 Oct 
1;46(5):1627–32. 
 
Also published in the International Journal of Epidemiology is an article discussing 
Mendelian randomization as a novel approach for the prediction of adverse drug events 
and drug repurposing opportunities (32), which formed the basis of Chapter 4: 
 
Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a 
novel approach for the prediction of adverse drug events and drug repurposing 
opportunities. Int J Epidemiol. 2017 Dec 1;46(6):2078–89. 
 
The trend analysis examining prescribing practice for drugs for dementia in the CPRD, 
presented in Chapter 6, is available from Alzheimer’s Research & Therapy (35): 
 
Walker VM, Davies NM, Kehoe PG, Martin RM. What is the impact of regulatory 
guidance and expiry of drug patents on dementia drug prescriptions in England? A trend 
analysis in the Clinical Practice Research Datalink. Alzheimer’s Research & Therapy. 
2018 May 29;10:51. 
 
The assessment of antihypertensives for dementia prevention using electronic health 
record data, reported in Chapter 7, is currently under peer review and available from 
bioRxiv (21): 
 
Walker VM, Davies NM, Martin RM, Kehoe PG. Comparison of antihypertensive drug 
classes for dementia prevention. bioRxiv. 2019 Jan 12;517482. 
 
The assessment of antihypertensives for dementia prevention using genetic data, reported 
in Chapter 8, has been made available as an advance article from the International 





Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihypertensive drugs 
for the prevention of Alzheimer’s disease: a Mendelian Randomization study. Int J 
Epidemiol. 2019 Jul 4; Advance article. 
 
1.9.2. Contributions to scientific meetings 
 
I presented the paper “Power calculator for instrumental variable analysis in 
pharmacoepidemiology”, described in Chapter 3, at the UK Administrative Data 
Research Network Annual Research Conference 2017 in Edinburgh, UK. 
 
I presented the paper “Mendelian randomization: a novel approach for the prediction of 
adverse drug events and drug repurposing opportunities”, which formed the basis of 
Chapter 4, at the University of Bristol Population Health Symposium 2016 in Bristol, UK 
and at the International Society for Pharmacoepidemiology mid-year meeting 2018 in 
Toronto, Canada. 
 
I presented posters, based on the paper “What is the impact of regulatory guidance and 
expiry of drug patents on dementia drug prescriptions in England?” detailed in Chapter 
6, at the Alzheimer’s Research UK Research Conference 2016 in Aberdeen, UK and at 
the University of Bristol brain research showcase and networking day 2018 in Bristol, 
UK. 
 
I presented “Can treatments for hypertension be repurposed for the treatment of 
dementia?” at the Society of Epidemiologic Research annual conference 2018 in 
Baltimore, United States of America (USA); at the European Congress of Epidemiology 
2018 in Lyon, France and the International Society for Pharmacoepidemiology annual 
meeting 2018 in Prague, Czech Republic. These presentations combined results from 










This chapter has three parts, the first of which concerns dementia. Specifically, I describe 
the public health problem dementia poses, the epidemiology of the condition and the 
currently available treatments. The second concerns drug repurposing. This part starts 
with an introduction to the concept of drug repurposing; followed by a description of the 
antihypertensive drugs that are of interest for this thesis; and the existing evidence for 
them as drug repurposing candidates for dementia prevention. The final part concerns 
observational pharmacoepidemiology. This covers the strengths and limitations 
compared with randomized clinical trials, which are considered the gold standard, and 
the motivation for using instrumental variable designs to analyse observational data in 
this thesis. This leads on to Chapters 3 and 4, which formally introduce instrumental 
variable analysis using electronic health record data and genetic data respectively. 
 
2.2. Public health problem  
 
There are estimated to be 50 million people living with dementia worldwide. (37) This 
includes 850,000 people in the UK. (38) As of 2015, dementia was the leading cause of 
death in the UK and “dementia is the only condition in the top 10 causes of death 
without a treatment to prevent, cure or slow its progression”. (39,40) This is despite 
investment in 1120 unique drug targets between 1995 and 2014. (3,5,41) Consequently, 
as stated in Section 1.2, there is a substantial unmet clinical need for new treatments for 
dementia where benefits to patients, society and the public purse can be gained.  
 
2.3. Epidemiology of dementia 
 
Dementia is a progressive condition, which describes several symptoms relating to 
memory loss and difficulties with thought or speech. The condition results from damage 
to the brain by other diseases and so has several different forms depending on the cause 




for approximately 62% of all cases, but other common forms include vascular dementia 
(~17%), mixed dementia (~10%) and Lewy body dementia (~4%). (42)  
 
The pathology of Alzheimer’s disease is characterised by structural changes to the brain, 
specifically the formation of amyloid plaques and neurofibrillary tangles. The amyloid 
cascade hypothesis suggests that these structures form due to over-production of 
neurotoxic forms of amyloid beta. The excess amyloid beta causes damages to nerve cells 
and forms plaques. These changes in turn cause modifications to the protein tau, which is 
associated with the building of microtubules – an important part of the structural 
integrity of neurons. Consequently, tau aggregates to form neurofibrillary tangles that 
interfere with cell function and health. The mechanisms and pathways linking amyloid 
beta and tau still remain unclear, but are the focus of much research intended to find 
effective disease modifying treatments. (43,44)  
 
Several cardiovascular risk factors in midlife have been linked with the development of 
Alzheimer’s disease in later life, though this relationship is not yet fully understood. (45–
47) As the causes of Alzheimer’s disease remain unknown, it is thought that risk factors 
may help to provide a greater insight into the biological mechanisms of the disease. 
Hypertension, hypercholesterolaemia, and type 2 diabetes are of interest as risk factors 
due to the large number of people diagnosed with these conditions and the availability of 
commonly prescribed drugs that could be potentially repurposed (Section 2.5). This 
thesis will focus on hypertension. 
 
2.4. Current dementia treatments 
 
There are currently four licensed treatments that provide symptomatic relief for patients 
with Alzheimer’s disease in the UK – three acetylcholinesterase inhibitors (donepezil, 
rivastigmine, galantamine) and one N-methyl-D-aspartate (NMDA) receptor antagonist 
(memantine). These drugs are collectively referred to as drugs for dementia in the British 
National Formulary but are licensed for use in Alzheimer’s disease only. (48) They are 
currently taken by approximately 54%, 72% and 13% of people with mild, moderate, and 
severe dementia respectively. (49) This was estimated to cost £28 million for the year 
2017 in England alone. (50) There are no drugs currently licensed for the symptomatic 




dementia with Lewy bodies or mixed dementias that include Alzheimer’s disease listed 
in the British National Formulary. (49) At present, there are still no disease-modifying or 
preventative drugs for any form of dementia. Plus, given the large number of failed 
attempts in this therapy area, the success rate for Alzheimer’s disease drug development 
is estimated to be just 0.5%. (3,5,41) This has led to some drug companies withdrawing 
from drug development for dementia. (1) As well as, the formation of ambitious large-
scale commercial and non-commercial partnerships, such as the European Prevention of 
Alzheimer’s Dementia (EPAD) Consortium, to try and overcome the cost burden to any 
single organisation. (51) 
 
2.5. Drug repurposing 
 
Given the lack of current treatments for dementia, and the significant cost of traditional 
drug development endeavours, drug repurposing is a promising alternative. The 
medicines and healthcare product regulatory agency suggest that traditional drug 
development efforts can take up to 15 years and more than a billion pounds to develop a 
drug from a chemical compound to the point where it can be sold on the pharmacy shelf. 
(52) Drug repurposing, the testing and use of existing drugs for new indications, is 
considered a time- and cost-effective alternative to these traditional methods. The key 
advantage of this technique is that the drugs considered have already been subject to the 
initial testing required for regulatory approval and, in some cases, already exist in generic 
form and so are highly economical. Consequently, drug repurposing is growing in 
popularity and many areas of medicine have already benefited from its application; 
including cancer, smoking cessation, obesity and Parkinson’s disease. (4,5) 
 
Drug repurposing opportunities can be discovered throughout the drug development 
process. However, prior to the approval of a novel drug, its risk-benefit profile cannot be 
fully known. This is because pre-approval clinical trials are principally for demonstrating 
the drug’s efficacy for its intended indication. This limits the trial’s ability to assess safety 
and identify novel indications in a number of ways. (53) Firstly, the comparatively small 
number of patients exposed to a drug during a pre-approval clinical trial means that only 
very common or very large drug effects can be detected. Secondly, the length of time that 
patients are exposed to the drug in this setting is relatively short. Thirdly, the recorded 




effects or those that are unrelated to the drug’s indication. Finally, the participants of a 
study may not represent the broad range of patients seen in clinical practice or may be 
limited in some way – for example, phase I trials have previously been restricted to male 
participants only. (54) As a result of these limitations, continued assessment of drugs 
post-approval, as is conducted in this thesis, is necessary in order to fully develop their 
profile and identify potential drug repurposing opportunities. 
 
2.6. Antihypertensive drugs  
 
This thesis will focus on whether antihypertensive drugs can be repurposed for the 
prevention of dementia. Hypertension is a mostly symptomless, chronic illness 
characterised by blood pressure in excess of 140/90 mm/Hg. A 2014 health survey for 
England found the prevalence of hypertension to be 32% among men and 27% among 
women surveyed. (55) Most of these cases are examples of ‘essential hypertension’ – this 
means the cause of excess pressure is unknown. Though the cause of essential 
hypertension is unknown, the condition is a known risk factor for many other diseases, 
including Alzheimer’s disease and vascular dementia. (56,57) This is thought to be due to 
the strain it puts on the heart and vascular system, which can in turn cause or relate to 
the development of cerebrovascular disease and, in a proportion of cases, different forms 
of stroke. Treatments for hypertension are among the most commonly prescribed in 
primary care and are used by 83% of men and 89% of women who are diagnosed with 
the condition, according to the 2014 health survey for England. (55,58) There are several 
drug classes available for the treatment of the condition, including beta-adrenoceptor 
blockers, calcium channel blockers, a range of diuretics, and drugs affecting the renin-
angiotensin system. These drug classes have variable effects on blood pressure but are 
reported, on average, to reduce systolic blood pressure by 9mmHg. (59)  
 
Many antihypertensive drugs have been proposed as drug repurposing candidates for the 
prevention of dementia. Most notably, they were one of the key treatment groups 
highlighted in a consensus study of experts conducted by Corbett et al in 2012. (5) As 
discussed in Section 1.2, there are several reasons for this. These include the observed 
associations between midlife hypertension and later-life risk of Alzheimer’s disease and 
vascular dementia (5–8); the increased recognition of the role of vascular dysregulation in 




blood-pressure lowering and related to other pathological processes in Alzheimer’s 
disease, for certain drug classes. (9–11)  
 
2.7. Current evidence concerning repurposing antihypertensives 
 
A systematic review and meta-analysis conducted in mid-2018 by Larsson et al 
summarized the evidence concerning repurposing antihypertensives for dementia 
prevention available at that time. (12) The results from this meta-analysis are presented in 
Figure 2.1. Larsson et al identified five randomized controlled trials and 13 prospective 
studies that had compared antihypertensives against non-use for dementia. They also 
identified a further seven observational studies that had compared antihypertensive drug 
classes against each other, but no trials. (12–19) Four out of the five trials that compared 
antihypertensives against non-use had point estimates that suggested a protective effect, 
however three of these four trials failed to exclude the null. This resulted in the meta-
analysis finding an overall relative risk of 0.84 (95% confidence interval (CI): 0.69 to 
1.02). The results from observational studies were similar with a relative risk of 0.77 (95% 
CI: 0.58 to 1.02) for dementia based on three comparable studies and 0.78 (95% CI: 0.66 
to 0.91) for Alzheimer’s disease based on five comparable studies. The evidence for 
comparing antihypertensives was mixed with one study (of three) suggesting angiotensin-
converting enzyme inhibitors were protective (13–15); three studies (of four) suggesting 
angiotensin-II receptor blockers were protective (15–18); and one study (of one) 
suggesting calcium channel blockers were protective (19) when compared against other 
antihypertensive drug classes. Larsson et al concluded their review by stating “available 
evidence from RCTs and prospective studies indicates that antihypertensive therapy 
might have a role in preventing dementia and AD”. However, there are several issues 
with the evidence collected to date. In particular, the fact that most of the trials included 
in the meta-analysis were from populations with high cardiovascular morbidity and were 
designed around cardiovascular related primary outcomes. This could mean that the 
proportion of dementia cases that derived from vascular mechanisms will be 







Figure 2.1: Summary of results concerning the use of antihypertensives to prevent dementia and 
Alzheimer’s disease from the Larsson et al (2018) meta-analysis. 
 
Note that the number of studies in the meta-analysis may differ from the number of studies reported in 
the systematic review. Reproduced from Larsson, S. C., & Markus, H. S. (2018). Does Treating 
Vascular Risk Factors Prevent Dementia and Alzheimer’s Disease? A Systematic Review and Meta-





Since the publication of this systematic review and meta-analysis, research has continued 
into the possible repurposing of antihypertensives for dementia prevention and two key 
new studies have been published. The first was a study by Barthold et al that compared 
Alzheimer’s disease incidence between users of renin-angiotensin system acting drug 
classes and non-renin-angiotensin system acting drug classes across sex, race, and ethnic 
groups in the USA. (62) This study found that angiotensin-II receptor blockers may 
reduce the risk of Alzheimer’s disease in certain groups, namely white and black women 
and white men. This study is important because evidence to date for the use of these 
drugs to prevent dementia in non-white populations has been limited; renin-angiotensin 
system acting drugs are reported to function differently in non-Caucasians; and rates of 
dementia are higher among African Americans. (62) The second key study was the 
SPRINT-MIND trial, which assessed the effect of intensive vs standard blood pressure 
control using a range of antihypertensive medications on probable dementia, mild 
cognitive impairment and a composite outcome combining probable dementia and mild 
cognitive impairment, have also been released. (63) The trial found evidence to suggest 
that intensive blood pressure control was beneficial for the mild cognitive impairment 
and composite outcomes. Meanwhile, the estimate for the primary cognitive outcome of 
probable dementia included the null within its CI but may have been underpowered due 
to the early termination of the trial. There are also a number of trials concerning 
repurposing antihypertensives for dementia prevention currently ongoing, which are 
summarized in Table 2.1. 
 
Given the lack of conclusive trial evidence published to date, and the limitations of the 
conventional observational study designs (Section 2.8.1) used to date, further research 
into the potential repurposing of antihypertensive drugs for the prevention of dementia is 
warranted.  
 
2.8. Observational pharmacoepidemiology  
 
As described in the previous section, several observational studies have investigated 
repurposing antihypertensives for dementia prevention to date. However, these studies 
have used case-control designs with logistic regression and cohort designs with survival 
analysis, which may be subject to certain biases. Below I describe several key limitations 




is followed by several strengths, which will help motivate my choice to use observational 
data and causal inference to provide new evidence concerning the potential repurposing 
of antihypertensives for dementia prevention. The strengths and limitations are 
summarized in Table 2.2. 







• Allows measurement of effectiveness 
• Long follow up 
• Unexpected effects can be studied 
• Large sample size 
• Heterogeneous treatment effects can be detected 








s • Ascertainment bias 
• Collider bias 
• Immortal time bias 
• Confounding by indication 
• Time dependent confounding 
 
 
Table 2.1: Currently ongoing trials concerning repurposing antihypertensives for dementia 
prevention. 
Trial Name  Trial ID 
Treatment 
comparison 





Candesartan's effects on Alzheimer's disease 




Health evaluation in African Americans using 




Reducing pathology in Alzheimer's disease 




Risk reduction for Alzheimer's disease (rrAD) NCT02913664 
Losartan vs 
amlodipine  
Telmisartan vs perindopril in hypertensive 






Reproduced from Kehoe, P. G. (2018). The coming of age of the angiotensin hypothesis in 
Alzheimer’s disease: Progress toward disease prevention and treatment? Journal of Alzheimer’s 






2.8.1. Limitations of observational pharmacoepidemiology 
 
2.8.1.1. Ascertainment bias 
 
Ascertainment bias results from distortion in the number of recorded events. (64) For 
example: patients with chronic conditions, such as diabetes, are more likely to see a GP 
frequently. This in turn increases their opportunity of receiving other diagnoses, such as 
dementia. In this situation, controlling for consultation rate can help to minimize this 
form of bias. 
 
2.8.1.2. Collider bias 
 
A collider is a variable that is a common effect of two other variables. If the common 
effect is conditioned on in the analysis, an association is induced between the two 
variables, leading to bias within the results. (65) This is illustrated in Figure 2.2. An 
example of collider bias in a pharmacoepidemiological study would be conditioning on 
an event that happened as a result of a patient’s prescription, as this could obscure the 
effect of the prescribed drug. This is because the measured outcome results from both the 
prescribed drug and the event that occurred due to the prescribed drug. To prevent this 
form of bias from affecting results, measures such as only using data inputted prior to the 
index date to define covariates can be implemented. (66) 
Figure 2.2: Illustration of collider bias. 
 
Two coins are tossed independently. If either coin is a head, a bell rings. If we know that one of the 
coin tosses was a tails and we heard the bell, then we can infer that the other coin toss must have 
been a head. The bell is therefore a collider and an association is induced between the two 
independent coin tosses when it is conditioned on. Reproduced from Gage, S. H., Davey Smith, G., 
Ware, J. J., Flint, J., & Munafò, M. R. (2016). G = E: What GWAS Can Tell Us about the 






2.8.1.3. Immortal time bias 
 
Immortal time is a period of follow up in which an event cannot occur. This causes bias 
by altering the ratio of ‘exposed’ and ‘unexposed’ time considered in an analysis. 
Immortal time bias has two forms: excluded immortal time bias or misclassified 
immortal time bias, which are illustrated in Figure 2.3. (67) Excluded immortal time bias 
occurs when follow up starts on an inconsistent index date. For example, following a 
patient from exposure to the treatment of interest ensures they have survived long enough 
to receive that treatment i.e. they are immortal in the period prior to follow up. To 
resolve this, follow up should start on a consistent index date, such as diagnosis of the 
treatment indication, and any time prior to exposure is considered ‘unexposed’. 
Misclassified immortal time bias occurs when periods of follow up are incorrectly 
categorised as ‘exposed’ or ‘unexposed’. For example, assigning a patient to the 
‘exposed’ group from cohort entry instead of first exposure to the treatment of interest 
will result in an immortal period between these two dates. To avoid this type of bias, 
follow up of patients who receive the treatment of interest should include both ‘exposed’ 
and ‘unexposed’ periods according to date of treatment. (67–69) 
Figure 2.3: Illustration of misclassified and excluded immortal time bias. 
 
Reproduced from Suissa, S. (2007). Immortal time bias in observational studies of drug effects. 




2.8.1.4. Confounding by indication 
 
Confounding by indication occurs when the factors predisposing a patient to receive 
treatment are the same factors that predispose them to have an outcome. This induces an 
artificial association between the exposure and the outcome, as illustrated in Figure 2.4. 
For example, COX-2 inhibitors are a class of non-steroidal anti-inflammatory drugs that 
are marketed as being less likely to cause gastrointestinal adverse effects and so are more 
likely to be prescribed to people at increased risk of such effects. (70,71) Confounding by 
indication can be minimized by ensuring the exchangeability of patients between the 
exposed and unexposed groups and using methods such as instrumental variable 
analysis. 
 
2.8.1.5. Time dependent confounding 
 
Time dependent confounders are confounders that are both caused by the exposure and 
effected by the exposure. For example, consider comparing two drugs for 
hypercholesterolaemia with the goal of reducing coronary heart disease risk. Low density 
lipoprotein (LDL) cholesterol levels will naturally vary over time within an individual. 
LDL cholesterol will also be used to determine whether treatment is required, whether 
the treatment has worked, and whether future treatment is required. Consequently, 
values of LDL cholesterol measured after exposure to the drugs will be causally related to 
the exposure, which occurred before, and the outcome, which will occur afterwards. This 
can be difficult to overcome using conventional methods, however methods such as 
marginal structural models have been developed to overcome this type of confounding. 
(72) 





2.8.2. Strengths of observational pharmacoepidemiology 
 
2.8.2.1. Allows measurement of effectiveness 
 
Efficacy refers to how well a treatment works in the context of a randomized controlled 
trial, while effectiveness refers to how well a treatment works in the actual population. 
Randomized controlled trials measure efficacy, as the participants must meet strict 
criteria in order to be included. Observational studies can be used to estimate 
effectiveness. The advantage of measuring effectiveness over efficacy is that it gives a 
measure of how well the treatment would work in ‘reality’, rather than in an ideal or 
more highly controlled clinical trial setting. In particular, it allows the study of treatment 
effects among the general population rather than a randomized controlled trial 
population, which may not be representative of the general population. This is an 
important factor when considering the value of a treatment and the guidelines for its 
prescription. 
 
2.8.2.2. Long follow up 
 
Observational studies can have much longer follow-up than other study designs - this is 
especially true of observational studies using routinely collected data, such as the CPRD 
(Chapter 5). The cost of obtaining observational data compared to the cost of obtaining 
the information in a randomized controlled trial, which will have strict data collection 
policies and may require specially trained staff, means that the funds for such research go 
much further. Furthermore, the burden on participants is less, as they are not required to 
follow the strict treatment plans used in randomized controlled trials but instead operate 
as they would normally. 
 
2.8.2.3. Unexpected effects can be studied 
 
Observational studies can have the scope to detect unexpected effects as additional data 
is collected. This is not necessarily the case for randomized controlled trials where only 
data relevant to the outcome of interest and the covariates is collected. Unexpected 




indication it was intended for – or unfavourable – such as a drug with a rare adverse side 
effect – however both types of effect are important in the evaluation of a drugs’ safety.  
 
2.8.2.4. Large sample size 
 
The relatively low cost of data collection in observational studies compared with 
randomized controlled trials means large sample sizes are achievable. Again, this is 
especially true of routinely collected data, such as the CPRD (Chapter 5). Large sample 
sizes have many benefits including greater statistical power to detect treatment effects. 
This is important as even small treatment effects can have a large clinical impact for 
patients. A large sample size also allows for the identification of rare outcomes, which 
can be missed in small samples due to their infrequency. Although rare, these outcomes 
still need to be considered for treatment safety – especially for commonly prescribed 
treatments. 
 
2.8.2.5. Heterogeneous treatment effects can be detected 
 
Treatments for which the effect varies according to who receives it are heterogeneous. 
Observational studies allow the identification of subgroups of a population that may 
benefit more, or less, from a treatment. This is because they tend to collect data on a 
broader range of subjects where groups of patients are distinguishable from each other. 
Treatments with heterogeneous effects can appear to have no effect if the harmful effect 
caused to one group of patients balances the beneficial effect to another group. This leads 
to missed beneficial effects that could be improving the lives of patients. 
 
2.8.2.6. Reduced cost compared to randomized controlled trials 
 
Data collection for observational studies can cost much less than the comparable 
randomized controlled trials. The three main constraints on cost are the number of 
patients i.e. the sample size; the amount of information collected about a patient i.e. the 
covariates; and the amount of time a patient is followed i.e. the follow-up. For a given 
cost, an observational study could provide more information on one or more of these 
elements than the randomized controlled trial counterpart could. Alternatively, 




obtained from an observational study at a cost saving. This however must be balanced 
with the fact that in a trial you can specify the variables of interest and obtain highly 
specific information on them, whereas routinely collected data is not intended for 
research and so does not allow such specification. 
 
2.9. Motivation for using instrumental variable designs 
 
Typically, new interventions are investigated using randomized controlled trials, whereby 
patients are assigned to either the treatment of interest or a placebo and then compared. 
In observational pharmacoepidemiology, drug interventions are investigated without 
assignment to treatment, using existing data sources. The former is considered the gold 
standard; however, it is not always ethical or practical to intervene. For example, to 
assess the effect of using antihypertensive treatments in midlife on later life risk of 
dementia would require a very long follow-up and consequently be very costly. For these 
reasons, I will be using observational data. However, there is an argument for emulating 
the randomized controlled design so that I can take advantage of its features, such as the 
concept of randomization. (73) Randomisation is used to minimize biases, such as those 
described in Section 2.8.1, as the random assignment ensures an equal balance of 
covariates between the two groups. This means any difference between the treatment and 
control groups can be attributed to the treatment. Instrumental variable analysis, which 
will be described fully in Chapter 3, estimates the average causal effect of an exposure on 
an outcome by considering their association with a third variable, known as the 
instrument or instrumental variable. The randomization assignment in a double-blind 
randomized controlled trial is an example of an instrument. In this thesis, I will use 
‘randomization-like’ variables as instruments to analyse two forms of observational data: 
electronic health record data and genetic data. If these variables meet the instrument 
conditions provided in Section 3.2, then they should not be subject to the confounding 
and reverse causation issues that may have affected the observational studies conducted 









In this chapter, I introduced the public health problem that this research relates to – 
specifically, the continued lack of treatment options for the prevention of dementia 
despite the large numbers of people diagnosed with the condition each year. I then 
summarized the epidemiology of dementia and introduced the four existing treatments 
that can only address the symptoms of the condition. Further discussion of these 
treatments can be found in Chapter 6, which examines how these treatments are 
prescribed in England and the factors affecting their prescription. The chapter then moves 
onto discussion of drug repurposing and antihypertensive drugs as potential candidates 
for dementia prevention. This summarizes the existing evidence for this hypothesis, prior 
to the assessments conducted within this thesis. The final sections concern observational 
pharmacoepidemiology and my motivation for using instrumental variable designs to 
analyse such data. These sections include discussion of the strengths and limitations of 
observational pharmacoepidemiology, including that these methods can be implemented 
when randomized controlled trials are not feasible or ethical and they can have much 





Chapter 3. Methods: Instrumental variable analysis using 




The analysis of electronic health records in this thesis focuses on instrumental variable 
estimation. Instrumental variable analysis estimates the average causal effect of an 
exposure on an outcome by considering their association with a third variable, known as 
the instrument or instrumental variable. This approach accounts for confounding of the 
exposure-outcome association, regardless of whether it was measured, and is often used 
when estimating unmeasurable exposure-outcome associations. (24) To be an 
instrument, a variable must meet three conditions, which are discussed in detail in 
Section 3.2.1. When met, these conditions allow the instrument to be used to identify 
bounds for the average causal effect. (74) This is known as partial identification of causal 
effects. A fourth assumption concerning the instrument-outcome association is required 
to obtain a point estimate of the average causal effect. Commonly used assumptions are 
effect homogeneity and monotonicity, which are covered in Section 3.2.2. (74) Together, 
the four assumptions allow the effect of the exposure on the outcome to be estimated 
using the instrument-outcome and instrument-exposure associations as follows: 
 





The instrumental variable analysis model discussed here is often represented on a 
directed acyclic graph, as was previously demonstrated in Figure 1.1.  
 
There are many instruments to choose from when conducting an instrumental variable 
analysis. This thesis will use physicians’ prescribing preference as an instrument to proxy 
drug exposure using data from electronic health records. A description of this instrument 
can be found in Section 3.3. This thesis will also use Mendelian randomization. 
Mendelian randomization is a form of instrumental variable analysis that uses one or 





The current chapter will introduce the instrument assumptions, discuss the use of 
physicians’ prescribing preference as an instrument when using electronic health record 
data, and conclude with the development of a power calculator for instrumental variable 
analysis in pharmacoepidemiology. The motivation for the latter part of this chapter was 
the lack of literature concerning power calculations for studies in pharmacoepidemiology 
available at the start of my PhD, as most power calculators available until this point were 
developed for Mendelian randomization. I therefore derived and validated a power 
formula for studies using a single binary instrument to analyse the causal effect of a 
binary exposure on a continuous outcome. This work was completed under the 
supervision of Neil Davies, Frank Windmeijer, Stephen Burgess, and Richard Martin. 
The results have been published in the International Journal of Epidemiology. (86) 
 
3.2. Instrument assumptions 
 
3.2.1. The three instrument assumptions 
 
To conduct a valid instrumental variable analysis, the instrument must satisfy the 
following three conditions: 
IV1. The instrument must associate with the exposure  
IV2. The instrument must only affect the outcome through the exposure 
IV3. The instrument and the outcome must have no common causes  
These conditions are known as relevance, the exclusion restriction and independence 
and, as mentioned in the introduction, allow the identification of bounds for the average 
causal effect. (23) 
 
Relevance is the only instrument assumption of the three that is directly testable. This is 
done by regressing the exposure on the instrument to test whether they are associated. 
The magnitude of this association reflects the strength of the instrument for the 
instrumental variable analysis. In otherwise identical studies, stronger instruments will 
provide more power to detect effects and result in greater precision. The remaining 
instrument assumptions, namely the exclusion restriction and independence, cannot be 





3.2.2. The fourth instrument assumption 
 
As highlighted earlier, a fourth assumption, such as effect homogeneity or monotonicity, 
is required to refine the bounds for the average causal effect to a point estimate. Before I 
discuss the options for this assumption, I would like to introduce the following terms that 
will aid the explanation. Consider a binary instrument, 𝑍, to proxy a binary exposure, 𝑋. 
In this setup, the population can be separated into four subpopulations, as shown in 
Table 3.1. These subpopulations are unlikely to be identifiable in the data as it is usually 
unknown what the individual would have done if they received the alternate assignment 
however, they are relevant to the discussion of the effect we will obtain under the 
different fourth assumptions. (74). 
 
3.2.2.1. Effect homogeneity 
 
The assumption of effect homogeneity holds if the effect of the exposure on the outcome 
is the same for all individuals. For example, consider testing a new drug for the treatment 
of hypertension. The homogenous treatment effect assumptions require that the 
treatment causes a specific change in systolic blood pressure, say a 10mmHg reduction, 
for all individuals regardless of all other factors that may affect systolic blood pressure, 
such as weight and alcohol intake. This is rarely plausible and so weaker versions of the 
assumption have been derived, such as the assumption of no effect modification. 
Consider a binary instrument to proxy a binary exposure. The no effect modification 
assumption states “the average causal effect on the additive scale is equal by levels of Z 
[the instrument] in both the treated and in the untreated”. (74) This assumption can also 
be made using a multiplicative, rather than an additive, scale.  
 
Table 3.1: Subpopulations in an instrumental variable analysis with a binary instrument and 
binary exposure. 
 
Exposure received when the 
instrument 𝑍 = 0 
Exposure received when the 
instrument 𝑍 = 1 
Always-takers 1 1 
Never-takers 0 0 
Compliers 0 1 





Hernán and Robins (2006) have shown that effect homogeneity is an implausible 
assumption for binary outcomes, such as those used in this thesis. This is because 
heterogenous effects will always exist for a binary outcome unless one of three situations 
occur. That is: the treatment causes the outcome in the entire population; the treatment 
prevents the outcome in the entire population; or the treatment has no effect on the 
outcome. (23) I will therefore use an alternative fourth point-identifying assumption, 
monotonicity, which is discussed below, for my analysis. 
 
3.2.2.2. Monotonicity  
 
The assumption of monotonicity holds if the exposure received when the instrument 𝑍 =
1 is greater than or equal to the exposure received when the instrument 𝑍 = 0 for all 
individuals. In terms of the subpopulations defined in Table 3.1, this means there are no 
defiers. When this is the case, the instrumental variable estimate represents the average 
causal effect of the exposure on the outcome among the compliers – known as the local 
average treatment effect. (75) This is because the weighted instrument-outcome 
association in each of the other subpopulations is now zero, as there are no defiers and 
neither the never-takers or the always-takers are influenced by the instrument. 
Monotonicity can be a more reasonable assumption than effect homogeneity in some 
circumstances – for example, when considering a binary outcome as in the analyses in 
this thesis. 
 
As for all assumptions, there are limitations to assuming monotonicity as the fourth 
instrument assumption. Firstly, it is not always plausible to assume that there are no 
defiers in an analysis. (74,75) In addition, there may be concerns regarding the relevance 
of an estimate that applies to compliers only. This is because compliers are rarely 
identifiable in the population and so it is difficult to target those for whom the estimate 
applies. Also, policy decisions apply to the whole population, which will include non-
compliers, and so the estimate may not reflect the average treatment effect observed in 






3.3. Physicians’ prescribing preference 
 
Physicians’ prescribing preference is a common choice of instrumental variable in 
pharmacoepidemiology. (27,28,76–79) It potentially meets the three instrument 
conditions as prescribing preference effects the prescription issued by the physician (IV1: 
relevance), it is unlikely to relate to the patient’s outcome other than through the 
prescription issued (IV2: exclusion restriction) and it is not likely to share a cause with 
the patient’s outcome (IV3: independence). A directed acyclic graph illustrating these 
assumptions in the context of the study presented in Chapter 7 is provided in Figure 7.2. 
A visual representation of how instrumental variable analysis using this instrument can 
be thought of as analogous to a randomized controlled trial is provided in Figure 3.1.  
 
In this thesis, I will use physicians’ prescribing preference defined by the past seven 
prescriptions issued by the physician as an instrument for exposure. This will give a score 
between zero and seven that indicates how many of the previous prescriptions have been 
in favour of the treatment of interest rather than the control treatment. I opted to use the 
instrument in a categorical form to improve instrument strength, however this instrument 
is often used in a binary form. For this, the instrument takes a value of one if the 
physician prescribed the treatment of interest more than the control treatment and a 
value of zero if the physician prescribed the control treatment more than the treatment of 
interest. Note that an odd number of prescriptions should be used to prevent ties. In the 
following section, I discuss the development of a power calculator for analyses using 
binary instruments such as this. I hope to develop the calculator further in the future so 
that it is applicable to analyses using categorical and continuous instruments however, in 
the meantime, it can be used to provide conservative power estimates for such analyses 






Figure 3.1: Illustration showing how instrumental variable analysis using physicians’ prescribing 
preference as an instrument can be thought of as analogous to a randomized controlled trial. 
 
Naturally, physicians’ will favour drug A or drug B and this will affect their prescribing. 
Instrumental variable analysis therefore uses this preference, which is unlikely to share a cause with 
the patient’s outcome because patients have relatively little choice over which physician they see or 








Pharmacoepidemiological studies risk irrelevance if they are insufficiently powered to 
detect clinically meaningful treatment effects. Prior to starting a study, the statistical 
power to calculate a given treatment effect should ideally be calculated. This type of 
calculation is becoming increasingly important for grant and data request applications, 
which look to value the contribution of such studies, and is a requirement when applying 
for data from the CPRD – the main data source for this thesis (Chapter 5). However, 
when I applied for my CPRD data, there were not power calculators available for 
pharmacoepidemiological studies using instrumental variable analysis. This was the 
motivation for the final part of this chapter. Here, I present the derivation and validation 
of a power formula for studies using a single binary instrument to analyse the causal 
effect of a binary exposure on a continuous outcome in the context of 
pharmacoepidemiology. The code for this section is available from GitHub: 
https://github.com/venexia/PharmIV. 
 
3.4.2. Formula derivation 
 
The instrumental variable analysis under consideration requires the following three 
variables; namely a binary instrument 𝑍, a binary exposure 𝑋 and a continuous outcome 
𝑌. The outcome for patient 𝑖, for 𝑖 = 1, … , 𝑛, is modelled as follows: 
 
𝑌𝑖 = 𝛼 + 𝛽𝑋𝑖 + 𝑈𝑖 
 
where 𝑈𝑖 is a zero-mean error term containing unobserved confounders, determining 
both the outcome 𝑌𝑖 and the treatment 𝑋𝑖. The instrument 𝑍𝑖 affects treatment 𝑋𝑖, but is 






Let ?̃?𝑖 = 𝑌𝑖 − ?̅?, ?̃?𝑖 = 𝑋𝑖 − ?̅? and ?̃?𝑖 = 𝑍𝑖 − ?̅?, where ?̅?, ?̅? and ?̅? are sample averages. 
Denote by ?̃?, ?̃? and ?̃? the 𝑛-vectors of observations on ?̃?𝑖, ?̃?𝑖 and ?̃?𝑖 respectively. The two-
stage least squares (2SLS) estimator of 𝛽 is then given by: 
 
?̂? = (?̃?′?̃?)−1?̃?′?̃?. 
 





where 𝑃𝑧 = ?̃?(?̃?′?̃?)
−1?̃?′ and 𝜎2 = 𝐸(𝑈𝑖
2) is the residual variance. Note that conditional 




2 for 𝑖 = 1, … , 𝑛. 
 
Consider the term ?̃?′𝑃𝑧?̃?: 
 
?̃?′𝑃𝑧?̃? = ?̃?′?̃?(?̃?′?̃?)


























− 𝑋𝑍̅̅ ̅̅ ) ≈ 𝑝𝑍(𝑝𝑋𝑍 − 𝑝𝑋) 
 












Now consider the instrumental variable estimator of β. Using the asymptotic distribution 
?̂?~ 𝑁(𝛽, 𝜎2(?̃?′𝑃𝑧?̃?)
−1), the distribution of the t-test statistic under the null hypothesis 























The null hypothesis is rejected if |𝑡| > 𝑐𝛼 where 𝑐𝛼 is the critical value at significance 
level 𝛼. 
 
The power is the probability the test statistic will exceed the critical value, which is: 
 
𝑃(𝑡 > 𝑐𝛼) + 𝑃(𝑡 < −𝑐𝛼) =  Φ (−𝑐𝛼 +
𝛿
𝜎√(?̃?′𝑃𝑧?̃?)−1





where Φ(𝑠) is the cumulative standard normal distribution function evaluated at 𝑠. 
Power therefore increases as the value of 𝜎 decreases and/or the value of ?̃?′𝑃𝑧?̃? increases.  
 
By substituting ?̃?′𝑃𝑧?̃? and simplifying, you obtain the following formula for power: 
 
Power =  Φ (−𝑐𝛼 +
𝛿(𝑝𝑍(𝑝𝑋𝑍 − 𝑝𝑋))√𝑛
𝜎√𝑝𝑍(1 − 𝑝𝑍)









The formula requires a total of seven parameters to be specified. This includes four 
parameters that must always be specified - these are the significance level, 𝛼; the size of 
the causal effect, 𝛿; the residual variance, 𝜎2 = 𝐸(𝑈𝑖
2); and the sample size, 𝑛. As well as 
three that can be chosen from the following four parameters: 
 
• The frequency of the instrument, 𝑝𝑍 = 𝑃(𝑍 = 1) 
• The frequency of exposure, 𝑝𝑋 = 𝑃(𝑋 = 1) 
• The probability of exposure given the instrument 𝑍 = 1, 𝑝𝑋𝑍 = 𝑃(𝑋 = 1|𝑍 = 1) 
• The probability of exposure given the instrument 𝑍 = 0, 𝑝𝑋𝑍 = 𝑃(𝑋 = 1|𝑍 = 0) 
 
The chosen parameters must be specified so that the following holds:  
 
𝑃(𝑋 = 1) = 𝑃(𝑋 = 1|𝑍 = 0)𝑃(𝑍 = 0) + 𝑃(𝑋 = 1|𝑍 = 1)𝑃(𝑍 = 1) 
 
The formula for power is available for use via an online calculator, which can be found 
at https://venexia.shinyapps.io/PharmIV/. The packages for R and Stata can be 
downloaded from https://github.com/venexia/PharmIV. 
 
Note that the frequency of exposure in an instrumental variable analysis of this type is 
likely to be higher than a general population study because a drug is compared against 
one or more other drugs in a population of people with the indication for these 
treatments. General population studies on the other hand tend to compare a population 
who received the drug of interest with a population who did not receive it and 
consequently the frequency of exposure is generally much lower. The effect of varying 
the parameters within the formula on a study’s power is best presented graphically. 
Figure 3.2 illustrates an example of the effect of the frequency of the exposure 𝑝𝑋 =
𝑃(𝑋 = 1) on the power of a study to detect a causal effect of δ = −0.150 using an 
instrument with a frequency of 𝑝𝑍 = 0.200, a residual variance of 𝜎
2 = 1 and a sample 
size of up to 30,000 participants. Both increasing the frequency of exposure up to 50% 





Figure 3.2: Illustration of the effect of varying the input parameters on the power formula I proposed. 
 
 
The above power curves have been calculated for several values of the frequency of exposure 𝑝𝑋 = 𝑃(𝑋 = 1) to show the effect on the power of a study to detect a 
causal effect of δ = −0.150 using an instrument with a frequency of 𝑝𝑍 = 0.200, a residual variance of 𝜎




3.4.3. Formula validation 
 
To validate the power formula, I conducted a simulation by defining the three variables 
necessary to conduct instrumental variable analysis with a single instrumental variable as 
follows: 
 
Instrument: 𝑍𝑖  ~ Binomial(1, 𝑝𝑍)  
 
Exposure: 𝑋𝑖 ~ {
0, if 𝑐0 + 𝑍𝑖(𝑐1 − 𝑐0) +  𝑉𝑖  ≤ 0
1, if 𝑐0 + 𝑍𝑖(𝑐1 − 𝑐0) +  𝑉𝑖 > 0
  
 
Outcome: 𝑌𝑖 ~ 𝛿𝑋𝑖 + 𝑈𝑖  
 
Where 𝑝𝑍 = 𝑃(𝑍 = 1) is the frequency of the instrument, cj = Ф
−1(P(𝑋 = 1|𝑍 = 𝑗)) for 
𝑗 = 0,1 are the inverse cumulative standard normal distribution, or quantile, functions of 
the conditional probabilities of exposure given the instrument, δ is the causal effect, and 
𝑈𝑖 and 𝑉𝑖 are standard normally distributed error terms with covariance 𝜌.  
 
The formula uses a binary instrument, binary exposure and continuous outcome and so 
the above variables were simulated to recreate data of this form. The instrument 𝑍 is 
modelled by a binomial distribution parameterised by its frequency 𝑝𝑍 = 𝑃(𝑍 = 1). This 
ensures a binary variable with the correct probability of success. The exposure 𝑋 is also 
binary but is modelled using a threshold model. The variability in the equation for the 
exposure comes from the normally distributed error term 𝑉𝑖. The use of the model 
equation allows the exposure 𝑋 to be associated with the instrument 𝑍. The outcome 𝑌 is 
modelled by its model equation 𝑌𝑖 = 𝛿𝑋𝑖 + 𝑈𝑖. In the model, the instrument is valid as 
the outcome 𝑌 is only associated with the exposure 𝑋, as dictated by the causal effect 𝛿, 
and is not associated with the instrument 𝑍 other than through the exposure 𝑋. 
 
Using the generated data, I performed an instrumental variable analysis using the 
command ivreg2 in Stata. (80) From this analysis, I recorded the coefficient of the 
exposure 𝑋 with the 95% confidence interval. I then counted the number of simulations 




of simulations to determine the power. By running the simulation and calculating the 
formula using the same parameters, I was able to validate the formula against the 
simulation. 
 
The power calculated from both the simulation and the formula for several parameter 
combinations is presented in Table 3.2. The table contains 27 different simulations, and 
each was repeated 10,000 times. The simulations consider each combination of three 
values of the frequency of exposure, 𝑝𝑋 =  0.100, 0.250, 0.500; three values of the 
probability of exposure given the instrument 𝑍 = 1, 𝑝𝑋𝑍 = 0.150, 0.300, 0.450; and three 
values of the sample size, 𝑁 = 10000, 20000, 30000. I set the frequency of the 
instrument, 𝑝𝑍 = 0.200; the causal effect, 𝛿 = −0.150; the residual variance, 𝜎
2 = 1; and 
calculated 𝑃(𝑋 = 1|𝑍 = 0) according to the following equation: 
 
𝑃(𝑋 = 1|𝑍 = 0) =
𝑃(𝑋 = 1) − 𝑃(𝑋 = 1|𝑍 = 1)𝑃(𝑍 = 1)






The formula and the simulation consistently provide similar results with an absolute 
mean difference of 0.4% for the parameter combinations presented. There is also no 
discernible pattern in the differences suggesting systematic bias is not present. Further to 
this, the power is consistent with its behaviour in other established power calculations. 
For example, increasing sample size universally improves power for all parameter 
combinations. 
 
The effect of confounding was removed as a parameter from the formula because the 
power was insensitive to its value in the simulation setting. This is demonstrated in Table 
3.3 that shows the simulation results for the same analysis with the effect of confounding 
taking different values between 0 and 1. Without accounting for the effect of 
confounding, the formula estimates the power of this analysis to be 32.3%. For the values 
of the effect of confounding listed, the simulation estimates power between 30.7% and 
33.1%. As the power estimated by the formula lies within this interval, and the power 
estimated by the simulation is not monotonic for increasing values of the effect of 






Table 3.2: Comparison of power as calculated by the power formula I proposed and by simulation. 
𝒑𝑿 𝒑𝑿𝒁 
10,000 patients 20,000 patients 30,000 patients 
Formula Simulation Formula Simulation Formula Simulation 
0.100 
0.150 6.6% 6.1% 8.3% 7.9% 10.0% 9.8% 
0.300 32.3% 33.3% 56.4% 55.5% 73.8% 73.9% 
0.450 74.7% 75.6% 96.0% 95.9% 99.5% 99.5% 
0.250 
0.150 11.7% 11.4% 18.6% 18.3% 25.5% 25.5% 
0.300 6.6% 5.4% 8.3% 7.9% 10.0% 9.8% 
0.450 32.3% 32.8% 56.4% 56.1% 73.8% 73.7% 
0.500 
0.150 74.7% 74.2% 96.0% 95.9% 99.5% 99.6% 
0.300 32.3% 32.5% 56.4% 57.1% 73.8% 73.7% 
0.450 6.6% 5.0% 8.3% 7.2% 10.0% 10.1% 
 
The above results are based on an instrumental variable analysis where the significance level, 𝛼 =
0.05; the size of the causal effect, 𝛿 = −0.150; the residual variance, 𝜎2 = 1; and the frequency of 
the instrument, 𝑝𝑍 = 0.200. 
 
Table 3.3: The effect of confounding on power in the power formula simulation. 













The above results are based on an instrumental variable analysis where the significance level, 𝛼 =
0.05; the size of the causal effect, 𝛿 = −0.150; the residual variance, 𝜎2 = 1; the sample size, 𝑛 =
10,000; the frequency of the instrument, 𝑝𝑍 = 0.200; the frequency of exposure, 𝑝𝑋 = 0.100; and 
the probability of exposure given the instrument 𝑍 = 1, 𝑝𝑋𝑍 = 0.300. The formula estimates the 







As for any power calculation, you are limited by the formulae and parameters, which 
simplify the dataset being considered. Power calculated from such formulae cannot 
account for dataset characteristics outside of these parameters. For example, the formula 
makes no allowance for the presence of missing data – a known limiting factor on the 
power of a study. By allowing for missing data in the anticipated sample size, 
conservative estimates for the power of a study can be obtained using the formula 
presented. As mentioned earlier, further work is also needed in order to establish the 
formula for power in other scenarios that use instrumental variable analysis within a 
pharmacoepidemiology context. This includes analyses with binary outcomes and 




In this chapter, I have introduced instrumental variable estimation and covered the 
assumptions necessary to conduct this type of analysis. I have also described the 
instrument that I will use for the analysis of electronic health records in this thesis, 
namely physicians’ prescribing preference. The chapter concludes with the derivation and 
validation of a formula to calculate the power for instrumental variable analysis with a 
single binary instrument, binary exposure and continuous outcome in the context of 
pharmacoepidemiology. This work was motivated by my own application to the CPRD 
for data and has resulted in an online tool, as well as packages in R and Stata, that allow 
others to implement the formula. The next chapter will consider Mendelian 
randomization, which is a form of instrumental variable analysis that exploits genetic 
variation to proxy exposure, and is the other key method used in this thesis to assess 









Mendelian randomization is a special case of instrumental variable analysis that assesses 
the causal effect of an exposure on an outcome by using one or more genetic variants to 
proxy the exposure. (81–84) The genetic variant(s) chosen to proxy an exposure will be a 
naturally occurring equivalent – for example, a drug that influences levels of an enzyme 
will be proxied by one or more genetic variants that determine the level of that enzyme in 
the body. Genetic variants meet the three instrument conditions, introduced in Section 
3.2.1. This is because genetic variants are known to associate with the exposure (IV1: 
relevance) as they are selected from strong, replicated signals in genome wide association 
studies (GWASs) that search for the genetic variants associated with a given phenotype 
across the genome. Genetic variants are unlikely to affect both the outcome and the 
exposure other than through the same pathway (IV2: exclusion restriction) due to 
Mendel’s second law of independent assortment, which suggests that variants for one 
trait will be inherited independently of variants for other traits. Finally, the factors 
determining a genetic variant are likely to be independent of the factors that determine 
the outcome (IV3: independence) because randomization at conception ensures that the 
environment should be equally distributed across variants. Methodological advances 
mean that Mendelian randomization studies can use summary data of genetic variant-
exposure and genetic variant-outcome associations from separate GWAS – known as 
two-sample Mendelian randomization. (85,86) I will take advantage of this 
methodological advance, which is explained in detail later in this chapter (Section 4.4). 
 
Mendelian randomization has been used to assess the relationship between a wide range 
of exposures and outcomes. However, there was relatively little discussion focussed on 
using Mendelian randomization for drug repurposing when I commenced my PhD. This 
chapter explains how Mendelian randomization can be used to predict drug repurposing 
opportunities, as well as exploring the strengths and limitations of using this method in 
this context. It is based on work that I led on, under the supervision of George Davey 




Journal of Epidemiology. (32) The published work considers Mendelian randomization 
for the prediction of both adverse drug events and beneficial drug repurposing 
opportunities (collectively referred to as ‘unintended drug effects’); however, this chapter 




Drug repurposing opportunities have a desirable risk-versus-reward trade off, as alluded 
to in Section 2.5. This means they are often sought directly by pharmaceutical companies 
using purpose-built technology platforms. (4) Strong signals identified in these databases 
are then investigated using data from a range of sources, including randomized 
controlled trials either pre- or post-approval of the drug, meta-analyses of such trials, 
observational studies, and information from basic science. (53) However, these 
traditional approaches to predicting drug repurposing opportunities, particularly 
observational studies, are likely to be subject to several biases. Potential biases include an 
inability to determine causality, confounding by indication and other usually unobserved 
confounders. To overcome such limitations, I proposed Mendelian randomization (81–
83) as a novel approach for the prediction of drug repurposing opportunities. The use of 
this method in this way is yet to be fully realised. This has been demonstrated by Finan et 
al, who mapped GWAS signals to a “set of genes encoding drug (and druggable) targets” 
to quantify how much of the genome may be considered “druggable”. They identified 
144 licensed drug targets as having a “discordant disease association and target 
indication considered to imply a potential repurposing opportunity”. (87) In particular, 
the synthesis of evidence from Mendelian randomization with that from other sources, in 
the spirit of triangulation, could improve causal inferences of drug effects. (20) This is 
demonstrated by the choice of methods presented in this thesis.  
 
To demonstrate the use of Mendelian randomization for the prediction of drug 
repurposing opportunities, consider a Mendelian randomization study designed to 
predict such opportunities associated with statins. Statins inhibit the enzyme 3-hydroxy-
3-methylglutaryl-coA reductase (HMGCR) to lower LDL cholesterol and consequently 
reduce the risk of coronary heart disease. To proxy exposure to statins, a Mendelian 




the mechanism of statins. This can be thought of as analogous to a randomized 
controlled trial if patients were randomized based on genetic variation, as demonstrated 
in Figure 4.1. The key distinction between Mendelian randomization and a randomized 
trial is that Mendelian randomization can be done using routine genotyping data, 
without the exposure of patients to the drug.  
 
Potential drug repurposing opportunities can occur at different points along a drug 
pathway. This results in three different types of effect: drug substance specific effects; 
mechanism effects; and biomarker effects. These effects are presented in Figure 4.2 in 
terms of the statin example discussed previously. Note that to illustrate these effects in 
relation to a single drug class, the figure and the following explanation include adverse 
drug event examples. The first effect type, drug specific effects, arise because different 
compounds within the same drug class can have different effects. This is demonstrated in 
the case of statins by cerivastatin, which is suggested to have an increased risk of fatal 
rhabdomyolysis compared with other statins. This has led to it being withdrawn from the 
market. (88–92) The second effect type, mechanism effects, result from changes to a 
specific enzyme or biological pathway that are independent of changes to the biomarker. 
Several statins are thought to have lipid independent effects, i.e. changes resulting from 
HMGCR inhibition and not LDL cholesterol manipulation. These effects include 
improvement of endothelial function, though there is limited direct evidence for this in 
humans at present. (93–97) The final effect type, biomarker effects, are the effects arising 
from biomarker manipulation, which are independent of the mechanism of 
manipulation. For statins, these are effects resulting from changes in LDL cholesterol 
level, such as the increased risk of type 2 diabetes. (98–101) Ference et al demonstrated 
this effect by considering three mechanisms that lower LDL cholesterol: HMGCR, 
proprotein convertase subtilisin–kexin type 9 (PCSK9), and the LDL receptor. They 
found that “each set of gene-specific variants... had a very similar effect as the other sets 
on the risk of diabetes per unit decrease in the LDL cholesterol level.” (102) 
Understanding the difference between these three effect types is key to understanding 




   
Figure 4.1: Illustration showing how Mendelian randomization can be thought of as analogous to a 
randomized controlled trial. 
 
To predict drug repurposing opportunities, the mechanism that the drug alters must be identified so 
that a suitable proxy for the drug can be found. Naturally, this mechanism will differ between 
individuals because of genetic variation. Mendelian randomization therefore uses the random 






Figure 4.2: Illustration comparing when drug specific, mechanism, and biomarker effects occur in drug and Mendelian randomization pathways.  
 
This diagram shows when different effects occur along the drug pathway and their equivalences in the Mendelian randomization pathway. Mendelian 
randomization can be used to predict mechanism and biomarker effects through the comparison of multiple mechanisms (Section 4.6.1.4; Figure 4.3). 







Yin et al investigated the relationship between serum calcium and the risk of migraine in 
a two sample Mendelian randomization study, with a genetic score that explained 1.25% 
of variation in serum calcium levels. They found “an elevation of serum calcium levels 
by a hypothetical 1mg/dl … was associated with an increase in risk of migraine (OR 
[odds ratio] = 1.80, 95% CI: 1.31 – 2.46, P =2.4 × 10−4)”. (103) This result was 
supported by the two other methods implemented in the paper: an analysis of electronic 
health records and a genetic co-heritability analysis. Several therapeutic options were 
then proposed based on this evidence, including a drug named Cinacalcet. Cinacalcet is 
already approved by the Food and Drug Administration in the USA and works by 
antagonising the calcium-sensing receptor to lower calcium levels. The genetic variant 
rs1801725 is in the calcium-sensing receptor gene and mimics the action of the drug. As 
the genetic variant is associated both with serum calcium levels and increased migraine 
susceptibility, it highlights the potential to repurpose Cinacalcet for the treatment of 
migraine. However, the authors note that Cinacalcet is approved for the treatment of 
“secondary hyperparathyroidism or hypercalcaemia in patients with parathyroid 
carcinoma”. Consequently, the use of this treatment for migraine has the potential to 
cause hypocalcaemia, among other side effects. In addition to Cinacalcet, the authors 
also highlight the potential to repurpose calcium channel blockers as a novel treatment 
for migraine. Existing evidence for this repurposing opportunity is mixed, however the 
authors suggest that the vasodilatory effects of calcium channel blockers, accompanied by 
direct manipulation of Ca2+ levels, could be beneficial based on their findings.  
 
4.4. Two-sample Mendelian randomization 
 
Two-sample Mendelian randomization uses summary data from different data sources 
for the instrument-exposure and instrument-outcome associations. These summary data 
are often obtained from databases of GWAS results, such as MR-Base 
(http://www.mrbase.org/). (104) Using two-sample Mendelian randomization has 
several advantages, most notably an increase in statistical power to detect causal effects. 
This increase in power is usually due to the increased sample size for the outcome, which 
often has a weaker association with the genetic variant chosen to proxy exposure and so 




A further advantage of two-sample Mendelian randomization is that it is less likely to be 
affected by winner’s curse. The curse occurs in one-sample Mendelian randomization 
when the instrument-exposure association is inflated, leading to its discovery (hence 
‘winners’), but also to an underestimate of the causal estimate obtained from Mendelian 
randomization. (106) Finally, two-sample Mendelian randomization, unlike one-sample 
Mendelian randomization, is biased towards the null in the presence of weak 
instruments. Further strengths and limitations of two-sample Mendelian randomization, 





Mendelian randomization can either be used on a single outcome, as described above, or 
combined with a ‘phenotype screen’ for the prediction of previously unsuspected drug 
effects (beneficial or adverse) on a wide range of outcomes. Phenome wide association 
studies (PheWAS) are an example of a phenotype screen that search for phenotypes 
associated with a given genetic variant. This contrasts with GWAS, which search for the 
genetic variants associated with a given phenotype. MR-PheWAS were proposed by 
Millard et al and use “automated screening with genotypic instruments to screen for 
causal associations amongst any number of phenotypic outcomes”. (107) This approach 
is hypothesis-free and could therefore be of great use for generating hypotheses 
concerning potential drug repurposing opportunities, particularly prior to the approval of 
a drug for a novel indication. Note that the hypothesis-free nature of this approach means 
that it will predict both beneficial and adverse effects, i.e. both drug repurposing 
opportunities and adverse drug events.  
 
Limited phenotypic screening with Mendelian randomization has previously been 
demonstrated in the literature by the Interleukin 1 Genetics Consortium. (108) The 
consortium studied the long-term effects of interleukin 1 inhibition by combining the 
SNPs rs6743376 and rs11687782, identified in a GWAS they conducted, in a genetic 
score. (109) The score was then used to test the causal effect of interleukin 1 inhibition on 
rheumatoid arthritis and four cardiometabolic diseases. They found that “Human genetic 
data suggest that long-term dual IL-1α/β inhibition could increase cardiovascular risk 




these results do not necessarily extend to inhibition of either of these interleukins alone. 
For example, a randomized controlled trial has found inhibition of IL-1β alone can 
reduce the risk of cardiovascular events. (110)  
 
Since the work of the Interleukin 1 Genetics Consortium, the development of tools such 
as MR-Base has made the implementation of Mendelian randomization in this way 
much simpler. (104) For instance, MR-Base contains a database of harmonized GWAS 
summary statistics that greatly reduces the work required to test multiple outcomes for a 
phenotypic screen. The provision of such tools therefore means there is immense 
potential to use Mendelian randomization for the prediction of drug repurposing 
opportunities, with or without a priori hypotheses. Furthermore, there is the possibility of 
combining Mendelian randomization, and the related genetic methods, with non-genetic 
approaches in order to better explore the relationship between the genome and phenome. 
(111) This is discussed by Bush et al who consider the possibility of linking genetic data 
with that from electronic health records and epidemiological studies to better characterize 
“the impact of one or more genetic variants on the phenome” in the PheWAS setting. 
(112) This type of approach could be a particularly powerful tool for the prediction of 
drug repurposing opportunities, however, is not possible using the CPRD – the main data 
source for this thesis – at the time of writing. 
 
4.6. Strengths and limitations 
 
I will now highlight some of the strengths and limitations of Mendelian randomization, 
particularly those that make it suited to the prediction of drug repurposing opportunities 
and those that it may be susceptible to in this context. The strengths and limitations 








4.6.1.1. Addresses confounding by indication 
 
If the factors that determine whether a patient is exposed are also the factors that 
determine whether a patient experiences an outcome, observational studies can be subject 
to confounding by indication (Section 2.8.1.4). This is because an artificial association is 
induced between the exposure and the outcome. (113) Ultimately, these artificial 
associations can lead to incorrect inference being made concerning a potential drug 
repurposing opportunity. In Mendelian randomization, a genetic variant is used to proxy 
exposure. The genetic variant is unlikely to be affected by the indications for the 
exposure, so the possibility of confounding by indication affecting the results is reduced. 
This can be demonstrated by considering statins prescribed for the prevention of coronary 
heart disease. Statins are indicated for the treatment of existing cardiovascular disease. 
However, patients with this indication are at an increased risk of death. Consequently, 
there is an observational association between statin use and increased risk of 
cardiovascular death. However, this association is not due to statin use – it is an artefact 
of existing cardiovascular disease, an indication for statin use. (114) Mendelian 
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randomization reduces confounding by indication as the SNP located on the HMGCR 
gene, used to proxy exposure to statins, is a germline variant. This means it won’t be a 
result of the existing cardiovascular disease and avoids confounding by indication. 
 
4.6.1.2. More robust to non-genetic confounding and reverse causation 
 
Mendelian randomization uses germline genetic variants that are less likely to be 
confounded by environmental, lifestyle or disease-related factors operating later in life. 
(84,115,116) Consequently, if a genetic variant is associated with an outcome only 
through its association with a drug effect, it is likely to be because the genetic variant 
causes the outcome. (117) Thus, Mendelian randomization should provide robust 
evidence about the causal effects of intervening on specific biological pathways. This is 
particularly important when considering physiological factors that change over the life 
course, such as LDL cholesterol and oestrogen levels, because the association of such 
factors with the outcome is likely to be heavily confounded by environment and lifestyle 
factors, as well as potentially being subject to reverse causation. For example, 
epidemiological studies have previously suggested that hormone replacement therapy 
could be protective against coronary heart disease. Results from these studies are 
summarized in a meta-analysis by Stampfer et al that found the relative risk to be 0.56 
(95% CI 0.50-0.61). (118) However, these results are contrary to a number of clinical 
trials. (119) Lawlor et al suggest a possible explanation for this contradiction is the effect 
of early life socioeconomic position. They found “adverse socioeconomic factors from 
across the life course were associated with use of HRT [hormone replacement therapy]” 
in a study using data from the British Women’s Heart and Health Study. (120) A 
Mendelian randomization study, which should not be subject to bias caused by 
socioeconomic position at any point in the life course, has since been conducted using 
data from young women in Hong Kong and older women in the Guangzhou Biobank 
Cohort Study. Unlike the observational studies, the Mendelian randomization analysis, 
which used genetically higher 17b-estradiol as a proxy for hormone replacement therapy, 
was in line with the results of the clinical trials. It concluded that “genetically higher 17b-
estradiol was not associated with any cardiovascular disease-related risk factor or with 
Framingham score (0.01, 95% confidence interval = -1.34 to 1.31).” (121) This 




is unlikely to be a suitable drug repurposing candidate for coronary heart disease, without 
concerns about bias due to socioeconomic position. 
 
4.6.1.3. Can be used either pre- or post-approval of a drug 
 
As highlighted earlier, Mendelian randomization can be implemented using routine 
genotyping data. This means a study using this type of analysis will not require patients 
to be exposed to the drug and can be conducted at any point during the drug 
development process and beyond. This has several benefits including: improving trial 
safety through pre-specification of likely adverse outcomes, improving trial efficiency by 
identifying worthy drug targets, and reducing the possibility of exposing patients to 
unnecessary risks and harm. The benefit of implementing Mendelian randomization 
prior to a trial has recently been demonstrated by the Selenium and Vitamin E Cancer 
Prevention Trial, which found that selenium did not lower prostate cancer risk but did 
increase the risk of type 2 diabetes. Following the trial, a Mendelian randomization study 
found genetically elevated selenium was not associated with prostate cancer risk and was 
positively associated with type 2 diabetes risk – mirroring the results of the trial. (122) 
Implementation of Mendelian randomization prior to the trial could therefore have been 
an informative step in the assessment of selenium as a possible chemoprevention target.  
 
4.6.1.4. Able to predict combined effects of drugs 
 
Mendelian randomization can be used to predict the combined effect of drugs by using a 
factorial design. This design separates patients into groups according to the first 
treatment and then, within those groups, separates patients into groups according to the 
second treatment and so on. In the case of two drugs (known as 2x2 factorial design), this 
results in four patient groups – one for each possible combination of two drugs. Assessing 
drug combinations is an important consideration as many medicines are only licensed for 
use when other treatments are either being used concurrently or have been previously 
used and failed. This makes the assessment of the ‘additive’ effect of drugs increasingly 
important. This approach is yet to be illustrated in the literature for a drug repurposing 
example, however it has been used to demonstrate the effect of combining an existing 
treatment to reduce LDL cholesterol, statins, with a novel treatment, PCSK9 inhibitors. 




prior to the corresponding trials. It found PCSK9 variants (the proxy for PCSK9 
inhibitors) to have a similar effect as HMGCR variants (the proxy for statins) on the risk 
of cardiovascular events (OR 0.81, 0.74-0.89 vs OR 0.81, 0.72-0.90) and the risk of type 2 
diabetes (OR 1.11, 1.04-1.19 vs 1.13, 1.06-1.20) for each 10 mg per decilitre decrease in 
LDL cholesterol level. (102) The Further Cardiovascular Outcomes Research With 
PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial was one of several 
PCSK9 inhibitor trials and considered the drug evolocumab for the reduction of LDL 
cholesterol in a population taking statins. It found the lipid lowering effect of evolocumab 
was in line with statins and “the rates of adjudicated cases of new-onset diabetes did not 
differ significantly between the two groups (hazard ratio, 1.05; 95% CI, 0.94 to 1.17)”. 
(123) Both analyses agreed that the lipid lowering effect of the two drugs was additive. 
This was investigated by Ference et al by considering the combination of PCSK9 and 
HMGCR variants in a 2x2 factorial Mendelian randomization approach. Given the 
overlap of the Mendelian randomization and the FOURER trial, further trial data is 
required to assess the risk of type 2 diabetes associated with the use of PCSK9 inhibitors. 
However, the consistency of analyses demonstrates the value of Mendelian 
randomization, particularly when considering the combined effects of drugs prior to 
patient exposure. Such investigations are an important element of the safety assessment 
of a drug, even when considering the repurposing of a drug already approved for use, as 
the drug is likely to be taken alongside others when prescribed to the general population. 
 
4.6.1.5. Aids the distinction of mechanism and biomarker effects 
 
Mendelian randomization is able to distinguish mechanism and biomarker effects by 
enabling a formal statistical comparison of the effect of a biomarker influenced by 
different drug-related mechanisms, as illustrated in Figure 4.3. (101,124,125) As genetic 
variants are unlikely to proxy specific drug substances; drug substance specific effects are 
difficult to ascertain. Mechanism effects are observed when results differ between 
analyses that consider different mechanisms for the same target disease. Biomarker 





Figure 4.3: Illustration of how Mendelian randomization can be used to distinguish mechanism and 
biomarker effects of drugs. 
 
This diagram shows that if a potential unintended drug effect is indicated by the SNPs 
corresponding to multiple mechanisms then it is suggestive of a biomarker effect. This is because the 
effect occurs regardless of the mechanism used to induce the change. If this is not the case, the 
unintended drug effect is suggestive of a mechanism effect relating to the SNPs that indicated it. This 
is because the effect is specific to just one mechanism that induces a change in the biomarker and not 





In practice, this is investigated by considering multiple studies of the same pathway or 
combination analyses, such as that explored earlier by Ference et al. In the Ference et al 
example, it was suggested that the cause of increased type 2 diabetes risk may be related 
to an LDL receptor-mediated pathway, i.e. may be a biomarker effect. This was due to 
the similarity of the effects observed for HMGCR variants (the proxy for statins) and for 
PCSK9 variants (the proxy for PCSK9 inhibitors). Further evidence for this hypothesis 
has been gained through specific assessment of potential shared pathways by Ference et 
al and other genetic studies that have found similar results. (101,102,126)  
 
4.6.1.6. Addresses missing data 
 
As explained in Section 4.4, two-sample Mendelian randomization is implemented using 
summary data about genetic variants meaning it does not require individual level data. In 
theory, provided there are robust genetic variants for the drug exposure of interest and 
there is a large GWAS of the outcome, Mendelian randomization should not be limited 
by missing or incomplete data. This could potentially overcome an issue that is often 
problematic in other observational study designs. (127) However, this has not been 
formally assessed to date and warrants further research.  
 
4.6.1.7. Limits associative selection bias 
 
Associative selection bias occurs when patients are selected into a study due to both their 
exposure and disease statuses. (82) This is also known as Berkson’s bias, named after 
Joseph Berkson, and can be demonstrated by considering a scenario where patients are 
selected from a hospital. (128) In this case, the fact that the patient is in hospital effects 
both their exposure and disease statuses and consequently induces bias. This is because 
the selection of patients from the hospital means the analysis is conditioned on a binary 
variable that indicates whether a patient is in hospital or not and only the sub population 
for which the variable ‘in hospital’ is true have been analysed. (129) Such bias is reduced 
in Mendelian randomization as the factors that led patients to have the value true for the 
variable ‘in hospital’ are unlikely to be the factors that determined the genetic variants 
they received from their parents at conception. This prevents association of the 





4.6.1.8. Minimizes regression dilution bias 
 
Mendelian randomization estimates are of lifelong exposure, which can mean estimates 
do not match those obtained from clinical practice. This is discussed in detail later as a 
limitation of Mendelian randomization. However, there are some benefits associated 
with this, specifically that it minimizes regression dilution bias. Regression dilution bias 
occurs as a result of measurement error in the exposure that, at the population level, can 
lead to an underestimate of the causal effect of an exposure on an outcome. As 
Mendelian randomization uses genetic variants and measures lifelong exposure, 





4.6.2.1. Drug repurposing opportunities for rare diseases may not be detected 
 
Single sample Mendelian randomization studies, where the instrument-drug and 
instrument-outcome associations are recorded in the same dataset, are not suited to 
detecting drug repurposing opportunities for rare diseases. This is because the data for 
these diseases, if available, is likely to lack the power needed to identify an effect. This 
has been demonstrated in the literature by a rare but serious potential adverse effect of 
statins: rhabdomyolysis. The global incidence of rhabdomyolysis is unknown but it is 
uncommon, with an estimated 26,000 cases per year occurring in the US according to the 
1995 National Hospital Discharge Survey. (130,131) Prevalence estimates of the 
condition are also difficult to obtain – this is due in part due to the previously disputed 
clinical definition for the condition. (132) The rare nature of rhabdomyolysis means that 
Mendelian randomization studies drawing on information from one dataset, as is the 
case for single sample Mendelian randomization, are unlikely to have sufficient power to 
detect it as a mechanism effect of statins. (133–136) For example, in UK Biobank (one of 
the largest studies with genetic data available at present), just 322 of 392,242 participants 
with ICD-10 diagnosis codes have the M62.8 code for ‘other specified disorders of 
muscles’, which includes rhabdomyolysis. This number would be further reduced once 
participants were restricted to those with statin exposure prior to the onset of the 




disentangle whether rhabdomyolysis is a mechanism effect of statins that is more 
pronounced for cerivastatin or a drug-specific effect of cerivastatin. Two-sample 
Mendelian randomization studies, where the instrument-drug and instrument-outcome 
associations are recorded in separate datasets, may be the best approach to overcome this 
limitation. This is because the two-sample approach allows the use of a case-control 
GWAS for the rare event, which is likely to provide a greater number of cases than other 
study designs. Predicting drug repurposing opportunities for rare diseases will require a 
hypothesis free approach and, while this is theoretically possible, it will be hard to 
achieve with the currently available resources. To make this approach feasible, databases 
of GWAS for classical rare unintended drugs effects - including GWAS implementing 
case-control designs - should be curated so that drugs can be tested against them in a 
Mendelian randomization framework.  
 
4.6.2.2. Choice of genetic variant can lead to missed or conflicting effects 
 
Drug repurposing opportunities may be missed if you chose a genetic variant to proxy 
exposure downstream of the effect you are interested in. Consider once more the statin 
example used to illustrate the effect types that can be investigated using Mendelian 
randomization. Using genetic variants at the biomarker level, i.e. those related to LDL 
cholesterol level, to investigate statins will miss the mechanism effects, such as the lipid-
independent improvement to endothelial function. Alternatively, the choice of genetic 
variant may lead to conflicting results. This can happen if the chosen genetic variants 
alter the relationship between the exposure and the biomarker or effect multiple 
biomarkers related to a single disease. Given these issues, careful consideration must be 
given to the choice of genetic variant used for Mendelian randomization analyses. 
 
4.6.2.3. Horizontal pleiotropy 
 
Horizontal pleiotropy occurs when a genetic variant influences multiple phenotypes 
through distinct pathways. (83) This can bias a Mendelian randomization estimate as the 
estimate will include the effect of the variant through pathways other than that of 
interest, violating the exclusion restriction assumption (IV2 – Section 3.2.1). Horizontal 
pleiotropy is opposed to vertical pleiotropy, which occurs when the instrument SNP(s) 




the outcome of interest and does not invalidate the Mendelian randomization 
assumptions. Methods such as weighted median and MR-Egger regression are potentially 
more robust to horizontal pleiotropy. (133,137) These methods use multiple SNPs and so 
estimates should not be as affected by SNPs subject to horizontal pleiotropy. In the case 
of the weighted median estimates, up to 50 per cent of SNPs included can be invalid 
instruments and the estimate will remain consistent. (133) Horizontal pleiotropy can also 
be assessed using leave-one-out analyses that calculate the estimate without each SNP in 
turn to identify whether a SNP is having an undue effect on the overall estimate. Using 
such methods and having the biological knowledge to support your chosen genetic 
variants, should help to minimize issues such as horizontal pleiotropy. 
 
4.6.2.4. Estimates are of lifelong exposure 
 
Mendelian randomization estimates indicate lifelong perturbations in an exposure. 
Therefore, careful consideration of the exposure and its timing must be made to avoid 
misinterpretation of results. (138,139) For example, some exposures are cumulative 
whereby repeated exposure, over a sustained period, results in the outcome. Mendelian 
randomization analyses of such exposures are likely to overestimate the effect observed 
in other study designs, including randomized controlled trials, as these designs consider 
much shorter periods of exposure with lower compliance. A further example is time-
dependent exposures. Mendelian randomization analyses of this type of exposure can 
provide misleading evidence about the effect of manipulating an exposure after the 
critical period. This is because the Mendelian randomization estimate will, by definition, 
include any critical periods in its assessment of lifelong exposure. 
 
4.6.2.5. Lack of genetic variants concerning disease progression 
 
A large proportion of the genetic variants that have been identified to date are concerned 
with the incidence of disease. Consequently, it is difficult to use the proposed approach to 
predict drug repurposing opportunities that will alter the progression of a disease. In 
2017, Paternoster et al reported that “only a small proportion of GWAS studies (~8% of 
associations curated in the GWAS Catalog (p<1x10-5)) have attempted to identify 
variants associated with disease progression or severity and those that have are mostly 




disease in the future, there must be an increased focus on large GWAS concerning 
disease progression in the interim to fill this gap in the literature. 
 
4.6.2.6. Collider bias in case-only studies 
 
If a Mendelian randomization study uses only the cases of the disease - for example, 
when studying disease progression - it can be affected by collider bias (Section 2.8.1.2). 
(65) This occurs because the analysis is conditioned on disease onset and so an 
association is induced between the instrument and the confounders that effect both 
disease onset and progression. (140) This is illustrated in Figure 4.4. Overcoming this 
issue is an area of active research. (141)  
4.6.2.7. Genomic confounding 
 
Mendelian randomization can be subject to genomic confounding, which occurs when 
the causality of a genetic variant is misinterpreted. An example of this is population 
stratification. Genetic variants occur at different frequencies in different populations. 
This means if, for instance, different ethnicities have different rates of outcomes, 
differences due to ethnicity could be incorrectly ascribed to the risk factor of interest.  
 
Figure 4.4: Illustration of how collider bias can affect Mendelian randomization when only disease 
cases are analysed. 
 
In this diagram, conditioning on disease onset induces an association between the exposure and the 
risk factors meaning the exposure can affect disease progression via an indirect path. Reproduced 
from Paternoster, L., Tilling, K., & Davey Smith, G. (2017). Genetic epidemiology and Mendelian 
randomization for informing disease therapeutics: Conceptual and methodological challenges. PLoS 






4.6.2.8. Weak instrument bias 
 
Instruments are termed weak when the correlation between the instruments and the 
exposure is low. (142) A commonly cited threshold is a partial F statistic of the 
association between the instrument and the exposure of less than 10. (30,74) Weak 
instruments will result in low power to detect a causal effect. (143–145) They also induce 
bias, as such instruments may explain only a small proportion of the association between 
the exposure and outcome. Weak instrument bias is not specific to Mendelian 
randomization, however Mendelian randomization is particularly susceptible to it. This 
is because GWASs often investigate only common genetic variants or combine the effect 
of rare genetic variants. Consequently, individual genetic variants may explain very little 
of the observed variation. 
 
4.6.2.9. Linkage disequilibrium  
 
SNPs that have non-random associations with each other are said to be in linkage 
disequilibrium. (146) Many Mendelian randomization methods require SNPs not to be in 
linkage disequilibrium and so measures, such as clumping, must be taken in order to 
identify independent SNPs. This can limit the number of SNPs included in the final 
analysis. If SNPs in linkage disequilibrium are included in the analysis, confounding may 
be introduced through the non-random associations that exist between the SNPs. 
Ultimately, this could lead to incorrect inference concerning drug repurposing 
opportunities and negates the benefits of this method over non-genetic observational 
methods. SNPs in linkage disequilibrium are primarily an issue for two-sample 
Mendelian randomization, where the non-random associations between them lead to 
SNPs in high linkage disequilibrium regions being given excess weight in an analysis. 
One-sample Mendelian randomization using allele scores will not be affected by this 
issue. 
 
4.6.2.10. Combining genetic variants within a model can confound results 
 
The combination of genetic variants, especially when little is known about the biological 
effect of those variants, can confound estimates. For example, in Mendelian 




disease, combining genetic variants can exacerbate the effect of collider bias. This is 
because a set of genetic variants associated with disease incidence will be inversely 
associated with any other set of genetic variants associated with disease incidence via 
another pathway. The combination of these sets will then bias the association of the 




In this chapter, I have introduced Mendelian randomization as a method for predicting 
drug repurposing opportunities and covered the strengths and limitations of using the 
method in this way. I have also provided examples of Mendelian randomization 
predicting drug repurposing opportunities from the literature and discussed MR-
PheWAS, an extension of Mendelian randomization that is particularly beneficial in this 
context. This chapter motivates the use of Mendelian randomization in Chapter 8, where 
I implement this method to assess whether antihypertensives can be repurposed for the 









This thesis makes use of the CPRD, an ongoing UK-based primary care database, 
established by Value Added Medical Products (VAMP) Health in 1987. VAMP Health 
incentivised clinical practices to join the database by offering free computer systems with 
ongoing maintenance in exchange for anonymised patient data. In 1993, the Department 
of Health acquired the database and it became known as the General Practice Research 
Database (GPRD). In 2012, the database received its current name, the CPRD. At 
present, the National Institute for Health Research and Medicines and Healthcare 
Products Regulatory Agency fund the database however other groups, such as the 
Wellcome Trust and Medical Research Council, fund studies using the data. (147) The 
CPRD’s Independent Scientific Advisory Committee (ISAC) monitor all data requests 
for such studies and seek approval from an ethics committee, scientific committee and 
the National Information Governance Board Ethics and Confidentiality Committee 
when needed. (148) The protocol [ISAC Protocol 15_246R] for the data used in this 
thesis was submitted for a larger project that includes investigating the effects of 
commonly prescribed drugs on the prevention and treatment of dementia, Parkinson’s 
disease and amyotrophic lateral sclerosis. These additional exposures and outcomes are 
discussed in this chapter to fully explain the data extraction process however only those 
relating to hypertension and dementia were ultimately used in this thesis. The protocol 
was published in BMJ Open prior to the commencement of the studies it describes. (36)  
 
This chapter introduces the CPRD as a data source, including its strengths and 
limitations, and describes the structure of the data. I then introduce the additional data, 
available through data linkage, that is utilized in this thesis and provide more specific 
details about the study population I used in my analyses. With this context in place, I 
describe the steps I took to clean the data and define the events and diagnoses. The final 
section of this chapter covers the covariates I considered. All code lists referenced in this 
chapter have been made available online: http://rebrand.ly/repurposing-
antihypertensives-dementia-codelists. (149,150) As has the code used for data cleaning: 
https://github.com/venexia/CleanCPRD. The information presented here is relevant to 




5.2. Data source 
 
The CPRD contains “over 11.3 million patients from 674 practices in the UK… and 
includes over 79 million person-years of follow-up”. (147) Specifically, for each patient, 
the database contains all contact between them and their general practice. This means 
there are data available “on demographic information, prescription details, clinical events 
(symptoms, diagnoses), preventive care provided, tests, immunisations, specialist 
referrals, hospital admissions and their major outcomes, and details relating to death”. 
(147) These data are primarily recorded by general practice staff either during a 
consultation or as a result of feedback from other sources, such as secondary care, using a 
system of codes (see Section 5.7). In addition to this, 58% of practices included in the 
CPRD have given permission for their data to be linked with other data sources, such as 
Office of National Statistics (ONS) and Hospital Episodes Statistics (HES), allowing 
further information concerning their patients to be obtained.  
 
The CPRD is “broadly representative of the UK general population” with approximately 
7% of the population registered in a participating practice in 2013. (147) At the last 
census in 2011, the CPRD was generally comparable for age, sex and ethnicity with a 
slight underrepresentation of younger people. (147,151) The database has also been 
shown to be representative of body mass index when compared against the Health 
Survey for England. (152) However, at a practice level, the CPRD is less representative 
with respect to the size and location of practices. (153) A 2010 systematic review found 
the CPRD to be accurate in terms of diagnostic coding, though acute conditions are not 
recorded as well as chronic conditions. (154) Of particular relevance to this thesis, the 
validity of codes for dementia diagnoses is generally reported to be high. (155) 
 
5.2.1. Strengths of the data source 
 
The CPRD has many strengths as a data source. (147,156) Firstly, it provides a large 
quantity of population-based data. As noted in Section 2.8.2.4, this provides greater 
statistical power to detect treatment effects and means the database can be used to study 
rare outcomes. Secondly, it includes access to outpatient information and original 
medical records, which may enhance the more conventional recorded data. Thirdly, as 




measure the effectiveness of treatments as opposed to their efficacy (see Section 2.8.2.1). 
Fourthly, the long follow up of patients means that outcomes with long latency can be 
studied (see Section 2.8.2.2). A further strength of the database is that it can be used 
when clinical trials are not ethical or practical, such as for studies concerning outcomes 
in pregnant women. Finally, it includes high quality measurement of some data such as 
those listed in the Quality and Outcomes Framework, for which data collection is 
incentivised. Historically, this has been shown to improve data collection coverage. (147) 
 
5.2.2. Limitations of the data source 
 
Despite the many strengths of the CPRD, the database is also subject to some 
weaknesses. (147,156) Most notably, the database has complex missingness that can be 
difficult to quantify. This issue is exacerbated by the fact that the absence of a code 
indicating a disease or prescription can reflect either genuine absence of that disease or 
prescription or a missing data item. Secondly, there is a lack of standardized definitions 
for diagnoses that may limit the comparability of studies.  Researchers continue to work 
to overcome these issues as demonstrated by the setup of code list repositories to aid the 
standardization of definitions. (157) Thirdly, the core CPRD dataset mostly captures 
information from primary care and is therefore reliant on information from other 
services, such as secondary care, being manually added to records. Of particular concern 
is diagnoses received from a specialist that may not necessarily be re-recorded in primary 
care records. Fourthly, while the CPRD is generally representative of the UK population, 
there are several patient groups – for instance, patients at some residential homes – that 
are known to be missing. (147) Finally, the data included in the CPRD are electronic 
medical records and so are a secondary data source. This means data was not collected 
for a specific research question and you cannot specify how or what data is collected. 
 
5.2.3. Rationale for using the data source 
 
There are two key reasons why I chose to use the CPRD as the main data source for this 
thesis. The first key reason was the long follow-up of patients in the dataset. This was 
essential for my investigations into whether antihypertensive drugs have a causal effect 
on incident dementia as the drugs are typically prescribed in mid-life, while incident 




ensure the outcome of interest was measured. Non-electronic-health-record data sources, 
such as clinical trial data, are unlikely to have the required length of follow-up for this 
type of analysis. The second key reason is the size and depth of the dataset. The CPRD is 
“one of the largest databases of longitudinal medical records from primary care in the 
world” and has linkages to other data sources such as ONS and HES. (147) By using one 
of the largest datasets possible, I maximized the size of the cohort for my study and 
consequently the power, allowing detection of even very small effects of my drugs of 
interest. By using data with linkages to other data sources, I was able to perform 
sensitivity and specificity analyses and obtain additional information on patients that was 
not present in the main dataset.  
 
5.3. Data structure 
 
The CPRD provide their data in tab-delimited format; arranged according to its type. 












Each patient in the database has a unique patient identifier that allows extraction of their 
details. Similarly, each practice and staff member have unique identifiers. The basic 
demographics and registration of the patients is contained in the patient file, the details of 
each of the practices in the practice file and the staff details in the staff file. This thesis 
will predominantly make use of the following five file types: clinical, referral, 
immunisation, test and therapy, as these are the files necessary to identify the diagnostic 




support this information allowing access to information about consultation type and test 
results. 
 
5.4. Data linkage 
 
As part of the protocol, access to three linked datasets was requested. Firstly, the ONS 
death registry because cause-specific mortality is more accurately recorded in the registry 
than in the general practices that contribute to the CPRD. (158) Secondly, the HES data 
to allow investigations into service use, though this was not ultimately studied in this 
thesis. Finally, the Index of Multiple Deprivation, which provides a practice postcode-
based indicator that can be used as a proxy to adjust for socioeconomic position.  
 
5.5. Data specification 
 
The data extract used in this thesis is taken from the March 2016 CPRD Gold snapshot 
and contains records from 1st January 1987 to February 29th 2016. To be included in the 
extract, patients had to qualify for one of the cohorts presented in the study protocol. (36) 
These were based on the diagnosis definitions provided in Table 5.1. In addition to 
having a diagnosis of interest: patients had to be aged 40 and over; attend an ‘up to 
standard’ practice; and have data deemed ‘acceptable’ by the CPRD.  
 
5.6. Data cleaning 
 
To use the data, I converted the tab-delimited files to Stata dataset files. During this 
process, I could format the variables containing dates so that they were ready for use in 
Stata functions. I also took the opportunity to compress the datasets to make the use of 
these files as efficient as possible in the analysis. I saved the resulting Stata dataset files in 
a directory labelled ‘raw’. To use the data, I load from this directory and save into a 
working data directory to prevent any changes to the original data.  
 
5.7. Defining events 
 
There are two types of event relevant to this thesis, namely diagnostic and treatment 




events are defined using product codes. Read codes and product codes uniquely identify 
clinical terms and prescriptions respectively in the CPRD. (159) Note that the linked data 
from the ONS and HES databases uses International Classification of Diseases (ICD) 
codes, not Read codes, and so equivalent code lists are required (Section 5.9). 
To define events according to Read or product codes, I created code lists that detailed 
each of the codes relating to a given event. To determine relevant Read codes, I searched 
their descriptions using the medical dictionary within the CPRD code browser 
application (version 3.0.0). To identify the product codes for a given treatment, I 
searched the drug substance names provided by the British National Formulary guidance 
for each treatment in the product dictionary of the same application. Search terms for 
both the Read and product codes are provided in Appendix B. The code lists were later 
refined under the guidance of my supervisors to ensure only relevant codes were included 
and are available from the data.bris Research Data Repository. (150) For each code list, I 
matched patients in the relevant CPRD files with the listed codes using the ‘joinby’ 
command in Stata. Note that Read codes are recorded in four file types; namely clinical, 
referral, immunisation and test files; while product codes are recorded only in therapy 
files. Restricting the dataset to just the patients who matched a code on the code list 
allowed me to create an event list detailing the patient ID, the specific code recorded and 
the date. As the event list details each unique event, patients can appear more than once 
on this list. I therefore created a patient list for each code list that contained each patient 
only once with the date of their first recorded code and the number of entries they have 
on the event list. This assumes that the event date is the first date on which a relevant 
code is recorded.  
 
To define events using test results, I took a similar approach in defining event and patient 
lists. The CPRD record test results in test files with an ‘enttype’ number and several 
columns containing data related to the test. For example, an ‘enttype’ number of one 
indicates a blood pressure reading and the diastolic and systolic blood pressure readings 
are recorded alongside this in data columns 1 and 2 respectively. The additional clinical 
details files do not contain event dates but instead provide an id, known as ‘adid’, which 
links to the clinical files. To simplify the extraction of additional clinical details, I created 
dated additional clinical detail files by merging the dates from the clinical files using the 






Table 5.1: Diagnosis definitions for analyses using the CPRD in this thesis. 
Diagnosis Definition 
‘At risk of’ hypertension 
Patients with one or more codes on any of the following lists: 
• At risk of hypertension 
• Systolic blood pressure test between 120-139 mmHg 
• Diastolic blood pressure test between 80-89 mmHg  
Hypertension 
Patients with one or more codes on any of the following lists: 
• Hypertension 
• Systolic blood pressure test of 140 mmHg or above 
• Diastolic blood pressure test of 90 mmHg or above 
• Treatment for hypertension 
‘At risk of’ 
hypercholesterolaemia 
Patients with one or more codes on any of the following lists: 
• At risk of hypercholesterolaemia 
• Total cholesterol level test between 4-5 mmol/L  
• LDL level test between 2-3 mmol/L  
Hypercholesterolaemia 
Patients with one or more codes on any of the following lists: 
• Hypercholesterolaemia 
• Total cholesterol level test above 5 mmol/L 
• LDL level test above 3 mmol/L 
• Treatment for hypercholesterolaemia 
‘At risk of’  
type 2 diabetes 
Patients with one or more codes on the list ‘at risk of type 2 
diabetes’ without codes on the list ‘type 1 diabetes’. 
Type 2 diabetes 
Patients with one or more codes on any of the following lists: 
• At risk of type 2 diabetes 
• Type 2 diabetes 
• Treatment for type 2 diabetes 
• Unspecified diabetes, if recorded after age 40 
• Treatment with insulin, if recorded after age 40 
Without codes on the list ‘type 1 diabetes’. 
Dementia 
Patients with one or more codes on any of the following lists: 
• Possible AD 
• Probable AD 
• Non-specific dementia 
• Other dementia 
• Vascular dementia 
• Treatment for dementia 
Parkinson’s disease 
Patients with one or more codes on any of the following lists: 
• Parkinson’s disease 
• Treatment for Parkinson’s disease 
Amyotrophic  
lateral sclerosis 
Patients with one or more codes on any of the following lists: 
• Amyotrophic lateral sclerosis  







Figure 5.1: Decision tree for determining dementia subtype for analyses using the CPRD in this thesis. 
 
Note: some analyses refer to the category ‘Non-AD and mixed dementias’ or ‘Non-AD dementia’. These categories combine individuals from ‘Vascular 
dementia’ and ‘Other dementias’ in a single group. Patients in these groups may also have ‘Alzheimer’s disease’ codes recorded. Analyses referring to ‘any 




indicated a diagnosis by restricting the events to the ‘enttype’ and data combinations of 
interest. The result of this is an event list equivalent to those created using the codes lists 
that are described above. As before, I created a patient list from the event list that 
contained each patient only once with the date of their first recorded code and the 
number of entries they have on the event list.  
 
Once all the event and patient lists were created, I could refer to them when constructing 
the cohorts for each of the analyses detailed in this thesis. Analysis-specific use of these 
code lists is detailed in the relevant chapters. 
 
5.8. Defining diagnoses 
 
The diagnoses in this thesis are defined in Table 5.1. It is assumed that treatment implies 
diagnosis, so a diagnosis may be defined by both diagnostic and treatment events. All of 
the code lists referred to in the table are available from the referenced online source. (150) 
For some of the analysis presented in this thesis, it was necessary to define dementia by 
its subtypes. For example, when studying the currently licensed treatments as in Chapter 
6, which are only indicated for use by those with Alzheimer’s disease. The decision tree 
used to define dementia subtype is presented in Figure 5.1.  
 
5.9. ICD-10 equivalences 
 
As explained above, diagnosis definitions in the CPRD are determined by Read codes, 
whereas both the ONS death registry and the HES inpatient dataset use codes from the 
International classification of diseases (ICD). The ICD is maintained by the World 
Health Organization and is currently in its 10th revision: ICD-10. To use this data, I 
created ICD-10 code lists that correspond to the Read code lists used for the CPRD data 
extract. As before, these code lists were then refined under the guidance of my 
supervisors and have been made available online. (149)  
 
ICD-10 and Read codes do not map to each other exactly, with ICD-10 codes generally 
covering multiple Read codes. As I had been conservative and specific with the approach 
to the Read codes, I included ICD-10 codes on multiple code lists where appropriate. 




specific ICD-10 codes. For example, the ICD-10 code 'F03' represents 'Unspecified 
dementia' and is defined as including the following diagnoses, many of which are ‘not 
otherwise specified’ (NOS): 
• Presenile dementia NOS 
• Presenile psychosis NOS 
• Senile dementia NOS 
• Primary degenerative dementia NOS 
• Senile dementia, depressed or paranoid type 
• Senile psychosis NOS 
There are Read codes for each of the above bullet points and for 'Unspecified dementia'. 
In the Read code lists, 'Unspecified dementia' and 'Primary degenerative dementia NOS' 
were assigned to the non-specific dementia code list and the remaining codes to the 
possible Alzheimer’s disease code list. I therefore chose to include the ICD-10 code ‘F03’ 
for ‘Unspecified dementia’ on both the non-specific dementia and possible Alzheimer’s 
disease ICD-10 code lists to account for the multiple Read codes it relates to. Equivalent 
code lists were required because both the ONS and HES databases are used for sensitivity 





Some analyses presented in this thesis adjust for covariates, all of which are listed in 
Table 5.2. Collider bias (Section 2.8.1.2) could occur if events that happened because of 
the prescription the patient was issued are conditioned on. To prevent this bias from 
affecting the results, covariates are defined using data inputted prior to the first 





This chapter introduced the CPRD, an ongoing UK-based primary care database 
containing over 11.3 million patients, which provided the electronic health record data 
for this thesis. It included information on the data structure; rationale for the linkages to 




on how the data were cleaned; and definitions for the diagnoses, treatments, and 
covariates used in this thesis. The data described in this chapter will be used in Chapter 6 
to examine prescribing trends for dementia drugs and Chapter 7 to assess whether 
antihypertensives can be repurposed for dementia prevention. 
Table 5.2: Covariate definitions for analyses using the CPRD in this thesis. 
Covariate Definition 
Body mass index 
Defined as the value recorded in the additional clinical 
details files or calculated using the most recent height 
and weight measurements. Measurements are restricted 
to those taken over age 25 to ensure they are adult 
measurements. 
Smoking status 
Defined as a three-factor variable: current, former or 
never smoker. Variable assigned using the additional 
clinical details files and code lists obtained from the 
referenced study. (28) If conflicting records of smoking 
status exist, current smoker takes precedence over other 
statuses, followed by former smoker. 
Alcohol consumption 
Defined using the additional clinical details files, which 
provides a measure of alcohol consumption in units per 
week. 
Consultation rate 
Calculated by dividing the total number of clinic visits by 
the length of time in the dataset prior to a patient’s index 
date. This gives an estimate of average consultations per 
year. 
Socioeconomic position 
Determined using linked data from the Index of Multiple 
Deprivation, where 1 = least deprived and 20 = most 
deprived. 
Previous history of coronary-
artery disease 
Defined using a Read code list, refined under the 
guidance of a practicing GP. 
Previous coronary-bypass 
surgery 
Defined using a Read code list, refined under the 
guidance of a practicing GP. 
Cerebrovascular disease 
including stroke 
Defined using a Read code list, refined under the 
guidance of a practicing GP. 
Other major chronic illness 
Defined using an adapted Charlson index that included 
the following conditions: rheumatological disease, peptic 
ulcer disease, myocardial infarction, congestive heart 
disease, peripheral vascular disease, cerebrovascular 
disease, dementia, chronic pulmonary disease, mild liver 
disease, diabetes, hemiplegia, renal disease, diabetes with 
complications, cancer, moderate liver disease, metastatic 
tumour, and AIDS. (141,142) This covariate is included 
in the analysis because people who have more chronic 
conditions, such as diabetes, may have higher rates of 
consultation, which may also increase the opportunity 
for recording other diagnoses such as dementia. This is 










There are currently four licensed treatments that provide symptomatic relief for patients 
with Alzheimer’s disease in England - three acetylcholinesterase inhibitors (donepezil, 
rivastigmine, galantamine) and one NMDA receptor antagonist (memantine). These 
drugs are collectively referred to as ‘drugs for dementia’ in the British National 
Formulary, despite their licensing for Alzheimer’s disease only. (160) Since the first of 
these drugs became available in 1997, there have been several changes in national 
guidelines for the treatment of Alzheimer’s disease, as well as several initiatives to 
encourage better diagnosis and treatment of the disease. Despite this, there has been little 
research into whether such changes to guidelines and initiatives have directly influenced 
clinical practice. (33,34) This chapter examines how prescription rates in England have 
changed in response to these factors since their launch up to 1st January 2016. As detailed 
in Section 1.6, the motivation for this chapter was primarily to identify factors that may 
influence prescribing in this therapy area and consequently effect repurposed drug 
candidates in the future. However, the analysis also provides other useful information 
such as when breaks in the prescription of these drugs have occurred, which could be 
exploited as natural experiments for progression studies. The analyses presented in this 
chapter, conducted under the supervision of Neil Davies, Richard Martin and Patrick 
Kehoe, have been published in Alzheimer’s Research & Therapy. (35) 
 
6.2. Background  
 
This chapter will focus on factors at a national level that may have influenced 
prescribing. Specifically, it will look at how prescribing was affected by changes in NICE 
guidance (including the 2006 guidance that was subject to legal challenges); the addition 
of dementia to the QOF; the introduction of ambitious government dementia strategies 
and the expiry of drug patents. The timings of each of these changes, which may have 
influenced aspects of drug prescribing and clinical practice, are discussed further below 
and summarized in Table 6.1. To my knowledge, there were two existing studies that 
considered prescribing trends at the time I conducted this study and they mainly focused 




of the previous studies because it considers trends since the launch of these drugs and 
allows consideration of multiple factors affecting prescribing by using a joinpoint model 
(Section 6.3.3) as a hypothesis-free approach. 
 
6.2.1. NICE guidance on the prescribing of drugs for dementia 
  
In the past NICE guidance has used scores from the mini mental state examination 
(MMSE), in combination with other measures, to guide whether a patient should be 
prescribed a drug for dementia. The test, proposed in 1975 by Folstein et al, scores a 
patient’s cognition out of 30, where normal cognition is considered as a score of 24 or 
more. (161) The original NICE guidance, issued in 2001, on the use of drugs to treat 
Alzheimer’s disease recommended that the three acetylcholinesterase inhibitors should 
be used for all patients scoring 12 or above on the MMSE until the drugs were deemed 
no longer effective. (162,163) In November 2006, NICE revised their guidance so that the 
use of acetylcholinesterase inhibitors was restricted to patients with moderate 
Alzheimer’s disease – this was defined as patients scoring between 10 and 20 points on 
the MMSE. The 2006 guidance was also the first to consider the use of the NMDA 
receptor antagonist, memantine, which was recommended for use only in clinical trials 
for patients with moderate to severe disease. (164) This revision of the guidance was 
Table 6.1: Events potentially influencing dementia drug prescribing in England that occurred 
between May 1997 and January 2016. 
Event Date Event 
May 1997 Donepezil first recorded in CPRD 
September 1998 Rivastigmine first recorded in CPRD 
January 2001 
Galantamine first recorded in CPRD 
First NICE guidance released 
December 2002 Memantine first recorded in CPRD 
November 2006 NICE recommend restricting drug access 
September 2007 QOF revised to include dementia 
February 2009 First National Dementia Strategy launched 
March 2011 NICE remove recommendation restricting drug access  
January 2012 Galantamine patent expired 
February 2012 Donepezil patent expired 
May 2012 Prime Minister’s Dementia Challenge launched 
July 2012 Rivastigmine patent expired 
April 2014 Memantine patent expired 






controversial due to the way in which it assessed cost effectiveness, which was expected 
to restrict access to these drugs, and was ultimately the subject of a high court challenge 
by the Alzheimer’s society and two drug manufacturers: Eisai and Pfizer. (165–167) This 
led to a further revision being made to the NICE guidance at the end of March 2011, 
which recommended acetylcholinesterase inhibitors for patients with mild to moderate 
Alzheimer’s disease and memantine for patients with moderate to severe Alzheimer’s 
disease, or who could not tolerate acetylcholinesterase inhibitors. (168) For the duration 
of this study, treatment had to be initiated by a specialist and was deemed effective as 
long as there had been “an improvement or no deterioration in MMSE score, together 
with evidence of global improvement on the basis of behavioural and/or functional 
assessment.” (163) 
 
6.2.2. Inclusion of dementia on the QOF 
 
QOF is a voluntary incentive program, introduced in 2004, to improve services in 
primary care. (169) Dementia first appeared in QOF as an ‘indicator’ in September 2007. 
(170) There are currently three indicators for dementia included in the framework. The 
first requires that the practice establish and maintain a register of patients diagnosed with 
dementia and the further two indicators refer to the ongoing management of the disease. 
(171) The inclusion of dementia on the QOF could have encouraged more of a focus on 
the diagnosis and pharmacological management of the disease in participating practices.  
 
6.2.3. Government dementia strategies 
 
The first National Dementia Strategy was launched by the Department of Health in 
February 2009. The aim of that strategy was “to ensure that significant improvements are 
made to dementia services across three key areas: improved awareness, earlier diagnosis 
and intervention, and a higher quality of care”. (172) This strategy was followed in 2012 
by the Prime Minister’s Dementia Challenge, which looked to improve care and research 
by 2015, and more recently the Prime Minister’s Challenge on Dementia 2020. (173,174) 
The most recent strategy aims to build on the work of its predecessors to make England 
the best place for both dementia care and research. In general, such strategies may help to 





6.2.4. Drug patents 
 
The charity King’s fund found that the prescription of generic drugs over their patented 
alternatives has “saved the NHS [National Health Service] around £7.1 billion and 
allowed more than 490 million more items to be prescribed to patients” between 1976 
and 2013. (177) Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease 
became available generically from 2012, while NMDA receptor antagonists became 
available generically from 2014. (178) Therefore, in recent years the cost of drugs for 
dementia has reduced significantly from previous years. This serves as a potential factor 
in rates of prescribing, particularly in publicly funded health care services such as the 
National Health Service in England. The patent information for each of the individual 
drugs is provided in Table 6.2.  
6.3. Methods 
 
6.3.1. Study design and setting 
 
This study was a joinpoint analysis of the proportion of patients, who were eligible for 
treatment and had a diagnosis of ‘probable Alzheimer’s disease’, that received their first 
prescription for the treatment of interest in each month in the CPRD. The CPRD is 
described fully in Chapter 5. Patients were defined as eligible for their first prescription if 
they had the diagnosis of interest with no previous prescription for the treatment of 
interest. The time period was measured in units of one month as this was the smallest 
clinically meaningful measure that could realistically be defined. I investigated treatment 
rates as a proportion of eligible patients, because the underlying rate of diagnosis of 
Alzheimer’s disease, as well as non-Alzheimer’s disease and mixed dementias, has 
changed over time in the CPRD. This is illustrated in Figure 6.1 using patients who 
received a diagnosis prior to 1st January 2016 and are from an English practice with a 
last data collection date in 2016 to reflect the present study.
Table 6.2: Patent information for the British National Formulary category ‘drugs for dementia’. 
Generic name Patent name Drug class Patent expiry 
Donepezil Aricept Acetylcholinesterase inhibitor January 2012 
Rivastigmine Exelon Acetylcholinesterase inhibitor February 2012 
Galantamine Reminyl Acetylcholinesterase inhibitor July 2012 







Figure 6.1: Patients diagnosed with dementia in English practices within the CPRD between 1987 and 2015. 
 
The data presented are restricted to patients who received a diagnosis prior to 1st January 2016 and are from an English practice with a last data collection date in 





The four drugs for dementia were separated according to drug class, i.e. 
acetylcholinesterase inhibitors and NMDA receptor antagonists for the analysis. 
Exposure date was taken to be the date on which the first prescription requesting the 
drug(s) being considered was recorded. This allowed patients who had previously been 
prescribed acetylcholinesterase inhibitors to be included in the NMDA receptor 
antagonist analysis. This is necessary as NMDA receptor antagonists may be prescribed 
alongside acetylcholinesterase inhibitors and are often given to patients later in the course 




Patients were included in this study if they had a diagnosis of dementia as defined in 
Section 5.8; had data available between January 1st 1987 and December 31st 2015; and 
attended an English practice with a last data collection date in 2016. The latter two 
conditions ensured all data were complete for the timeframe being considered and were 
subject to the guidelines and initiatives being studied. Diagnosis date was taken to be the 
first date on which a code relating to dementia, regardless of whether it was for a 
diagnosis or a treatment, was recorded.  
 
6.3.3. Statistical analysis 
 
As highlighted earlier, this study used joinpoint analysis. A joinpoint can be thought of as 
a break point between two fitted models, which allows the models on either side to take 
different values. Joinpoint analysis works by adding one joinpoint at a time and testing 
for statistical significance using the Monte Carlo Permutation method. Once adding 
joinpoints no longer effects the result, or the maximum number of pre-specified 
joinpoints is reached, the analysis is complete. (179) It is usual practice to start with zero 
joinpoints – that is to have one model that is fitted to all the data. Joinpoint analysis has 
been developed for incidence rates and so prevalent drug use, which requires 
consideration of both incidence and continued drug use, cannot be studied in this way. 
 
The analysis of each treatment of interest in this study started on the first day of the 
month following the first recorded prescription for that treatment. For example, the first 




analysis of this drug class started on 1st January 2003. For each patient, the month and 
year of both their diagnosis and their first prescription were used. For each month, I 
calculated: (A) the number of patients receiving their first prescription in that month; and 
(B) the number of patients with a diagnosis who had not received treatment before the 
first of the month. Dividing A by B provided the proportion of patients with diagnoses 
who received their first prescription for the treatment of interest each month. I also 





 for proportion 𝑝 and sample size 𝑛 for observation 𝑖 
 
The trend analysis using joinpoint models was then conducted. The optimum number of 
joinpoints, as determined by the software and up to a maximum number of two, was 
used to select the model. The period between two joinpoints is referred to as a ‘segment’ 
and they are numbered chronologically. The model used assumes that the rate of 
prescription “changes at a constant percentage of the rate of the previous year” and so is 
determined by the following equation: ln 𝑦 = 𝑥𝑏. This allows consideration of the 
monthly percent change. The trend over the entire study period is summarized using the 
average monthly percent change. This is calculated as the average of the monthly percent 
changes, weighted by segment length. (179) All analysis was conducted using Joinpoint 
Regression Program (version 4.3.1.0) and Stata (version 14.1). (80,181) The model 
specifications for the joinpoint analyses are the software’s default with dependent 
variable type set to ‘proportion’ and the maximum number of join points set to two. The 
Stata code used in this analysis is available from GitHub: 
https://github.com/venexia/DementiaDrugsCPRD. 
 
6.3.4. Sensitivity analyses 
 
6.3.4.1. Representativeness of the study population compared with the CPRD as a whole 
 
As highlighted in Section 5.2, the CPRD is “broadly representative of the UK general 
population”. (147,153) However, I was concerned that restricting the study population to 




compared the distribution of patients and practices eligible for the study by nation with 
those eligible for the study in the complete dataset to see whether the distributions were 
maintained. I also compared the distribution of patients and practices eligible for the 
study between regions in England to see if any of the other selection criteria, such as a 
last data collection date in 2016, could have influenced the results.  
 
6.3.4.2. Sensitivity and specificity of the diagnosis definitions 
 
It is difficult to differentiate dementia subtypes however, drugs for dementia are currently 
only licensed for the treatment of Alzheimer’s disease. Consequently, it was important to 
know the sensitivity and specificity of the diagnosis definitions – particularly if I wanted 
to identify any off-license use of these drugs for other dementia subtypes. Sensitivity 
indicates whether patients in the CPRD have been ‘correctly diagnosed’ based on the 
information in the comparator dataset, while specificity indicates whether patients have 
been ‘correctly not diagnosed’. I was able to calculate these quantities using linked data 
from the ONS death registry and the HES inpatient dataset as the comparators for the 
data from the CPRD. HES outpatient data was excluded from the sensitivity analysis as 
it is known that less than 5.0% of patients have a diagnosis recorded in this dataset. (182) 
Note that I do not believe the ONS death registry and the HES inpatient dataset to 
represent a ‘gold standard’ for this comparison as both will be subject to missing data. 
However, these datasets do offer a secondary source of data to that from the CPRD, 
which consists of the same patients but is likely to be subject to different recording issues. 
 
First, I defined the following four terms based on where a patient had codes recorded: 
• True positive: the code is in the CPRD and is in the linked data 
• False positive: the code is not in the CPRD, but is in the linked data 
• True negative: the code is not in the CPRD and is not in the linked data 
• False negative: the code is in the CPRD, but is not in the linked data 
 
I then calculated the sensitivity and specificity (183): 
 
Sensitivity =  
true positives





Specificity =  
true negatives
true negatives + false positives
 
 
6.3.4.3. Alternative outcomes 
 
I repeated the main analysis, which considers the diagnosis ‘probable Alzheimer’s 
disease’, with relaxed diagnosis definitions to test the sensitivity of the results to this 
outcome definition. I did this in two ways: (1) introducing codes that represented what 
may be lesser degrees of confidence in the accuracy of Alzheimer’s disease diagnosis 
(termed ‘any Alzheimer’s disease’) and (2) introducing codes capturing other types of 
dementia (termed ‘any dementia’). By repeating the same analysis with different 
definitions, I was able to assess whether the joinpoints selected in the model were 
consistent across the definitions. 
 
6.3.5. News search 
 
Several of the national guidelines and initiatives considered in this study may have 
increased awareness of dementia, including Alzheimer’s disease. To investigate this, I 
downloaded the Google trends data for news searches in England for the disease term 
‘Alzheimer’s Disease’ from 1st January 2008 up to 1st January 2016. (184) 
Unfortunately, data were not recorded prior to 2008 and so I cannot comment on the 




6.4.1. Trend analysis for acetylcholinesterase inhibitors 
 
The average monthly percent change for the proportion of patients with probable 
Alzheimer’s disease receiving their first prescription for an acetylcholinesterase inhibitor 
during the study period was 6.0 (95% CI: -6.4 to 19.9) (Figure 6.2). This represents the 
weighted average for three trends that occurred between June 1997 and December 2015. 
The first trend was for a steady increase in the proportion of patients to receive their first 
prescription for an acetylcholinesterase inhibitor. This is reflected in the monthly percent 




rate, which corresponded to a monthly percent change of 67.2 (95% CI: -96.6 to 8179.8) 
– note that this estimate is very uncertain because it is only based on seven data points. 
The final trend had a monthly percent change of -1.6 (95% CI: -10.4 to 8.1), falling below 
zero for the first time since the launch of these drugs. The trend changes were estimated 
to have occurred in October 2012 (95% CI: September 2011 to April 2013), and, less than 
a year later, in May 2013 (95% CI: November 2012 to April 2014).  
 
6.4.2. Trend analysis for NMDA receptor antagonists 
 
Figure 6.3 presents the equivalent analysis for the NMDA receptor antagonist, 
memantine. Memantine became available in January 2003 and was prescribed much less 
than the other drugs, despite similar numbers of eligible patients. This is partly related to 
the indication of these drugs. Memantine was originally recommended for more 
advanced disease than the acetylcholinesterase inhibitors and is often added to a 
prescription of acetylcholinesterase inhibitors following progression of the disease. 
Despite this, as observed for the acetylcholinesterase inhibitors, the point estimate for the 
average monthly percent change in the proportion of patients with probable Alzheimer’s 
disease receiving their first prescription for an NMDA receptor antagonist was positive 
(15.4; 95% CI: -77.1 to 480.9), though the 95% CI around this estimate was large. The 
initial trend for prescribing of this drug showed a reduced number of prescriptions in the 
time that followed the launch with a monthly percent change of -5.3 (95% CI: -12.6 to 
2.6). This changed around March 2011 (95% CI: August 2010 to April 2011) to an 
increasing trend with a monthly percent change of 30309.9 (95% CI: unknown). This 
estimate for the monthly percentage change is unreliable as it is based on just three data 
points – specifically the monthly estimates for March 2011, April 2011, and May 2011. 
However, it indicates a distinct change from the previously decreasing trend for 
prescribing these drugs. Following this, in June 2011 (95% CI: April 2011 to November 
2011) until the end of the study in December 2015, this trend reduced to a monthly 
percent change of 20.7 (95% CI: 15.3 to 26.4) .This indicates a continuing increase in the 
prescriptions for NMDA receptor antagonists in recent years, albeit substantially reduced 





Figure 6.2: Acetylcholinesterase inhibitor prescriptions in patients with probable Alzheimer’s disease in the CPRD between June 1997 and December 2015. 
 
This graph shows the proportion of patients with probable Alzheimer’s disease receiving their first prescription for an acetylcholinesterase inhibitor each 
month from June 1997 to December 2015. The fixed lines indicate events with the potential to effect prescription rates during the study period. The 







Figure 6.3: NMDA receptor antagonist prescriptions in patients with probable Alzheimer’s disease in the CPRD between January 2003 and December 
2015. 
 
This graph shows the proportion of patients with probable Alzheimer’s disease receiving their first prescription for an NMDA receptor antagonist each 
month from January 2003 to December 2015. The fixed lines indicate events with the potential to effect prescription rates during the study period. The 





6.4.3. Sensitivity analyses 
  
6.4.3.1. Representativeness of the study population compared with the CPRD as a whole 
 
There is a total of 135,144 patients from 675 practices that have a diagnosis of dementia 
recorded in the CPRD according to the definition in Section 5.8. Table 6.3 and Table 6.4 
show the distribution of these patients and practices, respectively, at the national level. 
Out of the 135,144 patients recorded as having dementia in the CPRD, 47.2% of patients 
qualify for the study. In England, this percentage is slightly lower at 38.8% of patients. 
Given the similarity of these percentages and the fact that 76.7% of patients in the CPRD 
are registered at an English practice, the English population is likely to be representative 
of the CPRD dataset as a whole. Table 6.4 confirms the observations from Table 6.3 with 
the distribution of practices mostly in line with the distribution of patients, providing 
further evidence for the English practices being representative of the CPRD as a whole. It 
is worth noting that the percentage of patients qualifying for the study in other nations of 
the UK is much higher than in England. This is due to the other criteria, namely that 
practices should have their last data collected in 2016. While many practices outside of 
England met this criterion, data collection is less consistent in England. This is discussed 
in further detail below.  
 
Table 6.5 and Table 6.6 show the distribution of patients and practices within England 
respectively at the regional level. Ideally, there would be consistency in both the 
percentage of patients and practices that meet the study criteria, as this would preserve 
the representativeness of the CPRD dataset. The South East Coast has both the most 
practices and patients that meet the study criteria. On the other hand, the East Midlands 
does not have any patients that qualify for the study. This is because, in the data extract 
(March 2016 snapshot), there has been no data collected from a practice in the East 
Midlands since 2014. Despite these regions, the average percentage of patients included 
in the study is 38.8% (interquartile range: 19.2 to 41.0). Similarly, the percentage of 
practices included in the study is 37.4% (interquartile range: 19.5 to 45.2). This indicates 
reasonable consistency across the dataset. Furthermore, the consistency must be weighed 
against other factors, such as data quality. For this reason, the slight compromise in 
consistency resulting from the exclusion of practices in the East Midlands and elsewhere, 






















Table 6.3: The distribution of patients by nation in the prescribing trends study. 
Nation Study CPRD Percentage 
England 40202 103595 38.8 
Northern Ireland 4380 5146 85.1 
Scotland 11114 15214 73.1 
Wales 8090 11159 72.5 
Total 63786 135114 47.2 
 
 
Table 6.4: The distribution of practices by nation in the prescribing trends study. 
Nation Study CPRD Percentage 
England 195 522 37.4 
Northern Ireland 21 22 95.5 
Scotland 67 79 84.8 
Wales 44 52 84.6 
Total 327 675 48.4 
 
 Table 6.5: The distribution of patients by region in England in the prescribing trends study. 
Region Study CPRD Percentage 
North East 504 2365 21.3 
North West 6383 15914 40.1 
Yorkshire and the Humber 561 5109 11.0 
East Midlands 0 4574 0.0 
West Midlands 3731 11552 32.3 
East of England 1975 10435 18.9 
South West 4718 12587 37.5 
South Central 7659 16041 47.7 
London 5544 11817 46.9 
South East Coast 9127 13201 69.1 
Total 40202 103595 38.8 
 
Table 6.6: The distribution of practices by region in England in the prescribing trends study. 
Region Study CPRD Percentage 
North East 3 12 25.0 
North West 29 80 36.3 
Yorkshire and the Humber 3 29 10.3 
East Midlands 0 25 0.0 
West Midlands 20 58 34.5 
East of England 9 52 17.3 
South West 19 60 31.7 
South Central 28 54 51.9 
London 37 87 42.5 
South East Coast 47 65 72.3 





6.4.3.2. Sensitivity and specificity of the diagnosis definitions 
 
As stated in Section 6.3.4.2, I do not believe the ONS death registry and the HES 
inpatient dataset to represent a ‘gold standard’ against which I can calculate the 
sensitivity and specificity of the diagnosis definitions. However, these data sources do 
allow comparison of the diagnoses recorded for the same set of patients and are therefore 
a useful validation of the CPRD results. To be included in this analysis, patients had to 
have linkage across the three datasets, namely: CPRD Gold, the HES inpatient dataset, 
and the ONS death registry. Consequently, the 29,362 patients included in this analysis 
are all deceased and so the recorded diagnoses can be considered final. 
 
Table 6.7 presents the sensitivity and specificity of the diagnoses using the HES inpatient 
dataset as the comparator. Sensitivity for the diagnosis possible Alzheimer’s disease is 
poor (37.3%), however the other diagnoses perform better with non-AD and mixed 
dementias performing the best (71.6%). Sensitivity estimates the proportion of people in 
the CPRD that have been ‘correctly diagnosed’ based on the information in the HES 
inpatient dataset. Therefore, the estimate of 37.3% indicates that 37.3% of people 
identified as having possible Alzheimer’s disease in the CPRD had the same diagnosis 
recorded in the HES inpatient dataset. The specificity of the diagnoses is generally much 
better across all diagnoses (≥ 62.9%) with the diagnosis probable Alzheimer’s disease 
being the most specific (79.1%). Specificity estimates the proportion of people in the 
CPRD that have been ‘correctly not diagnosed’ based on the information in the HES 
inpatient dataset. Therefore, the estimate of 79.1% indicates that 79.1% of people 
identified as not having probable Alzheimer’s disease in the CPRD were also recorded as 
not having probable Alzheimer’s disease in the HES inpatient dataset. The higher 
specificity of the code lists reflects the conservative approach taken with the Read code 
lists, which are used in combination to determine diagnosis. While sensitivity is low for 
the Alzheimer’s disease diagnoses, particularly the possible cases, the larger sample size 
used in the study (that includes patients without linked data) potentially provides greater 
power, even if some patients are missed. 
 
Table 6.8 presents the sensitivity and specificity of the diagnoses using the ONS inpatient 
dataset as the comparator. The general pattern across diagnoses is much the same as that 




probable Alzheimer’s disease and non-AD and mixed dementias have slightly higher 
sensitivity but lower specificity than the previous analysis. Meanwhile possible 
Alzheimer’s disease performs slightly worse for both sensitivity and specificity. This is 
likely due to the ONS death registry recording diagnoses at the time of, or after, death. 
Because of this, you might expect possible diagnoses to be less relevant and potentially 
other forms of evidence to be available to preclude conditions (for example, through post 
mortem). Overall, both these comparisons indicate variable sensitivity with high 
specificity of the diagnoses. Encouragingly, the definition of probable Alzheimer’s 
disease, which is used in the main analysis, performs well against both comparators. 
 
6.4.3.3. Alternative outcomes 
 
The results of the analysis with the alternative, more relaxed, outcome definitions can be 
found in Table 6.9. The table shows that the joinpoint analysis is consistent regardless of 
the diagnosis definition used for NMDA receptor antagonists. On the other hand, the 
joinpoint estimates for the acetylcholinesterase inhibitors vary according to the diagnosis 
definition used, though the two sensitivity analyses are reasonably consistent with each 
other. 
 
6.4.4. News search 
 
Figure 6.4 presents the Google trends data for news searches in England for the disease 
term ‘Alzheimer’s Disease’ each month from January 2008 to December 2015 inclusive. 
There were no strong trends in the interest for the search term with values indicating both 
low and high interest occurring throughout the period studied. Months with insufficient 
data, indicating little interest in the search term, became less common over the period 
studied – the most recent occurring in August 2015. Interest peaked in September 2012 







Table 6.9: Comparison of trend analysis results for alternative outcome definitions in the prescribing 
trends study. 
 Probable AD Any AD Any dementia 











Joinpoint 1: Oct 2012 
(Sep 2011 – Apr 2013) 
Joinpoint 2: May 2013  
(Nov 2012 – Apr 2014) 
Eligible: 21342 
Treated: 6449 
Joinpoint 1: Jun 1999 
(Apr 1998 – Dec 2000) 
Joinpoint 2: Jun 2001  
(Sep 2000 – Mar 2002) 
Eligible: 38650 
Treated: 9896 
Joinpoint 1: Aug 2000  
(Jun 1998 – Nov 2000) 
Joinpoint 2: Jan 2001  






Joinpoint 1: Mar 2011 
(Aug 2010 – Apr 2011) 
Joinpoint 2: Jun 2011  
(Apr 2011 – Nov 2011) 
Eligible: 18930 
Treated: 1309 
Joinpoint 1: Sep 2010  
(Dec 2009 – Apr 2011) 
Joinpoint 2: Nov 2011  
(Apr 2011 – Mar 2012) 
Eligible: 35625 
Treated: 1961 
Joinpoint 1: Aug 2010  
(Nov 2009 – Dec 2010) 
Joinpoint 2: Nov 2011  
(Aug 2011 – Mar 2012) 
 
Table 6.7: Sensitivity and specificity of diagnoses in the CPRD compared against HES. 
 
Patients in  
CPRD dataset 
Patients in HES 
inpatient dataset  
Sensitivity  Specificity 
Probable AD 8069 5007 59.4 79.1 
Possible AD 8259 6461 37.3 74.5 
Non-AD and  
mixed dementias 
13034 6206 71.6 62.9 
 
Table 6.8: Sensitivity and specificity of diagnoses in the CPRD compared against ONS. 
 
Patients in  
CPRD dataset 
Patients in ONS 
death registry  
Sensitivity  Specificity 
Probable AD 8069 1863 65.5 75.1 
Possible AD 8259 4752 36.0 73.4 
Non-AD and  
mixed dementias 






Figure 6.4: Google trends data for news searches in England for the disease term ‘Alzheimer’s Disease’ between January 2008 and December 2015. 
 
 
This graph shows the interest in the disease term ‘Alzheimer’s disease’ each month from January 2008 to December 2015 inclusive. Interest is given as a 
percentage scaled against peak popularity, which is represented as a value of 100% and occurred for the downloaded data in September 2012. Values of 







The first trend change for the proportion of patients with probable Alzheimer’s disease 
receiving their first prescription for an acetylcholinesterase inhibitor occurred in October 
2012 (CI: September 2011 to April 2013). There were two potentially relevant events that 
occurred at this time. Firstly, the patents expired on the three drugs in this class in 2012 – 
galantamine in January 2012; donepezil in February 2012; and rivastigmine in July 2012. 
Secondly, the Prime Minister’s Dementia Challenge was launched in May 2012. It is 
likely that the reduction in cost of these drugs, which resulted from their patents expiring, 
in combination with increased awareness of dementia due to the Prime Minister’s 
Dementia Challenge led to the observed increase in prescription rates. In addition to 
these factors, a large amount of literature concerning acetylcholinesterase inhibitors had 
been published ahead of the revisions to the NICE guidance in 2011. Although this is 
unlikely to have directly caused a change in prescribing, it could contribute to the long 
term steady increasing trend for prescribing these drugs. A systematic review, which 
covers the literature through November 2014 (i.e. after all join points identified in the 
analysis but 13 months before the end of the study), summarizes the literature available 
at that time. It shows several studies were published between 2003 and 2008 that 
suggested patients with mild to moderate Alzheimer’s disease could benefit from 
acetylcholinesterase inhibitors with estimated “improvements on the order of 1.5 MMSE 
(30-point scale)”. (185) Therefore, a potential effect of the literature on prescribing cannot 
be ruled out, even though the authors of the review questioned whether such an 
improvement was clinically meaningful when all the evidence was presented together. 
Further to the support from the literature, the Google trends data for news searches in 
England also suggested increased awareness around the time of this trend change. The 
interest for the search term ‘Alzheimer’s disease’ was at its maximum in September 2012 
(based on the data available from January 2008 to December 2015 inclusive), which 
could indicate interest among the public. 
 
The second trend change in the Acetylcholinesterase inhibitor analysis occurred in May 
2013 (CI: November 2012 to April 2014), less than a year after the initial change for this 
drug class and with overlapping 95% CIs. This change signals the start of the first 
decreasing trend in prescriptions. This is not unexpected as patent expiry may have led to 




the drug were granted access at this time because of its newly reduced cost. This would 
result in the apparent decreasing trend once ‘catch up prescribing’ was complete, which is 
suggested by the trend analysis but is not as clear when considering the raw data points. 
These results differ from the sensitivity analyses that considered relaxed diagnosis 
definitions, though the ‘any Alzheimer’s disease’ and ‘any dementia’ analyses were in 
line with each other. This suggests that prescribing for patients with probable Alzheimer’s 
disease was more consistent, as one might expect, across the study than for other groups. 
This could indicate that patients with dementias other than probable Alzheimer’s disease, 
i.e. with unlicensed indications, were receiving these drugs and that their prescribing was 
subject to change over the period studied. Further to this, large increases in prescriptions 
are observed as the diagnosis definition is relaxed. This could provide further evidence 
for the possible unlicensed use of this drug class. The literature at that time also reflects 
ongoing discussion concerning the benefit of these drugs for indications other than 
Alzheimer’s disease. For example, a 2012 review by Rodda and Carter discusses their use 
in vascular dementia, dementia with Lewy bodies and Parkinson’s disease dementia. 
(186) Alternatively, it could be attributed to the fluctuating course of symptoms that 
some people with dementia experience or increased recognition of mixed diagnoses, 
where there is evidence of Alzheimer’s disease in addition to other forms of dementia; 
both of which might lead to treatment changes.  
 
The trend changes in the NMDA receptor antagonist analysis occurred in March 2011 
(CI: August 2010 to April 2011) and June 2011 (CI: April 2011 to November 2011). In 
March 2011, NICE introduced guidelines that recommended the prescription of 
memantine for patients with moderate to severe Alzheimer’s disease, or those people 
who could not tolerate acetylcholinesterase inhibitors. This replaced existing guidelines 
that restricted access to memantine to patients participating in clinical trials. It is 
therefore possible that these trend changes relate to the transition between the existing 
guidelines and those introduced in March 2011. In addition, the second highest peak in 
interest (88% of maximum interest) for the disease term ‘Alzheimer’s disease’ in the 
Google trends data for news searches in England in January 2011. In this month, the 
‘Final Appraisal Determination on Donepezil, galantamine, rivastigmine and memantine 
for the treatment of Alzheimer's disease’ was released. NICE defined this document as 
‘the appraisal committee’s final draft guidance about using a treatment or group of 




news searches around this time, and its alignment with the release of the final draft 
guidance, supports the idea of a transition in prescribing practice due to the NICE 
guidance. Finally, the evidence concerning the use of memantine is summarized in a 
technology appraisal conducted by NICE in 2011 to support their guidance. (168) This 
new information, based on several studies published prior to the trend change, might 
have played a role in changes to prescribing. Interestingly, neither of the trend changes in 
the NMDA receptor antagonist analysis align with those observed for the 
acetylcholinesterase inhibitors. This suggests that the NICE guidelines, which were 
implemented at the same time for both drug classes, may not have been as effective for 
acetylcholinesterase inhibitors as they appear to have been for NMDA receptor 
antagonists. This is likely because acetylcholinesterase inhibitors were available outside 
of clinical trials prior to the restrictive guidelines recommended in 2006. The sensitivity 
analyses conducted for the NMDA receptor antagonists were consistent with these 
results, regardless of the diagnosis definition used. The first of the joinpoints for all 
analyses occurred in the seven-month period between August 2010 and March 2011 and 
the second occurred in the six-month period between June 2011 and November 2011. 
This high level of consistency across diagnosis definitions indicates a clear pattern in 
prescribing, suggestive of a distinct change in practice. This provides additional support 
for the inferences concerning the impact of the 2011 NICE guidance on the NMDA 
receptor antagonist drug class. 
 
Overall, analysis of both drug classes indicates that inclusion of dementia in QOF had no 
effect on prescribing trends and the other factors had mixed effects. NICE guidance on 
the prescribing of drugs for dementia aligned with trend changes for NMDA receptor 
antagonists but not acetylcholinesterase inhibitors. The guidance that had the noticeable 
effect was released in March 2011 and allowed the NMDA receptor antagonist, 
memantine, to be used outside of clinical trials. All other guidance for both this drug and 
acetylcholinesterase inhibitors, including that which recommended restricting access, did 
not align with trend changes. Government dementia strategies also appear to have had 
mixed results, with the Prime Minister’s Dementia Challenge (launched May 2012) the 
only strategy to align with a trend change. Although this strategy is likely to have 
increased awareness of dementia around the time of the October 2012 trend change for 
acetylcholinesterase inhibitors, the patent expiry of the drugs in this class is more likely to 




led to a surge in prescribing, such as that observed in the trend analysis. The events 
considered here highlight the many factors that may have influenced prescribing rates 
and the challenges in assessing the impact of a given event. Over the period studied, the 
proportion of patients receiving prescriptions increased, irrespective of changing 
guidelines and other initiatives. Furthermore, given the increase in diagnoses of dementia 
and, more specifically, Alzheimer’s disease reported in the CPRD (Figure 6.1), the 
absolute number of prescriptions has increased considerably. 
 
6.6. Strengths and limitations 
 
The key strength of this study is the large sample of primary care data with prescribing 
information, provided by the CPRD. The data used in the present analysis contained 
40,202 patients diagnosed with dementia in England up to 1st January 2016 (note that 
data is restricted to practices with a last data collection date in 2016). This included 
10,651 patients with probable Alzheimer’s disease and a further 12,167 patients with 
possible Alzheimer’s disease. A further strength of the study is the long follow up of 
patients that allowed consideration of patients who did not receive immediate treatment. 
This is important as pharmacological interventions for Alzheimer’s disease have 
historically considered severity as part of the prescribing decision and so there was likely 
to be a treatment delay after initial diagnosis for those presenting with mild disease.  
 
The main limitation of this study is the likelihood of missed diagnoses. This is 
demonstrated within the dataset, as there were 1,231 patients receiving one of the 
treatments of interest who did not have any form of recorded dementia diagnosis. Missed 
diagnoses are likely to be due to: (1) outdated or non-specific diagnoses (i.e. type of 
dementia is not updated once established); (2) diagnoses received outside of primary care 
(i.e. from a specialist service); and (3) unrecorded diagnoses in primary care (i.e. a 
diagnosis is given but not added to a record). Missed diagnoses have been explored in 
sensitivity analyses by testing the sensitivity and specificity of the diagnosis definitions 
and by relaxing the diagnosis definition from ‘probable Alzheimer’s disease’ to include 
other less certain codes for the disease and other types of dementia. Neither of these 
sensitivity analyses provided any cause for concern. A final limitation of this study is the 
difficulty in determining the lag time between an event and a trend change to assess the 




impact – i.e. changes at a national level – and so any effect associated with them is 
expected to be evident if present. However, this prevents me from covering all the factors 
that may have influenced prescriptions for drugs for dementia during the study period – 




This chapter demonstrates that prescription rates in England do not always respond to 
factors such as regulatory guidance, recommendations or patent expiry and, when they 
do, not necessarily in a predictable way. This has potential implications on how novel 
drugs in this therapy area, including repurposed drug candidates, are used. In addition, 
the analysis has provided insight into the factors that may have influenced prescription 
rates of drugs for dementia in England since their launch in 1997. This is essential for 
accurate assessment of the effectiveness of these treatments and to adjust for them in 
other forms of analyses, particularly those concerning treatments to alter the progression 





Chapter 7. Results: Assessment of the effects of antihypertensive 




In Chapter 6, I demonstrated that the proportion of patients receiving drugs for dementia 
increased between June 1997 and December 2015, irrespective of changing guidelines 
and other initiatives. This highlights the huge unmet clinical need in this field. As 
discussed in Chapter 2, drug repurposing is one way in which this need could be met and 
antihypertensives have previously been highlighted as priority drug repurposing 
candidates. Therefore, in this chapter, I used instrumental variable analysis with 
physicians’ prescribing preference as an instrument for exposure, which was introduced 
in Chapter 3, to assess whether antihypertensive drugs can be repurposed for dementia 
prevention. As in Chapter 6, I used data from the CPRD (Chapter 5). Several 
observational studies have investigated repurposing antihypertensives for dementia 
prevention previously. (12–19) However, as discussed in Section 1.2, these studies have 
used case-control designs with logistic regression and cohort designs with survival 
analysis, which may be subject to unmeasured or residual confounding and reverse 
causation. Therefore, the rationale for the study described in this chapter was to use 
instrumental variable analysis, which can be robust to confounding and reverse causation 
if certain assumptions are met, to provide new evidence about the potential effects of 




7.2.1. Study design 
 
I conducted a prospective new user cohort study in the CPRD, the design of which is 
detailed in Figure 7.1. (188) The CPRD is described fully in Chapter 5. The a priori 







Figure 7.1: Study design diagram for the assessment of the effects of antihypertensive drugs on 
dementia prevention using electronic health record data. 
 
Study design diagrams, such as this, are a tool used in pharmacoepidemiology to describe the 
criteria applied to select patients for a study and the times when those criteria applied. The x-axis 
represents time and the boxes correspond to different restrictions. Patients entered the cohort when 
initially exposed to an antihypertensive drug (day 0, marked in purple). At this time, patients could 
not have been recorded as previously having accessed a drug of interest (washout window, marked in 
yellow) and could not have had a diagnosis preventing them from participating in the study 
(exclusion assessment, marked in orange), such as existing dementia, from ‘Start’ (i.e. the first day 
of data collection) to the day before they entered the cohort. Patients were also required to have 12 
months of data prior to cohort entry to define baseline covariates (covariate assessment window, 
marked in blue). Patients were followed until they were censored (follow-up window, marked in 
green). This diagram explicitly shows that there is no overlap of follow-up with the exclusion and 




Three amendments have been made to the study design since the publication of the 
protocol: 
 
1. ‘Centrally acting antihypertensives’ and ‘Loop diuretics’ were not considered as 
exposures because the former is primarily used for acute events, while the latter is 
primarily used for heart failure.  
 
2. The drug classes ‘Potassium-sparing diuretics and aldosterone antagonists’ and 
‘Thiazides and related diuretics’ were combined into a single category titled ‘Diuretics’ 
as prescriptions for the former in the data extract were rare.  
 
3. I used each drug class as the reference drug class in turn and presented all results in a 
matrix, instead of using beta-adrenoceptor blocking drugs as the reference drug class 




Patients were included in the analysis if they were aged 40 years or over and received a 
first prescription for an antihypertensive drug class of interest. Follow-up was stopped at 
the earliest of: a dementia outcome; death; end of registration at a CPRD general 
practice; or the end of follow-up for this study (29th February 2016). Patients were 
excluded if they were of unknown gender; had less than 12 months of ‘research quality’ 
data prior to their first prescription (to improve the identification of baseline covariates); 
or were initially prescribed multiple antihypertensive drug classes of interest. I also 
excluded patients prescribed an antihypertensive before 1st January 1996, as 1996 was the 




Seven antihypertensive drug classes based on the groupings in the British National 
Formulary were considered. (189) These were: alpha-adrenoceptor blockers, angiotensin-
converting enzyme inhibitors, angiotensin-II receptor blockers, beta-adrenoceptor 
blockers, calcium channel blockers, diuretics (either ‘thiazides and related diuretics’ or 




antihypertensives. To mimic a randomised controlled trial, exposure to the drug classes 
was analysed in an intention-to-treat framework, i.e. based on the first prescription 
irrespective of subsequent switches to, or additions of, other antihypertensive drug 
classes. (73,190) The index date for each patient was the date they received their first 
prescription for an antihypertensive drug. Treatment switching was not modelled, as it 




There were four outcomes defined for this analysis: probable Alzheimer’s disease, 
possible Alzheimer’s disease, vascular dementia and other dementias. See Figure 5.1 for 
the decision tree used to determine dementia subtype. I also considered any dementia, 




The instrumental variable analysis was adjusted for prescription year only. This was 
necessary as the number of antihypertensive prescriptions in the CPRD varied by year 
and so may have influenced both the instrument-exposure and instrument-outcome 
associations. All other potential covariates were thought to influence the exposure-
outcome association, but not the instrument-exposure or instrument-outcome 
associations, and so will be balanced across levels of the instrument if the instrument 
assumptions are met. The instrumental variable analysis was compared with a 
multivariable logistic regression analysis to assess the extent of confounding. The 
multivariable logistic regression analysis was adjusted for prescription year; sex; age at 
index; previous history of coronary heart disease, coronary-bypass surgery, or 
cerebrovascular disease; chronic disease; socioeconomic position; consultation rate; 
alcohol status; smoking status; and body mass index. All covariates were determined 






7.2.6. Statistical methods  
 
This study used instrumental variable analysis with physicians preferred antihypertensive 
drug class as an instrument to proxy for exposure, i.e. the actual drug class prescribed 
(Figure 7.2). Each drug class was used as the reference drug class for each of the other 
drug classes in a series of pairwise comparisons. Prescribing preference was derived from 
the prescriptions issued by the physician to their seven most recent patients who received 
an antihypertensive. (27,191) This resulted in an ordered categorical instrument 
indicating how many previous prescriptions the physician had issued for the drug class of 
interest over the reference drug class in the present pairwise comparison. I selected seven 
previous prescriptions to define this instrument as this is frequently used in the literature 
and is thought to balance instrument strength, which increases with additional 
prescriptions used, and recent prescribing trends, which are lost with additional 
prescriptions used. (25) The analysis used the ivreg2 package in Stata with ‘robust’ 
specified (to address arbitrary heteroskedasticity, i.e. non-normality in the outcome) and 
clustering by physician (to address both arbitrary heteroskedasticity and intra-group 
correlations between physicians). (192) To obtain a point estimate, I made a further 
assumption – in addition to the three standard instrument assumptions - of monotonicity 
(Section 3.2.2.2). That is, I assumed that physicians’ preferred drug class had one of three 
effects: it increased the likelihood of exposure in everyone; it decreased the likelihood of 
exposure in everyone; or it had no effect in everyone. Consequently, the results were 
interpreted as the effect among patients whose prescription was affected by their 
physicians’ preference (known as the local average treatment effect). (193) For each 
analysis, I present the partial F statistic to quantify and test the strength of the 
instrument-exposure association. I also present the results of endogeneity tests conducted 
using the option ‘endog’ in ivreg2. The analysis is presented in line with reporting 
guidelines. (194) All analyses were conducted in Stata (version 15MP) and R (version 








Figure 7.2: Illustration of the instrumental variable analysis model used for the assessment of the 
effects of antihypertensive drugs on dementia prevention using electronic health record data. 
 
As detailed in Section 3.2, instrumental variable analysis requires that the instrument: (i) be 
associated with the exposure of interest; (ii) affect the outcome only through its effect on the exposure of 
interest; and (iii) have no common causes with the outcome. To obtain a point estimate for this 
analysis, I also make a fourth assumption of monotonicity (Section 3.2.2.2). The measured 
confounders of this analysis are listed in the section ‘covariates’, however there is also likely to be 





7.2.7. Assessment of bias 
 
To assess bias, I constructed bias scatter plots for each outcome. These plots compare the 
association of each covariate with the exposure (obtained from multivariable linear 
regression analysis) and the instrument (obtained from instrumental variable analysis). 
(196,197) If all points on these plots were on the x-axis then this would indicate that the 
instrumental variable analysis would be less biased than multivariable linear regression 
analysis. Points above the x-axis but below the x=y line would indicate bias in both 
analyses that is greater in the multivariable linear regression analysis estimate, while 
points above the x=y line would indicate bias in both analyses that is greater in the 
instrumental variable analysis estimate. Points on the x=y line would indicate that the 
bias is equal for the two analyses. Any covariates found to be as, or more, biased for the 
instrumental variable analysis (i.e. on or above the x=y line) were adjusted for in a 
sensitivity analysis. 
 
7.2.8. Sensitivity analyses 
 
Beta-adrenoceptor blockers can be prescribed in low doses for the treatment of anxiety. 
(198). However, to be a suitable comparator, they must be prescribed for the treatment of 
hypertension. I therefore tested the effect of removing patients thought to be receiving 
these drugs for anxiety in two ways. Firstly, I did the analysis without people who both 
received a drug class of interest and had a Read code indicating anxiety, or other 
neurotic, stress-related and somatoform disorders in the same consultation (using a 
previously published code list). (199) Secondly, I did the analysis without people whose 
dose was in the bottom 25% for their index drug class.  
 
Differential prescribing occurs in women of child bearing age due to risks associated with 
some antihypertensives during pregnancy. (58) As participants can enter this study at the 
age of 40, this might affect the youngest members of the cohort. I therefore conducted a 
sensitivity analysis restricted to patients aged 55 and over at index. This age threshold is 








7.3.1. Patient characteristics  
 
A total of 849,378 patients, with a total follow up of 5,497,266 patient years, met the 
criteria for the analysis. Figure 7.3 outlines patient attrition and Table 7.1 presents patient 
characteristics of those remaining in the study. (201–203) The full cohort had a median 
age of 61 (interquartile range: 51 to 71) at index date and a median follow-up of 5.8 years 
(interquartile range: 2.6 to 9.8). Of the 849,378 patients, 410,805 (48%) had complete 
covariate information. This subset of patients was used when comparing instrumental 
variable and multivariable logistic regression analyses. The subset had a median age of 61 
(interquartile range: 51 to 71) at index date, and median follow-up of 5.6 years 
(interquartile range: 2.5 to 9.5). Incomplete covariate information was mainly due to 
missing values for the Index of Multiple Deprivation, which was used to adjust for 
socioeconomic position, as this measure is only available for patients in English 
practices. One notable feature of the patient characteristics is that 97% of patients 
receiving alpha-adrenoceptor blockers and 99.3% of patients receiving vasodilator 
antihypertensives were men - this difference persists regardless of the age at first 
prescription (Table 7.2).  
 
7.3.2. Alzheimer’s disease 
 
Figure 7.4 shows the results for probable and possible Alzheimer’s disease respectively. 
The results suggested that beta-adrenoceptor blockers were protective for both probable 
and possible Alzheimer’s disease when compared with other drugs. For example, beta-
adrenoceptor blockers were estimated to result in 8 (95% CI: 3 to 12; p-value=3.1 ×
10−3) fewer cases of probable Alzheimer’s disease and 9 (95% CI: 4 to 13; p-value 
=1.3 × 10−4) fewer cases of possible Alzheimer’s disease per 1000 people treated when 






Figure 7.3: Patient attrition for the assessment of the effects of antihypertensive drugs on dementia 








Table 7.1: Patient characteristics for the assessment of the effects of antihypertensive drugs on 


















































































































































N 67360 14717 195891 240864 139730 180946 9870 849378 
Median year of 
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SD: standard deviation 
(a) The Charlson index is a classification of 17 chronic diseases, including cancer and arthritis, 
which may alter mortality risk.  
(b) Index of Multiple Deprivation (IMD) 2010 score is a proxy for socioeconomic position that is 
measured as ‘twentiles’ with 1 indicating the least deprived and 20 indicating the most deprived. 
IMD 2010 score was missing for 38.6% (328,233 patients) of the whole sample.  
(c) Alcohol status was missing for 15.6% (132,387 patients) of the whole sample. For the purposes of 
this table, it has been classified as ‘ever’ (i.e. former or current) vs ‘never’. 
(d) Smoking status was missing for 6.4% (54,447 patients) of the whole sample. For the purposes of 
this table, it has been classified as ‘ever’ (i.e. former or current) vs ‘never’. 
(e) Body mass index, or a calculated body mass index from height and weight measurements, was 
missing for 15.7% (128,830 patients) of the whole sample. 
Table 7.2: Exposure by age and sex for the assessment of the effects of antihypertensive drugs on 
dementia prevention using electronic health record data. 
Drug class / 
Age group  




 5,979  
 (93.4) 
15,289  
 (97.1)  
22,482  
 (98.0)  
16,141  
 (97.5)  
 6,653  
 (96.3)  
 806  
 (94.7)  





II receptor  
blockers  
42,697  
 (62.1)  
57,932  
 (62.9)  
45,726  
 (60.0)  
32,124  
 (50.4)  
14,881  
 (42.1)  
 2,482  
 (32.6)  
 49  







 2,994  
 (63.1)  
 4,366  
 (61.5)  
 3,742  
 (55.2)  
 2,479  
 (44.7)  
 1,010  
 (36.2)  
 125  
 (21.6)  
 1  







 (39.3)  
69,672  
 (45.7)  
49,775  
 (48.2)  
30,948  
 (43.0)  
11,579  
 (35.7)  
 1,522  
 (26.2)  








 (50.6)  
31,237  
 (55.8)  
45,022  
 (53.8)  
32,318  
 (42.7)  
12,832  
 (34.9)  
 1,721  
 (23.7)  
 31  





 (33.3)  
38,671  
 (39.2)  
47,552  
 (40.9)  
45,820  
 (34.2)  
22,961  
 (28.9)  
 3,660  
(23.1)  
 93  






 2,440  
 (99.2)  
 3,381  
 (99.5)  
 3,033  
 (99.7)  
 907  
 (98.6)  
 103  
 (91.3)  
 5  
(40.0)  
 1  
 (0.0)  




 (48.5)  
220,548  
 (55.2)  
217,332  
 (56.3)  
160,737  
 (47.7)  
70,019  
 (40.5)  
10,321  
 (31.5)  
 210  









Figure 7.4: Instrumental variable estimates for the risk of probable and possible Alzheimer’s disease using electronic health record data. 
 




7.3.3. Non-Alzheimer’s disease dementias 
 
Figure 7.5 shows the results for vascular and other dementias respectively. The 
magnitude of the differences between drug classes is smaller for these outcomes. 
However, vasodilator antihypertensives were suggested to be protective with an 
estimated 5 (95% CI: 0 to 9; p-value=0.04) fewer cases of vascular dementia and 6 (95% 
CI: 1 to 11; p-value=0.02) fewer cases of other dementias per 1000 people treated when 
compared with calcium channel blockers. Angiotensin-II receptor blockers were also 
indicated to be protective for vascular dementia with an estimated 7 (95% CI: 4 to 10; p-
value=1.4 × 10−5) fewer cases of vascular dementia per 1000 people treated when 
compared with alpha-adrenoceptor blockers. 
 
7.3.4. Any dementia 
 
Figure 7.6 shows the results for any dementia. These results reflected the dementia 
subtype analyses and emphasised the effects observed, perhaps due to the increased 
sample size. For example, beta-adrenoceptor blockers were estimated to result in 28 (95% 
CI: 19 to 38; p-value=5.2 × 10−9) fewer cases per 1000 people treated compared with 
alpha-adrenoceptor blockers. Meanwhile, vasodilator antihypertensives were estimated 
to result in 27 (95% CI: 17 to 38; p-value=4.4 × 10−7) fewer cases per 1000 people treated 
compared with diuretics. 
 
7.3.5. Comparison with multivariable logistic regression 
 
The results of the multivariable logistic regression are provided in Figure 7.7. 
Endogeneity tests indicated evidence to reject the null that the exposure was endogenous, 
indicating a difference between the instrumental variable analysis and ordinary least 
squares results, for a small number of the analyses run. Most of these analyses considered 
alpha-adrenoceptor blockers as the drug class of interest. The complete results, including 
the endogeneity test results and first stage regression results from the instrumental 






Figure 7.5: Instrumental variable estimates for the risk of non-Alzheimer’s disease dementia using electronic health record data. 
 






Figure 7.6: Instrumental variable estimates for the risk of any dementia using electronic health record data. 
 












7.3.6. Assessment of bias  
 
Bias scatter plots were used to assess bias among the subset of patients with complete 
covariate information (Figure 7.8). The bias term was larger in the instrumental variable 
analysis, compared to the multivariable linear regression analysis, for socioeconomic 
position only. Bias terms were equally biased for body mass index, chronic disease, sex 
and age. These covariates, including socioeconomic position, were adjusted for in 
sensitivity analyses and were mostly found to produce consistent results with the main 
analysis (Appendix C). The exception was results concerning diuretics and beta-
adrenoceptor blockers after adjustment for age. These drug classes have the oldest and 
youngest median ages at index respectively (Table 7.1), which may explain why they 
were most effected by the adjustment. 
 
7.3.7. Sensitivity analyses 
 
There was minimal effect of removing those diagnosed with anxiety in the same 
consultation from the analysis (Figure 7.9). Similarly, I observed little difference after 
removing those who received a low dose initial prescription though there was a lack of 
power for some analyses (Figure 7.10). Finally, restricting the analysis to patients aged 55 
and over at index did not change the direction of effect for the results however, several 




Beta-adrenoceptor blockers and vasodilator antihypertensives reduced risk of probable 
and possible Alzheimer’s disease, vascular dementia, other dementias, and any dementia 
when compared with other antihypertensive drug classes. On the contrary, diuretics and 
alpha-adrenoceptor blockers increased risk of dementia outcomes when compared with 
other antihypertensive drug classes. The results concerning beta-adrenoceptor blockers 
and diuretics may be biased by age; however, this bias is no more extreme than that 
observed for multivariable linear regression. This study does not explore the effect of 
antihypertensives treatment compared to non-treatment on risk of dementia, which the 
meta-analysis of randomized controlled trials discussed in Section 2.7 suggests has a 





Figure 7.8: Bias scatter plot for covariates in the any dementia analysis using electronic health record data. 
 







Figure 7.9: Instrumental variable estimates for all dementia outcomes without patients diagnosed with anxiety in the same consultation using electronic 
health record data. 
 





Figure 7.10: Instrumental variable estimates for all dementia outcomes without patients who had a low dose initial prescription using electronic health 
record data. 
 





Figure 7.11: Instrumental variable estimates for all dementia outcomes for patients aged 55 and over at index using electronic health record data. 
 





Although there are currently some trials underway (Table 2.1), there have been no 
randomized controlled trials published to date that have directly compared 
antihypertensive drug classes to each other for the prevention or treatment of Alzheimer’s 
disease. However, as discussed in Section 2.7, a recent meta-analysis by Larsson et al 
identified seven prospective observational studies on this topic. (12–19) Relative to other 
antihypertensive drug classes: one study (of three) suggested angiotensin-converting 
enzyme inhibitors were protective (13–15); three studies (of four) suggested angiotensin-
II receptor blockers were protective (15–18); and one study (of one) suggested calcium 
channel blockers were protective (19). In contrast, this analysis suggested beta-
adrenoceptor blocker and vasodilator antihypertensives were among the most protective 
drug classes when compared with other antihypertensives. Also mentioned in Section 
2.7, is the study by Barthold et al comparing Alzheimer’s disease incidence between users 
of renin-angiotensin system acting drug classes (angiotensin-converting enzyme 
inhibitors and angiotensin-II receptor blockers) and non-renin-angiotensin system acting 
drug classes (beta-adrenoceptor blockers, calcium channel blockers, loop diuretics, and 
thiazide-like diuretics) across sex, race, and ethnic groups in the USA. (62) Barthold et al 
found that angiotensin-II receptor blockers may reduce the risk of Alzheimer’s disease in 
white and black women and white men. The study presented in this chapter is in a 
population of mainly white men and women and did not find such a clear distinction 
between angiotensin-II receptor blockers and non-renin-angiotensin system acting drugs. 
As already highlighted, the major difference between this observational study and those 
previously conducted is the statistical methods used. When the analysis assumptions are 
met, instrumental variable analysis should not be subject to unmeasured confounding, 
which may affect other types of analysis. 
 
Two of the existing studies also made use of the CPRD. The first, by Davies et al, 
investigated the effects of angiotensin converting enzyme inhibitors and angiotensin-II 
receptor blockers, compared with other antihypertensives, on various dementia 
outcomes. (15) There is a small overlap between the present study and Davies et al, 
which I estimate to be 5.2% at most (48,363 new users of antihypertensives in Davies et 
al vs 849,378 new users of antihypertensives in the present study). The second, by Goh et 
al, compared the effects of angiotensin-II receptor blockers and angiotensin-converting 
enzyme inhibitors against each other in relation to dementia as a single outcome. (18) As 




had a much larger sample of 426,089 participants (as opposed to 221,421 participants in 
my study) exposed to angiotensin-II receptor blockers and angiotensin-converting 
enzyme inhibitors. This made it difficult to calculate the overlap as many of these 
patients are likely to have been exposed to other antihypertensives. However, there were 
50,404 participants assigned to the drug classes angiotensin-II receptor blockers and 
angiotensin-converting enzyme inhibitors in this analysis that were not present in the 
Goh et al study as they received their initial treatment after 2010, i.e. after the final data 
extract for the Goh et al study. Despite the overlap of some of the data used in the 
present study with these studies in the literature, the study design and analysis differ 
considerably between them. One important distinction is that I systematically 
investigated all the major classes of antihypertensive drugs instead of focusing on those 
related to the renin-angiotensin system. This allowed me to consider multiple 
comparisons and potentially identify beneficial and harmful effects of non-renin-
angiotensin system acting drug classes. 
 
7.5. Strengths and limitations 
 
The key strength of this study was the large cohort of patients (consisting of 849,378 
patients with 5,497,266 patient years of follow-up) that would not be achievable in a 
randomized controlled trial. The size of this study meant there was ample power to 
detect even small differences between the drug classes of interest. There was also data on 
both male and female patients unlike some of the larger existing studies. (16) In addition, 
I used instrumental variable analysis, which should not be subject to unmeasured 
confounding when the assumptions hold, and an active comparator design, whereby 
antihypertensive drug classes were compared with other antihypertensive drug classes, to 
ensure patients were comparable. (73,188) These analysis features were important in the 
present study due to the risk of confounding. Despite finding some evidence of bias, the 
sensitivity analyses showed the effect on the results to be minimal with only minor 
changes in magnitude for most estimates. This includes the potential bias due to 
socioeconomic position, which was deemed the most extreme in my assessment. The 
only concern was potential confounding by age for results relating to beta-adrenoceptor 
blockers and diuretics, however this bias was no more extreme than that observed in the 





A limitation of the present study is that I cannot prove that the instrumental variable 
assumptions hold. The only assumption that can be empirically tested is the first, namely 
that the instrument is associated with the rates of prescribing (IV1: relevance –Section 
3.2.1). The proposed instruments had a minimum F statistic of 4702 in the main 
analyses, demonstrating they strongly associated with the exposure. The study may also 
have misclassified the exposure due to the use of the intention-to-treat framework, which 
defines exposure based on the first treatment prescribed. However, the benefits of this 
approach – such as preserving sample size and replicating ‘real world’ prescribing – 
outweigh the concerns. A further limitation, as for the study in Chapter 6, is that this 
study may have misclassified outcomes, which can occur when a diagnosis is not 
updated or recorded accurately in primary care records. Again, I took steps to overcome 
this by considering ‘probable’ and ‘possible’ definitions for Alzheimer’s disease, the most 
common form of dementia. I also included an ‘any dementia’ outcome that should not be 




This study provided new evidence about the potential effects of antihypertensives on risk 
of dementia through the novel application of instrumental variable analysis to this 
research question. I found small differences in drug class effects on risk of dementia 
outcomes. However, I showed the magnitude of the differences between drug classes is 
smaller than many observational studies, which may have been subject to unmeasured or 
residual confounding, have previously reported. These results will be discussed further in 
the context of the existing literature in Chapter 9, which will also cover the implications 





Chapter 8. Results: Assessment of the effects of antihypertensive 




As mentioned in Chapter 2 and demonstrated in Chapter 6, there is a huge unmet clinical 
need for novel drugs for dementia. In Chapter 7, I used instrumental variable analysis 
with physicians’ prescribing preference as an instrument for exposure to investigate 
whether antihypertensives could be repurposed for dementia prevention. In this chapter, 
I used genetic instruments in a Mendelian randomization framework, as proposed in 
Chapter 4, to assess this same question. This genetically-informed method used different 
data to my previous assessment and was therefore subject to different biases. 
Consequently, it provides another strand of evidence that can ultimately be considered in 
a triangulation framework to obtain a reliable answer concerning the potential 
repurposing of antihypertensives for dementia. (20) Mendelian randomization has 
previously been used to study the relationship between genetically-predicted blood 
pressure and Alzheimer’s disease but it has not been used to estimate the effects of the 
twelve most common antihypertensive drug classes on Alzheimer’s disease. (204–206) In 
this chapter, I used SNPs as genetic instruments, selected to mimic the action of the 
protein targets of antihypertensive drug classes, in a two-sample Mendelian 
randomization analysis of systolic blood pressure on Alzheimer’s disease. The rationale 
behind this chapter was to understand if there were differences between specific 
antihypertensive drug classes on Alzheimer’s disease risk, which could inform the 
prioritization of repurposing candidates, and provide evidence at the drug class level that 




8.2.1. Study design 
 
I conducted a two-sample Mendelian randomization analysis using summary data on 
SNPs from GWAS, as described in Section 4.4. I identified SNPs to proxy exposure to 
an antihypertensive drug on the basis that they mimicked the action of that drug on their 




inhibiting the enzyme angiotensin-converting enzyme. I therefore selected SNPs in the 
angiotensin-converting enzyme gene to use as a genetic proxy for this drug class. Effect 
sizes for these SNPs were then extracted from a GWAS of systolic blood pressure to 
estimate the instrument-exposure association. (207) The instrument-outcome association 
was estimated using the effect sizes for these same SNPs from a GWAS of Alzheimer’s 
disease. (208) All data used were publicly available and mostly obtained from European 
ancestry populations.  
 
8.2.2. Systolic blood pressure phenotype 
 
The systolic blood pressure phenotype was defined using a GWAS of the UK Biobank 
cohort. (207) UK Biobank consists of 503,317 Caucasian people from the UK, aged 
between 38 years and 73 years. (209,210) The GWAS was based on 317,754 of the 
participants.  
 
8.2.3. Alzheimer’s disease phenotype 
 
The Alzheimer’s disease phenotype was defined using the International Genomics of 
Alzheimer's Project GWAS Stage 1 results. These data were from a meta-analysis of 
17,008 Alzheimer’s disease cases and 37,154 controls of European ancestry. (208).  
 
8.2.4. Instrument selection 
 
I identified twelve antihypertensive drug classes in the British National Formulary. (189) 
They were: adrenergic neurone blocking drugs; alpha-adrenoceptor blockers; angiotensin-
converting enzyme inhibitors; angiotensin-II receptor blockers; beta-adrenoceptor 
blockers; calcium channel blockers; centrally acting antihypertensive drugs; loop 
diuretics; potassium-sparing diuretics and aldosterone antagonists; renin inhibitors; 
thiazides and related diuretics; and vasodilator antihypertensives. Using the drug 
substance information, I was able to identify pharmacologically active protein targets and 
the corresponding genes in the DrugBank database (version 5.1.1). (211) I then identified 
SNPs to instrument each target using the Genotype-Tissue Expression (GTEx) project 
data (Release V7; dbGaP Accession phs000424.v7.p2), which contains expression 




which consists of 714 donors, is 65.8% male and 85.2% white. SNPs marked as the ‘best 
SNP’ for the gene (defined by GTEx as the variant with the smallest nominal p-value for 
a variant-gene pair) in any tissue were selected for analysis. I considered SNPs identified 
in any tissue because: (i) as described below, these SNPs are validated by estimating their 
effect on systolic blood pressure prior to the main analysis so it was better to be inclusive 
at this stage; and (ii) it was difficult to determine the single most relevant tissue for 
systolic blood pressure. 
 
To validate the SNPs as instruments for antihypertensive drug targets, I estimated their 
effect on systolic blood pressure using two-sample Mendelian randomization. The SNP-
expression association, extracted from GTEx as described above, was on the scale of a 
standard deviation change in RNA expression levels for each additional effect allele. The  
SNP-systolic blood pressure association was extracted from the systolic blood pressure 
GWAS in UK Biobank and represented the standard deviation change in systolic blood 
pressure for each additional effect allele. Unlike published systolic blood pressure 
GWASs, this GWAS is not adjusted for body mass index to avoid bias in the two-sample 
Mendelian randomization estimates, which can potentially occur when both samples are 
not adjusted for the same factors. These associations were then used to estimate the effect 
of the protein target on systolic blood pressure (i.e. the standard deviation change in 
systolic blood pressure per standard deviation change in RNA expression levels). SNPs 
with evidence of an effect on systolic blood pressure were retained for the main analysis. 
This instrument selection process is presented in Figure 8.1. 
 
8.2.5. Statistical methods 
 
I used two-sample Mendelian randomization to estimate the effect of lowering systolic 
blood pressure on Alzheimer’s disease in three ways. First, I estimated the effect of 
specific drug classes by combining the effects of any of the drug targets associated with a 
given drug class. This used the instruments defined in the previous section and 






Figure 8.1: Flow chart summarizing the instrument selection process and Mendelian randomization 
analyses for the assessment of the effects of antihypertensive drugs on dementia prevention using 
genetic data. 
 





 whole on Alzheimer’s disease by combining all drug targets. Again, this used the 
instruments defined in the previous section and summarized in Figure 8.1. Finally, I 
estimated the overall effect of systolic blood pressure on Alzheimer’s disease by 
combining the effects of any genome-wide significant SNPs for systolic blood pressure. 
When multiple SNPs were being used as an instrument, ‘clumping’ was performed to 
identify independent SNPs using the linkage disequilibrium between them. SNPs absent 
in the outcome data were replaced by proxy SNPs in high linkage disequilibrium from 
the 1000 Genomes Project European data where possible. (104,213) Proxies were 
required to have a minimum R-squared value of 0.8 and palindromic SNPs were 
permitted if their minor allele frequency was less than 0.3. 
 
Prior to the analysis, data were harmonised to represent an increase in systolic blood 
pressure. Mendelian randomization was then performed using the inverse variance 
weighted method or, for single-SNP instruments, the Wald ratio. (84,214,215) Once 
complete, the Mendelian randomization results were transformed to be the odds ratio for 
Alzheimer’s disease per 10mmHg lower systolic blood pressure to make the effect 
comparable to taking an antihypertensive, which on average reduces systolic blood 
pressure by 9mmHg. (59) All analyses used genome reference consortium human build 
37 (GRCh37), assembly Hg19, and were performed in R (version 3.4.4) using the 
package ‘TwoSampleMR’. (104,195) All coding and editable results files are available 
from GitHub: https://github.com/venexia/MR-antihypertensives-AD. 
 
8.2.6. Sensitivity analyses 
 
As described in Section 4.6.2.3, Mendelian randomization estimates may be subject to 
horizontal pleiotropy. This is where the SNP(s) chosen to proxy the exposure affect the 
outcome by a different mechanism to that intended. (216) This invalidates the exclusion 
restriction assumption, which states that the instrument must only affect the outcome 
through the exposure (IV2 – Section 3.2.1). To estimate the extent of horizontal 
pleiotropy, I applied MR-Egger regression to all estimates based on ten or more SNPs. 
Note that a minimum number of SNPs is necessary to minimise weak instrument bias, 
which can affect MR-Egger analyses. The regression intercept for these analyses “can be 
interpreted as an estimate of the average pleiotropic effect across the genetic variants”. 




not balanced around the null. MR-Egger relies on the Instrument Strength Independent 
of Direct Effect (InSIDE) assumption, which specifies that the magnitudes of the genetic-
variant association and pleiotropic effects should not be correlated. It is often referred to 
as “a weaker version of the exclusion restriction assumption”. (137)  
 
To examine heterogeneity within the drug classes, I also considered the effects of 
individual drug targets on Alzheimer’s disease. This analysis allowed me to interrogate 
whether certain targets were driving the observed drug class effects. Drug classes with 
very heterogeneous target results can be considered to have less reliable estimates than 




8.3.1. Instrument selection  
 
I identified a total of 73 unique protein targets of antihypertensive drugs. Among these 
targets, 68 had an effect in one or more GTEx tissues and 58 of those 68 provided 
evidence that the target affected systolic blood pressure. Figure 8.2 summarizes the 
results of the Mendelian randomization analysis of expression on systolic blood pressure. 
A further six targets were excluded prior to the main analysis because neither the genetic 
instrument, nor a suitable proxy, were available in the outcome GWAS. Consequently, 
52 unique protein targets were ultimately analysed. 
 
8.3.2. Drug class effects 
 
There was limited evidence that reducing systolic blood pressure affected risk of 
Alzheimer’s disease at the drug class level with most estimates failing to exclude the null 
(Figure 8.3). For example, calcium channel blockers had an OR of 1.53 (95% CI: 0.94 to 
2.49; p-value=0.09; SNPs=17) and loop diuretics an OR of 0.78 (95% CI: 0.18 to 3.40; p-
value=0.74; SNPs=3) per 10mmHg lower systolic blood pressure. The exceptions to this  
were angiotensin-converting enzyme inhibitors (OR per 10mmHg lower systolic blood 
pressure: 13.20; 95% CI: 2.14 to 81.24; p-value=5.0 × 10−3; rs4968783) and potassium-
sparing diuretics and aldosterone antagonists (OR per 10mmHg lower systolic blood 





Figure 8.2: Heat map of estimates for the effect of gene expression on systolic blood pressure.  
 













8.3.3. Antihypertensive drug effect 
 
There was little evidence for an overall effect of lowering systolic blood pressure on 
Alzheimer’s disease when combining all identified drug targets (OR per 10 mmHg lower 
systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p-value=0.41; SNPs=59) (Figure 8.3). 
 
8.3.4. Systolic blood pressure effect 
 
There was also little evidence for an overall effect of lowering systolic blood pressure on 
Alzheimer’s disease, without consideration of the associated drugs, as indicated by the 
OR of 1.04 (95% CI: 0.95 to 1.13; p-value=0.45; SNPs=135) per 10 mmHg lower systolic 
blood pressure (Figure 8.3). 
 
8.3.5. Sensitivity analyses 
 
The Egger intercepts were close to zero for almost all analyses where they could be 
calculated (Table 8.1). In addition, the estimates from the inverse variance weighted and 
MR-Egger methods were similar for all analyses with both the point estimate and 
confidence interval for the inverse variance weighted method almost contained within 
the confidence interval for the MR-Egger method (Figure 8.4). Note that MR-Egger is 
susceptible to a lack of power hence the wide confidence intervals observed here. (137) 
 
The analysis of individual targets identified some targets that were likely to be driving the 
drug class effects (Figure 8.5). For example, the target NR3C2 is estimated to have an 
OR per 10 mmHg lower systolic blood pressure of 2.01e-3 (95% CI: 5.22e-6 to 0.78; p-
value=0.04; rs71616586) and is likely to have contributed to the extremely protective 
effect observed for potassium-sparing diuretics and aldosterone antagonists (OR per 10 
mmHg lower systolic blood pressure: 0.17; 95% CI: 0.02 to 1.33; p-value=0.09; SNPs=3). 
Table 8.1: Egger intercepts for the assessment of the effects of antihypertensive drugs on dementia 
prevention using genetic data. 
Analysis Intercept Standard Error P-value SNPs 
Overall 0.007 0.006 0.23 135 
Combined 0.013 0.008 0.10 59 
Beta-adrenoceptor blockers 0.001 0.018 0.95 10 
Calcium channel blockers 0.018 0.013 0.18 17 















Figure 8.5: Target level estimates for the effect of systolic blood pressure on Alzheimer’s disease from 







There was limited evidence to support an overall effect of lowering systolic blood 
pressure on Alzheimer’s disease risk (OR per 10 mmHg lower systolic blood pressure: 
1.04; 95% CI: 0.95 to 1.13; p-value=0.45; SNPs=135). There was also limited evidence 
that lowering systolic blood pressure via antihypertensive drug classes affected 
Alzheimer’s disease. For example, calcium channel blockers had an OR of 1.53 (95% CI: 
0.94 to 2.49; p-value=0.09; SNPs=17) and vasodilator antihypertensives had an OR of 
0.98 (95% CI: 0.30 to 3.14; p-value=0.97; SNPs=11) per 10mmHg lower systolic blood 
pressure. This was reflected in the overall effect of lowering systolic blood pressure on 
Alzheimer’s disease when combining all identified drug targets, which had an OR of 1.14 
(95% CI: 0.83 to 1.56; p-value=0.41; SNPs=59) per 10 mmHg lower systolic blood 
pressure. Despite this, there are some extreme results, such as angiotensin-converting 
enzyme inhibitors, which were associated with an increased Alzheimer’s disease risk 
(OR per 10 mmHg lower systolic blood pressure: 13.29; 95% CI: 2.14 to 81.24; p-
value=5.0 × 10−3; rs4968783). 
 
The cause of these extreme results could be due to a competing mechanism, as illustrated 
in Figure 8.6. I estimated the effect of exposure to a given drug class on Alzheimer’s 
disease using the effect of the instrument for that drug class on both systolic blood 
pressure (instrument-exposure association) and Alzheimer’s disease (instrument-outcome 
association). The analysis assumed that the effect I was estimating acted through systolic 
blood pressure, however there is potentially a competing mechanism by which the given 
drug class can affect Alzheimer’s disease. If a competing mechanism does exist and the 
instrument-exposure association (i.e. the effect of the drug class instrument on systolic 





blood pressure) is small, estimates from Mendelian randomization can become inflated 
as the competing mechanism means the instrument-outcome association (i.e. the effect of 
the drug class instrument on Alzheimer’s disease) remains large. This is more apparent if 
you consider the Wald ratio used to calculate the effect for single SNP instruments:  
 





In this analysis, I found a small effect of systolic blood pressure on Alzheimer’s disease 
and the extreme results were for drug classes that may well act through competing 
mechanisms. For instance, returning to the example of angiotensin-converting enzyme 
inhibitors, angiotensin-converting enzyme is proposed to affect vascular pathways (such 
as blood pressure), but also be responsible for the production of angiotensin-II that is 
thought to be associated with a number of the pathological processes (e.g. inflammation, 
oxidative stress, reduced blood flow) involved in Alzheimer’s disease. (217) Importantly 
it is also thought have independent effects on amyloid beta. (9) In addition, potassium-
sparing diuretics and aldosterone antagonists, which were also estimated to have an 
extreme effect (OR per 10 mmHg lower systolic blood pressure: 0.17; 95% CI: 0.02 to 
1.33; p-value=0.09; SNPs=3), have previously been suggested to have a role, 
independent of blood pressure, in preventing cognitive decline.(218) This explanation for 
the extreme results observed for certain drug classes, along with the limited evidence for 
an effect among the remaining drug classes, indicates that antihypertensives are unlikely 
to have an effect on Alzheimer’s disease via lowering systolic blood pressure. 
 
Two previous Mendelian randomization studies have studied the overall effect of systolic 
blood pressure on Alzheimer’s disease to date. These studies used different instruments 
and different systolic blood pressure GWAS, both to the present study and each other. 
(204,205) Østergaard et al found higher systolic blood pressure to be associated with a 
reduced risk of Alzheimer’s disease, while Larsson et al found little evidence of an effect 
of systolic or diastolic blood pressure on risk of Alzheimer’s disease. My results agree 
with Larsson et al in that there is unlikely to be an overall effect of systolic blood pressure 
on risk of Alzheimer’s disease. Using the instruments reported by Østergaard et al and 




(Figure 8.7). There was a small overlap in the choice of SNPs used to instrument systolic 
blood pressure between my study and those from the literature (Østergaard et al: 14 
SNPs; Larsson et al: 22 SNPs).
 
Gill et al recently conducted a study that combined Mendelian randomization using 
genetic variants related to antihypertensive targets with a PheWAS conducted in UK 
Biobank, however their analysis was restricted to beta-adrenoceptor blockers and calcium 
channel blockers. (206) Using the instruments reported by Gill et al with the data used in 
the current study, I was also able to reproduce their results (Figure 8.8). My results 
broadly agree with those reported by Gill et al for Alzheimer’s disease, despite the 
minimal overlap in the choice of SNPs used to instrument beta-adrenoceptor blockers 
and calcium channel blockers (Beta-adrenoceptor blockers: 6 SNPs; Calcium channel 
blockers: 10 SNPs). 
 
As discussed in Section 2.7, Larsson et al recently conducted a systematic review and 
meta-analysis on this topic. This study identified five randomized controlled trials that 
have investigated whether antihypertensives prevent dementia (not Alzheimer’s disease 
specifically) with an overall relative risk of 0.84 (95% CI: 0.69 to 1.02; p-value=0.10). 
(12) It is worth reiterating that most studies described in the meta-analysis were from 
populations with high cardiovascular morbidity and were designed around 
cardiovascular related primary outcomes. This means that the proportion of dementia 
cases that derived from vascular mechanisms in these trials might be disproportionately 
high compared with other study populations. (60,61) This difference might explain the 
more favourable point estimate obtained in the meta-analysis compared with the results 
presented in this chapter.  
 
The SPRINT-MIND trial, which was published after the meta-analysis, and is also 
discussed in Section 2.7, assessed the effect of intensive vs standard blood pressure 
control using a range of antihypertensive medications on probable dementia, mild 
cognitive impairment and a composite outcome combining probable dementia and mild 
cognitive impairment. The trial found evidence to suggest that intensive blood pressure 
control was beneficial for the mild cognitive impairment and composite outcomes. 




included the null within its confidence interval but may have been underpowered due to 
the early termination of the trial. There are several key differences between this trial and 
the analysis I present. First, my outcome of interest was Alzheimer’s disease and so 
cannot be directly compared against the mild cognitive impairment or dementia 
outcomes used in the trial. Second, the trial was designed to compare treatment goals, 
whereas my analysis was comparing treatment with no treatment. Depending on blood 
pressure at baseline, these might yield different results. Third, as noted for the trials 
included in the meta-analysis conducted by Larsson et al, the primary outcome for the 
SPRINT trial was cardiovascular, meaning participants in SPRINT-MIND are more 
likely to have cognitive impairment and dementia outcomes derived from vascular 
mechanisms. Finally, Mendelian randomization estimates are of lifelong exposure, 
whereas this trial intervened on blood pressure for a median of 3.34 years in people with 
a mean age of 67.9 years. It is therefore possible that the trial has identified a critical 
period in which altering blood pressure has a beneficial impact on cognitive outcomes, 
which I cannot distinguish. Overall, while not directly comparable to our study, the 
findings from this trial, as well as the Larsson et al meta-analysis, provide further 
evidence concerning the repurposing of antihypertensives for Alzheimer’s disease that 
can be considered together in a triangulation framework. 
 
8.5. Strengths and limitations 
 
A strength of this study was the use of two-sample Mendelian randomization that meant 
I was able to use the International Genomics of Alzheimer's Project GWAS for the 
outcome data, which contains information on 17,008 Alzheimer’s disease cases and 
37,154 controls. (208) The use of Mendelian randomization, over more conventional 
pharmacoepidemiological approaches, will have also addressed certain forms of 
confounding. This includes confounding by indication and confounding by the 
environmental and lifestyle factors of patients, which cannot be fully adjusted for using 
observational data. This is because measurement error and incomplete capture of all 
these potential confounding factors inevitably leads to residual confounding. Further 
strengths of using Mendelian randomization to predict drug repurposing opportunities 





Figure 8.7: Estimates for the effect of systolic blood pressure on Alzheimer’s disease from two-sample Mendelian randomization using previously reported systolic blood 
pressure instruments. 
 
Note that this analysis implemented my pipeline, including clumping, so there are a reduced number of SNPs in the instruments for Ostergaard et al (originally 25) 








Figure 8.8: Estimates for the effect of systolic blood pressure on Alzheimer’s disease from two-sample Mendelian randomization using previously reported 
antihypertensive drug instruments. 
 
Note that this analysis implemented my pipeline, including clumping, so there are a reduced number of SNPs in the instruments for beta-adrenoceptor blockers 






The limitations of this study are discussed in general in Section 4.6.2. They include the 
risk of horizontal pleiotropy, which I addressed in this study by conducting sensitivity 
analyses using MR-Egger when possible. Sensitivity analyses that considered the 
individual drug target effects also identified some heterogeneity that may have affected 
the drug class estimates. For example, the estimate for potassium-sparing diuretics and 
aldosterone antagonists may have seemed more protective due to the particularly large 
protective effect observed for one of the three targets under consideration: NR3C2. I was 
also limited in this study by the fact that Mendelian randomization estimates the effect of 
lifelong exposure, while drugs typically have much shorter periods of exposure. This 
means that the estimated effect sizes will not directly reflect what is observed in trials or 




This study provided further new evidence about the potential effects of antihypertensives 
on risk of dementia by using a different method, subject to different biases, to assess this 
research question. I found little evidence to suggest that lowering systolic blood pressure 
itself will affect risk of developing Alzheimer’s disease. This was accompanied by limited 
evidence for many of the antihypertensive drug classes that I tested. Despite this, there 
was some suggestion of an effect through non-blood pressure lowering mechanisms for 
some drug classes, namely: angiotensin-converting enzyme inhibitors and potassium-
sparing diuretics and aldosterone antagonists. This study and the non-genetic 
instrumental variable analysis study discussed in Chapter 7 will be considered together in 
Chapter 9 as two forms of evidence concerning the potential repurposing of 








In this chapter, I summarize the outputs relating to the specific aims of this thesis. First, I 
describe the development of a power calculator for non-genetic instrumental variable 
analysis studies in the context of pharmacoepidemiology. Second, I cover how 
Mendelian randomization can be used to predict drug repurposing opportunities. Third, I 
summarise my examination of the impact of regulatory guidance and patent expiry on 
dementia drug prescribing. Fourth, I describe the assessment of antihypertensive drugs 
using instrumental variable analysis with electronic health record data and, finally, I 
describe the assessment of antihypertensive drugs using instrumental variable analysis 
with genetic data. This chapter also includes a summary of my efforts to make my 
research open and reproducible and details of potential future work arising from this 
thesis. The chapter concludes with a discussion that draws everything together including 
the novel findings, innovative methods, overarching limitations and future work 
associated with this thesis.   
 
9.2. Power calculator for instrumental variable analysis in pharmacoepidemiology 
 
9.2.1. Principal findings 
 
In Chapter 3, I derived a power formula for studies using a single binary instrument to 
analyse the causal effect of a binary exposure on a continuous outcome in the context of 
pharmacoepidemiology. I then validated the formula using a simulation that generated 
realistic data where the power of the study was known. Finally, to allow others to easily 
implement the formula, I produced an online calculator and packages for R and Stata 
that are publicly available. 
 
9.2.2. Comparison with existing literature 
 
Prior to the development of my power calculator, the majority of power calculators for 
instrumental variable analysis had been developed for Mendelian randomization. (29,30) 




not sufficiently catered for by Mendelian randomization power calculators. This is 
because, unlike Mendelian randomization studies that often use a case-control study 
design, pharmacoepidemiology studies typically use a cohort study design. Further to 
this, pharmacoepidemiology studies usually report a risk difference for a binary exposure 
using a binary instrument, while Mendelian randomization studies report on a 
continuous exposure using a discrete or continuous genetic instrument (count of alleles 
or allele score respectively). As a result of these differences, as well as the stronger 
instruments and larger causal effects seen in pharmacoepidemiology, there was a need for 
a dedicated power calculator for instrumental variable analysis in the context of this field.  
 
9.2.3. Strengths and limitations 
 
The key strength of this power calculator is that it has been developed specifically for 
questions in the context of pharmacoepidemiology, which the existing power calculators 
did not cater for. It has also been designed to be accessible, with publicly available tools 
developed to allow others to implement the formula. However, the limitations of this 
research are that the power formula is only applicable when conducting an instrumental 
variable analysis study that has a single binary instrument, binary exposure and 
continuous outcome. It is also limited, like every power formula, by its parameters as 
they simplify the data and so can miss underlying complexities. 
  
9.2.4. Implications of this research 
 
The main implication of this research is the ability for others to calculate the power of 
instrumental variable studies using a single binary instrument, binary exposure and 
continuous outcome in the context of pharmacoepidemiology with ease, via the online 
power calculator and packages in R and Stata. (31) As noted in Section 3.4.1, this is 
increasingly important for grant and data request applications and as the interest in more 
complex analytical methods, such as instrumental variable analysis, in 






9.3. Mendelian randomization for predicting drug repurposing opportunities 
 
9.3.1. Principal findings 
 
In Chapter 4, I introduced Mendelian randomization as a novel approach for predicting 
drug repurposing opportunities. Specifically, I demonstrated the use of Mendelian 
randomization for predicting drug repurposing opportunities through examples from the 
existing literature and discussed the strengths and limitations of using this method for this 
purpose. Within the chapter, I also advocate the synthesis of evidence from Mendelian 
randomization and other approaches, in the spirit of triangulation, to improve causal 
inferences concerning drug effects. (20) I later provide an example of Mendelian 
randomization for drug repurposing through the application of this method to assess 
whether antihypertensives can be repurposed for dementia prevention in Chapter 8. 
 
9.3.2. Comparison with existing literature 
 
There is a large existing literature on Mendelian randomization that includes both 
methodological developments and applications of the method. (84,85,138,219) There is 
also a large existing literature concerning the use of genetics in drug discovery. (87,220–
222) However, Mendelian randomization has not been used to its full potential for 
predicting drug repurposing opportunities to date and discussion of specific 
pharmacoepidemiology issues, such as confounding by indication, is uncommon in the 
Mendelian randomization literature. This chapter and the accompanying article therefore 
highlight the potential of Mendelian randomization for this purpose and discuss the 
strengths and limitations that are specific to this application. (32) 
 
9.3.3. Strengths and limitations 
 
There are many strengths and limitations associated with the use of Mendelian 
randomization for predicting drug repurposing opportunities. Strengths include that it 
addresses confounding by environmental and lifestyle factors, confounding by indication, 
and reverse causation. All of which are of concern when conducting 
pharmacoepidemiology studies and may be particularly problematic for later life 




instrument bias, and the fact that estimates reflect lifelong exposure, which may not be 
realistic in terms of clinical intervention and may obscure critical periods of exposure. 
 
9.3.4. Implications of this research 
 
This research has contributed to the discussion of using Mendelian randomization for 
drug discovery in the literature, a key area of active research. The process of writing this 
chapter and the accompanying article has allowed me to collect together several 
examples of Mendelian randomization being used to predict drug repurposing 
opportunities. This has proved a useful tool for teaching – for example, the issues 
discussed in this chapter formed the basis of a lecture entitled ‘Use of Mendelian 
randomization in drug discovery and target validation’ for the Bristol Medical School 
Mendelian randomization short course in 2018 and 2019. 
 
9.4. Factors effecting existing dementia drug prescribing 
 
9.4.1. Principal findings 
 
In Chapter 6, I examined prescribing trends in England from the launch of the drugs for 
dementia up to 1st January 2016, using data from the CPRD. I found that the overall 
trend was for increasing prescriptions in each drug class over the period in which they 
were studied. I also found that prescriptions of acetylcholinesterase inhibitors increased 
at the end of 2012, probably in response to the patent expiry of these drugs earlier that 
year and, potentially, the Prime Minister’s Dementia Challenge launched in May 2012. 
However, neither this strategy nor patent expiry appeared to influence prescriptions of 
NMDA receptor antagonists. Instead trend changes in this drug class were driven by 






9.4.2. Comparison with existing literature 
 
The existing literature concerning factors influencing dementia drug prescribing in 
England has mainly focused on the impact of the National Dementia Strategy. (33,34) 
My findings were broadly in agreement with the existing literature in that there has been 
an increasing trend in prescribing of dementia drugs over time. However, I identified a 
trend change in 2012 as the largest factor influencing prescriptions rather than the launch 
of the National Dementia Strategy in 2009 that they consider. The main difference 
between my study and the existing literature is the use of a hypothesis-free approach that 
allowed me to consider multiple factors simultaneously. 
 
9.4.3. Strengths and limitations 
 
The key strengths of this research are the large sample of primary care data and the long-
follow up of patients within this sample. The large sample is important to maintain 
statistical power for the analysis, which involves multiple tests, while the long follow-up 
allowed patients who experienced a treatment delay to remain in the analysis. The 
limitations of this research include the potential for misclassified outcomes that affects all 
studies using electronic health record data as they are not designed for research use. This 
research may also be affected by difficulties in determining the time lag between events 
that may have influenced prescribing and the observed trend changes in prescribing, 
which make it difficult to determine causality.  
 
9.4.4. Implications of this research 
 
This research has identified several factors that may have affected prescriptions of 
dementia drugs over a twenty-year period. (35) I found that dementia drug prescribing 
does not always respond to factors such as regulatory guidance, recommendations, or 
patent expiry, and when it does, not necessarily in a predictable way. This has 
implications in terms of how changes to regulatory guidance and recommendations are 
communicated to clinicians in the future and how new drugs, including repurposed 
candidates, are used. In addition, this study provides knowledge of the dementia drug 
prescribing trends, which is necessary when adjusting for these medications in other 




9.5. Assessment of antihypertensive drugs using electronic health record data 
 
9.5.1. Principal findings 
 
In Chapter 7, I conducted an instrumental variable analysis using physicians’ prescribing 
preference as an instrument in electronic health record data. I found small differences in 
drug class effects on risk of probable Alzheimer’s disease, possible Alzheimer’s disease, 
vascular dementia, other dementias and any dementia. However, I showed the 
magnitude of the differences between drug classes is smaller than many observational 
studies have previously reported for these outcomes. I also showed that the bias in this 
study is likely to be less, or at least no more extreme, than that observed for multivariable 
linear regression. 
 
9.5.2. Comparison with existing literature 
 
The evidence for repurposing antihypertensives for dementia prevention from studies 
with an active comparator, such as that presented in Chapter 7, is summarized in Table 
9.1. The key difference between my analysis approach and those previously used is the 
assumptions that they rely on. For the instrumental variable analysis, I must assume 
relevance, the exclusion restriction, independence and monotonicity, whereas the non-
instrumental variable analysis observational studies assume no residual confounding. 
Violation of these assumptions may explain the difference in magnitude observed. 
Neither of these sets of assumptions can be tested fully however, there was an indication 
of potential residual confounding when I compared the instrumental variable analysis 
with an equivalent multivariable linear regression analysis. Despite this, the analyses 
broadly agree in that there is likely to exist some differential effects among 
antihypertensives classes in terms of dementia prevention. 
 
9.5.3. Strengths and limitations 
 
Like the examination of dementia drug prescribing trends, this study benefits from a large 
cohort of patients from the CPRD. For this study, this is particularly beneficial as it 
would be infeasible to obtain such a large sample in the equivalent randomized 




contrasts with the other methods that have been implemented prior to this study that 
have all assumed no residual confounding. Instead, this study relies on alternative 
assumptions and so is subject to different biases. This allows triangulation of evidence. 
(20) The key limitation of this study is that, other than the assumption of relevance, I am 
not able to test the instrument assumptions. The analysis also remains susceptible to 
misclassified outcomes as it uses electronic health record data that are not intended for 
research. 
 
9.5.4. Implications of this research 
 
This research provides a new source of evidence concerning the potential repurposing of 
antihypertensives for the prevention of dementia. (21) As noted at several points in this 
thesis, this is important as the current evidence concerning this hypothesis is 
inconclusive. This study is also one of the largest to investigate the potential repurposing 
of antihypertensives to date with 849,378 patients exposed to the drugs of interest and 
total follow-up of 5,497,266 patient-years. It is also one of the first studies (along with the 
Mendelian randomization presented in Chapter 8) to use causal inference methods to test 
this hypothesis and should be more robust to residual confounding than previously used 
study designs. 
  
9.6. Assessment of antihypertensive drugs using genetic data 
 
9.6.1. Principal findings 
 
In Chapter 8, I conducted a Mendelian randomization analysis, which found limited 
evidence that lowering systolic blood pressure, via antihypertensive drug classes, affected 
Alzheimer’s disease risk. I also found limited evidence for an effect of lowering systolic 
blood pressure on Alzheimer’s disease when combining all drug targets and without 
consideration of the associated drug targets. Considered together, this would suggest that 
if specific antihypertensive drug classes do affect Alzheimer’s disease risk, they are 




Table 9.1: Summary of evidence for repurposing antihypertensives for dementia prevention from studies using an active comparator. 
Analysis Outcome Summary of results Assumptions Potential sources of bias 
Instrumental variable 
analysis using electronic 
health record data 




vascular dementia; other 
dementias; any dementia 
Small differences in drug class 







Cannot prove all 
instrument assumptions 






Larsson et al of seven 
observational studies  
Dementia or  
Alzheimer’s disease 
One study (of three) suggesting 
angiotensin-converting enzyme 
inhibitors were protective (11–
13); three studies (of four) 
suggesting angiotensin-II receptor 
blockers were protective (13–16); 
and one study (of one) suggesting 
calcium channel blockers were 


















Angiotensin-II receptor blockers 
may reduce the risk of 
Alzheimer’s disease in certain 
groups, namely white and black 














9.6.2. Comparison with existing literature 
 
The evidence for repurposing antihypertensives for dementia prevention from studies 
with a non-active comparator, such as that presented in Chapter 8, is summarized in 
Table 9.2. My results were in line with those from the Larsson et al meta-analyses of 
clinical trials and observational studies, which found weak evidence to support 
repurposing antihypertensive drugs for dementia prevention. Given that the instrumental 
variable analysis using genetic data relies on different assumptions to the previously 
conducted analyses and is subject to different biases, this furthers the case against 
repurposing antihypertensives for dementia prevention via blood pressure lowering 
mechanisms. However, it does not exclude other non-blood pressure lowering 
mechanisms of antihypertensives – such as those proposed for renin-angiotensin system 
acting drugs as a result of the angiotensin hypothesis of Alzheimer’s disease. This 
hypothesis proposes that additional Alzheimer’s disease-related pathological processes, 
independent of any blood pressure effects, such as cognition, inflammatory and oxidative 
stress mechanisms – and potentially activities related to amyloid beta and tau pathology – 
are associated with renin-angiotensin system dysfunction. (217) 
 
9.6.3. Strengths and limitations 
 
The use of Mendelian randomization for this study will have addressed concerns 
regarding confounding by indication, environmental or lifestyle factors, and reverse 
causation, that may have been present for the more conventional pharmacoepidemiology 
studies. Specifically, the use of two-sample Mendelian randomization (compared to one-
sample Mendelian randomization) will have increased the power of this study as it 
allowed the use of a large GWAS of Alzheimer’s disease, maximizing the number of 
cases in the analysis. The main limitation of this study, as with all Mendelian 
randomization studies, is the risk of horizontal pleiotropy that occurs when the SNPs 
influence the outcome through a pathway other than that of interest. The inference from 
this study is also limited by the fact that the estimates refer to lifelong exposure, however  
drug exposure is likely to be shorter and occur later in life. This means estimates will not 




Table 9.2: Summary of evidence for repurposing antihypertensives for dementia prevention from studies using a non-active comparator. 
Analysis Outcome Summary of results Assumptions Potential sources of bias 
Instrumental variable 
analysis using genetic 




Limited evidence that 
lowering systolic blood 
pressure via antihypertensive 
drug classes affected 





Horizontal pleiotropy; weak 
instrument bias 
Meta-analysis by 
Larsson et al of five 
clinical trials 
Dementia 
Four studies of five found a 
weak protective effect, but the 
meta-analysis failed to exclude 
the null  
Trial arms are 
comparable with the 
exception of the 
treatment they 
receive 
Loss to follow-up could differ in the 
treatment arms; most of the trials 
were from populations with high 
cardiovascular morbidity and were 
designed around cardiovascular 
related primary outcomes 
Meta-analysis by 




Weak evidence for an effect on 
Alzheimer’s disease  
No residual 
confounding 
Unmeasured confounding; exposure 
misclassification; outcome 
misclassification; missing data 
Meta-analysis by 
Larsson et al of three 
observational studies 
Dementia  
Weak evidence for an effect on 
dementia, which failed to 
exclude the null 
No residual 
confounding 
Unmeasured confounding; exposure 
misclassification; outcome 







Intensive blood pressure 
control was beneficial for the 
mild cognitive impairment and 
composite outcomes compared 
with standard blood pressure 
control 
Trial arms are 
comparable with the 
exception of the 
treatment they 
receive 






9.6.4. Implications of this research 
 
Like the application of instrumental variable analysis using electronic health record data, 
the application of instrumental variable analysis using genetic data also provides new 
evidence concerning repurposing antihypertensives for dementia prevention and is one of 
the first studies to use causal inference methods. (22) This new evidence is subject to 
different biases than the existing literature and uses a different data source. Consequently, 
it is a key component of evidence when triangulating the evidence concerning this 
hypothesis.  
 
A further implication of this research is that is provides a ‘real-world demonstration’ of 
the use of Mendelian randomization for drug repurposing as I proposed in Chapter 4 and 
in the article ‘Mendelian randomization: a novel approach for the prediction of adverse 
drug events and drug repurposing opportunities’. (32)  
 
9.7. Open research 
 
Throughout my PhD, I have endeavored to make my research as open and reproducible 
as possible. I have summarized these efforts in Table 9.3. 
 
9.8. Future work 
 
9.8.1. Power formulae for other types of instrumental variable analysis in the context of 
pharmacoepidemiology 
 
A natural extension to the work described in this thesis would be to develop power 
formulae applicable for instrumental variable analyses other than those using a single 
binary instrument to analyse the causal effect of a binary exposure on a continuous 
outcome in the context of pharmacoepidemiology. In particular, there is a need to 
develop power formulae that can be applied when using a binary outcome, such as that 
studied in this thesis. The addition of formula for different binary/continuous 
instrument-exposure-outcome combinations to the existing online tool, and packages in 




Table 9.3: Summary of the open research efforts associated with this thesis. 
Chapter Data and coding files Paper 
Chapter 3. Methods: 
Instrumental variable 
analysis using electronic 
health record data 
The code for the simulations, the Shiny application and the packages in 
R and Stata is available from GitHub: 
https://github.com/venexia/PharmIV  
Available open access from 
the International Journal of 
Epidemiology, previously 
uploaded to bioRxiv.  
Chapter 4. Methods: 
Instrumental variable 
analysis using genetic data 
Not applicable. 
Available open access from 
the International Journal of 
Epidemiology, previously 
uploaded to bioRxiv. 
Chapter 5. Methods:  
The Clinical Practice 
Research Datalink 
Restrictions apply to the availability of CPRD data, which was used 
under license for this work. The code lists used to extract this data are 
publicly available: 
https://doi.org/10.5523/bris.1plm8il42rmlo2a2fqwslwckm2  
The code used to clean the CPRD data is available from GitHub: 
https://github.com/venexia/CleanCPRD  
Available open access from 
BMJ Open.  
Chapter 6. Results: 
Prescribing trends for 
drugs for dementia 
Restrictions apply to the availability of CPRD data, which was used 
under license for this work. The code lists used, in addition to those used 
in Chapter 5, are publicly available: 
https://doi.org/10.5523/bris.2h4rmk9v7pw2k23h7vgf9tx1ea  
The code used for this analysis is available from GitHub: 
https://github.com/venexia/DementiaDrugsCPRD 
Available open access from 
Alzheimer’s & Dementia, 
previously uploaded to 
PeerJ Preprints. 
Chapter 7. Results: 
Assessment of the effects 
of antihypertensive drugs 
on dementia prevention 
using electronic health 
record data 
Restrictions apply to the availability of CPRD data, which was used 
under license for this work. The code lists used, in addition to those used 
in Chapter 5, are publicly available: http://rebrand.ly/repurposing-
antihypertensives-dementia-codelists. 
The code used for this analysis is available from GitHub: 
https://github.com/venexia/repurposing-antihypertensives-dementia 
Available from bioRxiv. 
Currently under peer-
review. 
Chapter 8. Results: 
Assessment of the effects 
of antihypertensive drugs 
on dementia prevention 
using genetic data 
The data used in this chapter are publicly available and have been 
obtained from the sources listed in the README for the following 
GitHub repository: https://github.com/venexia/MR-antihypertensives-
AD, which also contains the code used for this analysis.  
Available open access from 
the International Journal of 
Epidemiology, previously 





9.8.2. MR-PheWAS using electronic health record data 
 
In Chapter 4, I suggest that the application of MR-PheWAS to a combination of genetic 
data and electronic health records could be particularly powerful. At the time of writing, 
this was not possible. However, the continued development of resources, such as UK 
Biobank and the Million Veteran Program, throughout my PhD means that we will soon 
be able to implement this type of analysis. (223,224) Future work should look to combine 
the developments that have been made in instrument selection for drug proxies – such as 
that presented in Chapter 8 – with an MR-PheWAS using electronic health record data. 
 
9.8.3. Assessment of antihypertensives for dementia progression 
 
This thesis has focused on repurposing antihypertensives for dementia prevention but, 
given the suggested links between hypertension and dementia (Chapter 2), it is possible 
that these drugs may have utility for dementia progression. As mentioned in the protocol 
for the CPRD element of this thesis, this could be studied using existing electronic health 
record data. (36) However, further work would be needed to conduct a Mendelian 
randomization analysis due to the current lack of GWAS on dementia progression. As 
noted in Chapter 4, the lack of progression GWAS is not specific to the dementia field 




There are three key novel findings, corresponding to each of the results chapters, that 
have arisen from this thesis. Firstly, prescriptions of dementia drugs have increased since 
their launch, but a join point analysis of prescribing trends suggests that the different 
classes of drugs have been affected by different factors during this time (Chapter 6). For 
instance, acetylcholinesterase inhibitor prescriptions responded most to expiry of their 
patents, while NMDA receptor antagonists responded most to changes in NICE 
guidance. Secondly, instrumental variable analysis using physician’s prescribing 
preference suggests that small differences exist between antihypertensive drug classes in 
terms of their effect on dementia prevention (Chapter 7). However, the magnitude of 
the differences is smaller than many observational studies have previously reported. 




pressure, via antihypertensive drug classes, affects Alzheimer’s disease risk (Chapter 8). 
This suggests that if specific antihypertensive drug classes do affect the risk of 
Alzheimer’s disease, they may not do so via systolic blood pressure. 
 
An important aspect of these novel findings is the innovative methods that have been 
applied to obtain them. An example of this is the use of joinpoint analysis to study the 
factors affecting prescribing of dementia drugs (Chapter 6). This allowed a hypothesis-
free approach to determine the key factors affecting trends rather than the targeted 
approaches used previously in the literature. A further example is the application of 
instrumental variable analysis to investigate whether antihypertensive drugs could be 
repurposed for dementia prevention (Chapters 7 and 8). Although both instrumental 
variable analysis using physician’s prescribing preference and Mendelian randomization 
have been applied in many therapy areas before, they have not previously been used for 
this research question. This thesis has also contributed an innovative method to the 
literature through the derivation of a novel power formula for instrumental variable 
studies using a single binary instrument to analyse the causal effect of a binary exposure 
on a continuous outcome in the context of pharmacoepidemiology, as well as the 
development of packages in R and Stata to implement it (Chapter 3).  
 
A key consideration when discussing the potential repurposing of antihypertensives for 
dementia prevention is biological plausibility. As such, plausibility is one of the nine 
Bradford Hill criteria outlined by Sir Austin Bradford Hill in 1965 for assessing causality. 
(225) As reasoned in Section 1.2, antihypertensive drugs have been proposed as drug 
repurposing candidates for dementia for several reasons that relate to their biological 
plausibility. These include the observed associations between midlife hypertension and 
later-life risk of Alzheimer’s disease and vascular dementia (5–8); the increasing 
recognition that one of the earliest pathological events in the development of Alzheimer’s 
disease is vascular dysregulation (9); and suggestions that some antihypertensives may 
have other neurological benefits. However, an important aspect of each of these reasons 
is the timing of the intervention. Alzheimer’s disease is thought to have a long prodromal 
phase starting in midlife. Consequently, careful consideration must be given as to when 
an intervention would need to occur in order to modify the disease course. The 




thesis is limited in that I could not specify when in the life course antihypertensives were 
initiated. This meant the cohort for my analysis had a median age of 61 (interquartile 
range: 51 to 71) at index. This is likely to be too late in the life course for a primary 
prevention strategy (i.e. an intervention implemented prior to the onset of disease) to 
have an effect but may be informative when considering these drugs as a secondary 
prevention strategy (i.e. an intervention implemented after the onset of disease but before 
clinical symptoms). (51) The instrumental variable analysis using genetic data had a 
different relationship with timing because this analysis considered the lifelong effect of 
exposure to high blood pressure. A disadvantage of this approach is that it removes the 
opportunity to identify critical periods of exposure and means that exposures with mixed 
beneficial and adverse effects during the life course can appear to have a null overall 
effect. However, if the assumptions necessary for Mendelian randomization hold – 
specifically the “assumption that the proximal association of the genetic variant is with 
the risk factor, not with the outcome (nor with an alternative cause of the outcome)” – 
then the exposure must occur prior to the outcome. (226) This allows for assessment of 
the exposure as a primary prevention strategy, which can be difficult to assess using other 
study designs. 
 
This thesis has several limitations. Those pertaining to individual studies have been 
discussed in previous sections in this chapter however, there are some common themes 
that apply across studies. Firstly, this thesis uses secondary data, such as that from the 
CPRD and GWAS summary statistics. These data were not collected specifically for the 
research questions studied. This has implications in terms of the types of analyses that 
could be applied and aspects of the analyses, such as diagnosis definitions and available 
covariates. Secondly, several of the analyses presented have had issues associated with 
time. In particular, the analyses concerning repurposing antihypertensives may be limited 
with regards to the timing and duration of exposure they can consider – as discussed 
above. A further example of a time related issue is the difficultly in determining the time 
lag between events that may have influenced prescribing and the observed trend changes 
in the CPRD for the dementia drug prescribing trend analyses in Chapter 6. Thirdly, 
dementia as defined in much of the data used in this thesis represents a range of 
symptoms, such as memory loss, and not necessarily degenerative brain disease. This 




conditions differ in their causes, then causal effects estimated using the data may be 
attenuated due to the dilution of the outcome of interest. Furthermore, defining disease 
based on symptoms may also have implications regarding how the diagnosis is recorded 
– for example, those with more extensive vascular history may be misclassified as having 
vascular dementia. A final limitation of this thesis is specific to the analyses concerning 
repurposing antihypertensives for dementia prevention and is that these analyses were 
linked to the primary indication of the drugs, i.e. blood pressure lowering. In the 
assessment of antihypertensive drugs using electronic health record data, this occurred 
because patients were required to have hypertension (or another existing indication of 
these drugs) to receive the drugs. Consequently, the results obtained from these analyses 
may not generalize to other populations, such as those without hypertension. In the 
assessment of antihypertensive drugs using genetic data, this was the case because the 
instruments were chosen in such a way that the observed effects had to act through 
lowering systolic blood pressure. This meant I was unable to make inferences concerning 
drug effects that were independent of systolic blood pressure. 
 
The novel aspects of this thesis could be used to inform future work. For instance, while 
the derivation of a novel power formula for instrumental variable studies using a single 
binary instrument to analyse the causal effect of a binary exposure on a continuous 
outcome in the context of pharmacoepidemiology is a novel addition to the literature 
(Chapter 3), there are further formulae that could be derived. As proposed in Section 
9.8.1, a natural extension would be to consider formulae for different binary/continuous 
instrument-exposure-outcome combinations. The aim of this would be to ultimately 
provide a complete set of formulae for any instrumental variable analysis conducted in 
the context of pharmacoepidemiology. This thesis may also inform future work 
concerning the use of antihypertensive drugs for the treatment of dementia progression. 
One of the difficulties of studying disease progression is disentangling factors that are 
influencing incidence. Evidence concerning disease incidence, such as that presented in 
this thesis, can therefore be useful when interpreting results related to disease 
progression. 
 
To conclude, this thesis has provided new evidence concerning the potential repurposing 




electronic health record data suggested that, while differences between antihypertensives 
used for this purpose exist, they are smaller than previously reported in the literature. 
Meanwhile, instrumental variable analysis using genetic data suggested that there was 
little evidence that lowering systolic blood pressure, via antihypertensive drug classes, 
affected Alzheimer’s disease risk but did not exclude the possibility of other mechanisms 
related to these drugs having an effect. This thesis has also examined the factors that have 
influenced prescribing trends of licensed dementia drugs, such as regulatory guidance and 
patient expiry. Understanding how existing drugs are used in this therapy area is key to 
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Appendix B. CPRD search terms 
 
Table A.1: Medical code search terms. 
Medical Event Search Term 
Alzheimer’s disease *alzheimer* 
Amyotrophic lateral sclerosis *amyotrophic lateral sclerosis* 







Diabetes *type 2 diabetes* 





Hypertension *blood pressure* 
Hypertension *hypertension* 




Table A.2: Product code search terms. 
Drug Category Drug Subclass Drug Substance Search Term 
Hypertension Beta-adrenoceptor blockers  Propranolol hydrochloride *propranolol* 
Hypertension Beta-adrenoceptor blockers  Acebutolol *acebutolol* 
Hypertension Beta-adrenoceptor blockers  Atenolol *atenolol* 
Hypertension Beta-adrenoceptor blockers  Bisoprolol fumarate *bisoprolol* 
Hypertension Beta-adrenoceptor blockers  Carvedilol *carvedilol* 
Hypertension Beta-adrenoceptor blockers  Celiprolol hydrochloride *celiprolol* 
Hypertension Beta-adrenoceptor blockers  Co-tenidone *tenidone* 
Hypertension Beta-adrenoceptor blockers  Labetalol hydrochloride *labetalol* 
Hypertension Beta-adrenoceptor blockers  Metoprolol tartrate *metoprolol* 
Hypertension Beta-adrenoceptor blockers  Nadolol *nadolol* 
Hypertension Beta-adrenoceptor blockers  Nebivolol *nebivolol* 
Hypertension Beta-adrenoceptor blockers  Oxprenolol hydrochloride *oxprenolol* 
Hypertension Beta-adrenoceptor blockers  Pindolol *pindolol* 
Hypertension Beta-adrenoceptor blockers  Sotalol hydrochloride *sotalol* 
Hypertension Beta-adrenoceptor blockers  Timolol maleate *timolol* 
Hypertension Angiotensin-converting enzyme inhibitors Captopril *captopril* 
Hypertension Angiotensin-converting enzyme inhibitors Cilazapril *cilazapril* 
Hypertension Angiotensin-converting enzyme inhibitors Trandolapril *trandolapril* 
Hypertension Angiotensin-converting enzyme inhibitors Ramipril *ramipril* 
Hypertension Angiotensin-converting enzyme inhibitors Lisinopril *lisinopril* 
Hypertension Angiotensin-converting enzyme inhibitors Enalapril maleate *enalapril* 
Hypertension Angiotensin-converting enzyme inhibitors Fosinopril sodium *fosinopril* 
Hypertension Angiotensin-converting enzyme inhibitors Imidapril hydrochloride *imidapril* 
Hypertension Angiotensin-converting enzyme inhibitors Moexipril hydrochloride *moexipril* 




Hypertension Angiotensin-converting enzyme inhibitors Perindopril erbumine *perindopril* 
Hypertension Angiotensin-converting enzyme inhibitors Quinapril *quinapril* 
Hypertension Thiazides and related diuretics Bendroflumethiazide *bendroflumethiazide* 
Hypertension Thiazides and related diuretics Chlortalidone *chlortalidone* 
Hypertension Thiazides and related diuretics Cyclopenthiazide *cyclopenthiazide* 
Hypertension Thiazides and related diuretics Indapamide *indapamide* 
Hypertension Thiazides and related diuretics Metolazone *metolazone* 
Hypertension Thiazides and related diuretics Xipamide *xipamide* 
Hypertension Calcium channel blockers Amlodipine *amlodipine* 
Hypertension Calcium channel blockers Diltiazem hydrochloride *diltiazem* 
Hypertension Calcium channel blockers Felodipine *felodipine* 
Hypertension Calcium channel blockers Isradipine *isradipine* 
Hypertension Calcium channel blockers Lacidipne *lacidipine* 
Hypertension Calcium channel blockers Lercanidipine hydrochloride *lercanidipine* 
Hypertension Calcium channel blockers Nicardipine hydrochloride *nicardipine* 
Hypertension Calcium channel blockers Nifedipine *nifedipine* 
Hypertension Calcium channel blockers Nimodipine *nimodipine* 
Hypertension Calcium channel blockers Verapamil hydrochloride *verapamil* 
Hypertension Loop diuretics Bumetanide *bumetanide* 
Hypertension Loop diuretics Furosemide *furosemide* 
Hypertension Loop diuretics Torasemide *torasemide* 
Hypertension Alpha-adrenoceptor blockers Doxazosin *doxazosin* 
Hypertension Alpha-adrenoceptor blockers Indoramin *indoramin* 
Hypertension Alpha-adrenoceptor blockers Phenoxybenzamine hydrochloride *phenoxybenzamine* 
Hypertension Alpha-adrenoceptor blockers Phentolamine mesilate *phentolamine* 
Hypertension Alpha-adrenoceptor blockers Prazosin *prazosin* 




Hypertension Centrally acting antihypertensives Clonidine hydrochloride *clonidine* 
Hypertension Centrally acting antihypertensives Methyldopa *methyldopa* 
Hypertension Centrally acting antihypertensives Moxonidine *moxonidine* 
Hypertension Angiotensin-II receptor antagonists Azilsartan Medoxomil *azilsartan* 
Hypertension Angiotensin-II receptor antagonists Candesartan cilexetil *candesartan* 
Hypertension Angiotensin-II receptor antagonists Eprosartan *eprosartan* 
Hypertension Angiotensin-II receptor antagonists Irbesartan *irbesartan* 
Hypertension Angiotensin-II receptor antagonists Losartan potassium *losartan* 
Hypertension Angiotensin-II receptor antagonists Olmesartan medoxomil *olmesartan* 
Hypertension Angiotensin-II receptor antagonists Telmisartan *telmisartan* 
Hypertension Angiotensin-II receptor antagonists Valsartan *valsartan* 
Hypertension Vasodilator antihypertensive drugs Ambrisentan *ambrisentan* 
Hypertension Vasodilator antihypertensive drugs Bosentan *bosentan* 
Hypertension Vasodilator antihypertensive drugs Diazoxide *diazoxide* 
Hypertension Vasodilator antihypertensive drugs Hydralazine hydrochloride *hydralazine* 
Hypertension Vasodilator antihypertensive drugs Iloprost *iloprost* 
Hypertension Vasodilator antihypertensive drugs Minoxidil *minoxidil* 
Hypertension Vasodilator antihypertensive drugs Sildenafil *sildenafil* 
Hypertension Vasodilator antihypertensive drugs Sitaxentan sodium *sitaxentan* 
Hypertension Vasodilator antihypertensive drugs Sodium nitroprusside *nitroprusside* 
Hypertension Vasodilator antihypertensive drugs Tadalafil *tadalafil* 
Hypertension PSDs and aldosterone antagonists Amiloride hydrochloride *amiloride* 
Hypertension PSDs and aldosterone antagonists Eplerenone *eplerenone* 
Hypertension PSDs and aldosterone antagonists Spironolactone *spironolactone* 
Hypertension PSDs and aldosterone antagonists Triamterene *triamterene* 
Hypercholesterolaemia Statins Atorvastatin *atorvastatin* 




Hypercholesterolaemia Statins Pravastatin sodium *pravastatin* 
Hypercholesterolaemia Statins Rosuvastatin *rosuvastatin* 
Hypercholesterolaemia Statins Simvastatin *simvastatin* 
Hypercholesterolaemia Fibrates Bezafibrate *bezafibrate* 
Hypercholesterolaemia Fibrates Ciprofibrate *ciprofibrate* 
Hypercholesterolaemia Fibrates Fenofibrate *fenofibrate* 
Hypercholesterolaemia Fibrates Gemfibrozil *gemfibrozil* 
Hypercholesterolaemia Bile acid sequestrants Colesevelam (hydrochloride) *colesevelam* 
Hypercholesterolaemia Bile acid sequestrants Colestipol (hydrochloride) *colestipol* 
Hypercholesterolaemia Bile acid sequestrants Colestyramine *colestyramine* 
Hypercholesterolaemia Omega-3 fatty acid compounds Omega-3 Acid Marine Triglycerides *fish oil* 
Hypercholesterolaemia Omega-3 fatty acid compounds Omega-3 Acid Ethyl Esters *ethyl esters* 
Hypercholesterolaemia Ezetimibe Ezetimibe *ezetimibe* 
Hypercholesterolaemia Nicotinic acid group Acipimox *acipimox* 
Hypercholesterolaemia Nicotinic acid group Nicotinic acid *nicotinic* 
Type 2 diabetes Biguanides Metformin (hydrochloride) *metformin* 
Type 2 diabetes Sulphonylureas Chlorpropamide *chlorpropamide* 
Type 2 diabetes Sulphonylureas Glibenclamide *glibenclamide* 
Type 2 diabetes Sulphonylureas Gliclazide *gliclazide* 
Type 2 diabetes Sulphonylureas Glimepiride *glimepiride* 
Type 2 diabetes Sulphonylureas Tolbutamide *tolbutamide* 
Type 2 diabetes Other Antidiabetic Drugs Acarbose *acarbose* 
Type 2 diabetes Other Antidiabetic Drugs Alogliptin *alogliptin* 
Type 2 diabetes Other Antidiabetic Drugs Canagliflozin *canagliflozin* 
Type 2 diabetes Other Antidiabetic Drugs Dapagliflozin *dapagliflozin* 
Type 2 diabetes Other Antidiabetic Drugs Empagliflozin *empagliflozin* 




Type 2 diabetes Other Antidiabetic Drugs Linagliptin *linagliptin* 
Type 2 diabetes Other Antidiabetic Drugs Liraglutide *liraglutide* 
Type 2 diabetes Other Antidiabetic Drugs Nateglinide *nateglinide* 
Type 2 diabetes Other Antidiabetic Drugs Pioglitazone *pioglitazone* 
Type 2 diabetes Other Antidiabetic Drugs Repaglinide *repaglinide* 
Type 2 diabetes Other Antidiabetic Drugs Rosiglitazone *rosiglitazone* 
Type 2 diabetes Other Antidiabetic Drugs Saxagliptin *saxagliptin* 
Type 2 diabetes Other Antidiabetic Drugs Sitagliptin *sitagliptin* 
Type 2 diabetes Other Antidiabetic Drugs Vildaglipin *vildagliptin* 




Appendix C. Additional sensitivity analyses for the assessment of antihypertensive drugs using 
electronic health record data 
Figure B.1: Instrumental variable estimates for all dementia outcomes after adjustment for socioeconomic position using electronic health record data. 
 






Figure B.2: Instrumental variable estimates for all dementia outcomes after adjustment for body mass index using electronic health record data. 
 






Figure B.3: Instrumental variable estimates for all dementia outcomes after adjustment for chronic disease using electronic health record data. 
 





Figure B.5: Instrumental variable estimates for all dementia outcomes after adjustment for age using electronic health record data. 
 
F greater than 4094 for all analyses.  
 
 
Figure B.4: Instrumental vari ble estimates for all dem ntia outcomes after adjustment for sex using electronic health record data. 
 






Figure B.5: Instrumental variable estimates for all dementia outcomes after adjustment for age using electronic health record data. 
 
F greater than 4094 for all analyses.  
 
 
